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The rare Peutz-Jeghers syndrome (PJS) was first described by the 
Dutch physician Jan Peutz in 1921. The syndrome is characterized by 
mucocutaneous pigmentations, typical gastrointestinal polyps, and 
an increased cancer risk in the gastrointestinal tract as well as in 
other organs. PJS is caused by a germline mutation in the LKB1 tumour 
suppressor gene. Despite the strong association between LKB1 germline 
mutations and the increased cancer risk in PJS patients, the role of LKB1 in 
cancer development remains elusive. In this thesis, Susanne Korsse explores 
the link between Peutz-Jeghers syndrome, cancer and LKB1. She investigates 
the role of LKB1 signalling in cancer development and treatment, and 
elaborates on the prevalence and prevention of cancer in PJS. 
This research was conducted from 2010 till 2013 in the Erasmus MC 
University Medical Centre in Rotterdam, in collaboration with the 
Academic Medical Centre in Amsterdam, the Netherlands. 
boek_omslag_final.indd   1 21-04-13   20:54
  
 
PEUTZ-JEGHERS 
SYNDROME  
AND CANCER
Linked by LKB1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Susanne Elisabeth Korsse 
ISBN: 978-94-6169-390-7
Copyright © Susanne Elisabeth Korsse
All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system of 
any nature, or transmitted in any form or by any means without permission of the author.
Lay-out and printing: Optima Grafische Communicatie, Rotterdam, The Netherlands
Cover design: Olivier Heida, Bureau BlauwGeel. Met medewerking van FabLab Groningen en 
John Welling Fotografie.
Financial support for the printing of this thesis was kindly provided by: Bayer BV, Dpt of 
Gastroenterology and Hepatology Erasmus MC, Falk Pharma Benelux BV, Ferring BV, J.E. 
Jurriaanse Stichting, prof.dr. E.M.H. Mathus-Vliegen, MSD BV, Nederlandse Vereniging voor 
Gastroenterologie, Novartis Pharma BV, Tramedico BV, Vifor Pharma Nederland BV and Zam-
bon Nederland BV.
Peutz-Jeghers Syndrome and Cancer
Linked by LKB1
Peutz-Jeghers syndroom en kanker
Verbonden door LKB1
Proefschrift
ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam op gezag 
van de rector magnificus prof.dr. H.G. Schmidt en volgens besluit van het College voor 
Promoties.
De openbare verdediging zal plaatsvinden op vrijdag 14 juni 2013 om 13:30 uur door
Susanne Elisabeth Korsse geboren te Apeldoorn
Promotiecommissie
Promotoren: Prof.dr. E.J. Kuipers
Prof.dr. E.M.H. Mathus-Vliegen
Overige leden: Prof.dr. J.F. Lange
Prof.dr. R.M.W. Hofstra
Prof.dr. G.J.A. Offerhaus
Copromotoren: Dr. M.E. van Leerdam
Dr. W. van Veelen
Paranimfen: Drs. I.L. Holster
Drs. E.L.A. Toxopeus
Voor mijn ouders

CONTENTS
Chapter 1 General introduction and outline of the thesis 9
Chapter 2 Targeting LKB1 signalling in hereditary and sporadic cancer 19
Chapter 3 The cell polarity kinase LKB1 counteracts colon cancer cell 
motility through cytoskeletal rearrangement
43
Chapter 4 Identification of molecular alterations in gastrointestinal 
malignancies and dysplastic hamartomas in Peutz-Jeghers 
syndrome
57
Chapter 5 GNAS is not involved in gastrointestinal tumour formation in 
Peutz-Jeghers syndrome
77
Chapter 6 Small bowel endoscopy and Peutz-Jeghers syndrome 83
Chapter 7 Pancreatic cancer risk in Peutz-Jeghers syndrome patients: 
results of a large Dutch cohort study and implications for 
surveillance
101
Chapter 8 Breast cancer in Peutz-Jeghers syndrome: risk assessment 
and surveillance recommendation
113
Chapter 9 Peutz-Jeghers syndrome and family planning: the attitude 
towards prenatal diagnosis and pre-implantation genetic 
diagnosis
127
Chapter 10 General discussion and future perspectives 137
Chapter 11 Appendix 149
References 151
Summary 177
Samenvatting 179
Dankwoord 181
List of publications 183
List of co-authors 185
Curriculum Vitae 189
PhD portfolio 191

Chapter 1
General introduction and  
outline of the thesis

11
General introduction and outline of the thesis
PEUTZ-JEGHERS SYNDROME
Peutz-Jeghers syndrome (PJS) is an autosomal dominant inherited disorder, characterized by 
mucocutaneous pigmentations, hamartomas presenting as gastrointestinal polyps, and an 
increased cancer risk.
Historical background
The first notification of the typical skin findings of PJS goes back to 1896, when the London 
physician Sir Jonathan Hutchinson illustrated a case of twin sisters with ‘black pigmented 
spots on the lips, and inside of the mouth’ (Figure 1) [1]. These pigmentations were different 
from the typical brown freckles located on the wings of the nose and cheeks. A follow-up of 
the so-called ‘Hutchinson twins’ noted that one sister died of intestinal blockage at the age of 
20 years, and the second twin died of breast cancer at age 52 [2,3].
infancy. Early investigators noted that the cutaneous pig-
ment pattern can fade with age (Fig. 2). However, buccal
mucosa tends to persist (9, 10, 16, 17). This is important for
clinicians who are attempting to establish the diagnosis in
individuals suspected of Peutz-Jeghers syndrome.
On biopsy, the pigmented macules are characterized by
increased melanocytes at the epidermal-dermal junction,
with increased melanin in the basal cells (9, 18). No malig-
nant transformation has been ascribed to the hyperpigmen-
tation associated with Peutz-Jeghers syndrome. Case reports
of individuals from Peutz-Jeghers kindred having pigmen-
tation without polyposis, and the converse, have been re-
ported (9, 16, 19).
GI Polyposis
The predominant clinical features of Peutz-Jeghers syn-
drome are the result of GI polyposis. As noted by Jeghers et
al. (9), “the GI polyposis becomes clinically manifest early
in life.” In their series, the age of diagnosis or death ranged
between 9 and 39 yr. In Bartholomew’s review of 75 pa-
tients, the average age at diagnosis was 22 yr (17). In a
Japanese series of 222 patients with PJS, the average age of
diagnosis in male patients was 22 yr and in female patients,
26 yr (20). One-third of Peutz -Jeghers patients will expe-
rience symptoms during their first decade of life, and 50–
60% of patients will experience them before age 20 yr (21).
The major abdominal symptoms are abdominal pain sec-
ondary to recurrent intussusception and GI bleeding. In
Jeghers’ series (9), each patient underwent between one and
four abdominal surgeries. In our follow-up of the “Harris-
burg family,” which includes three of Jeghers’ initial 10
patients, 12 affected individuals have undergone 32 abdom-
inal operations and70 endoscopic polypectomies (22, 23).
The most common location of Peutz-Jeghers polyps is in
the small intestine (jejunum greater than ileum, greater than
duodenum), followed by the large intestine and stomach. In
a collective series of 182 cases reported from the Mayo
Clinic, 96% of patients had small bowel, 27% colon, 24%
rectum, and 24% stomach polyps (17, 22). In the Japanese
series, roughly equal distribution was noted in the small
bowel, large bowel, and stomach (20). The small and large
bowel polyps tend to be pedunculated, whereas stomach
polyps are sessile. The polyps can grow to very large size,
and combined with their pedunculated nature, results in
recurrent intussusception. In the Japanese series 47% of
Figure 1. Hutchinson illustration of mucocutaneous pigmentation in 9-yr-old twin girls reported initially by Dr. J. T. Connor.
Figure 2. Subtle perioral melanin pigmentation in a 31-yr-old
female with extensive small bowel polyposis and a family history
of Peutz-Jeghers syndrome. Cutaneous pigmentation was more
notable when the patient was younger. Prominent buccal pigmen-
tation is present. (Courtesy of Drs. V. Falanga and M. Tsoukas,
Department of Dermatology and Skin Surgery, Roger Williams
Medical Center, Boston University School of Medicine, Provi-
dence, RI).
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Figure 1. Illustration of mucocutaneous pigmentation in 9-yr-old twin girls by Sir J. Hutchinson (adapted 
from: McGarrity et al. [8]).
In 1921, the Dutch physician Jan Peutz (Figure 2, left) described the combination of gastro-
intestinal polyps and mucocutaneous pigmentations in three young siblings in the Netherlands 
Monthly Journal of Medicine (“Nederlandsch Maandschrift voor Geneeskunde”) [4]. More than 
20 years later, the American physician Harold Jeghers (Figure 2, right) described two patients 
with the same symptoms [3]. These observations led to the description of the syndrome in 
1949 by Jeghers, McKusick and Katz in the “New England Journal of Medicine”. Finally, in 
1954 the eponym Peutz-Jeghers syndrome was introduced by Bruwer and colleagues [5].
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The initial report by Peutz [1]
On December 6th, 1920, a 15-year-old boy was admitted
to the Johannes de Deo Hospital in The Hague and
was seen by Dr. Peutz for anorexia, nausea, abdominal
pain and weight loss. The boy also had numerous
distinctive pigment spots on his face (Figure 3). In
his publication in the ‘Nederlandsch Maandschrift
voor Geneeskunde’ (Netherlands Monthly Journal of
Medicine) in 1921, Peutz wrote: ‘When I saw the boy
for the first time, I thought that I saw someone I already
knew, such was his resemblance to an eleven-year-old
boy whom I had examined that summer and was
referred to me by colleague Kuynders because of the
highly remarkable pigmentation on the face and the
buccal mucosa, with the remark that other family
members apparently had the same spots. Proof was now
indeed established, since the two boys turned out to be
brothers’. The patient developed an ileus due to intus-
susception of a small bowel polyp and underwent
abdominal surgery. Pathological examination of the
resection specimen (Figure 3) by Professor Landsteiner
showed malignant degeneration of the polyp [1, 3].
Evaluation of the family revealed a similar pattern of
pigmentation in four of the patient’s siblings. For three
of the children, including the above-mentioned patient,
intestinal polyps were confirmed. In addition, two of the
children with pigmentation had nasal polyposis (Figure
4). In his concluding paragraphs, Peutz attributed the
intestinal polyps with malignant potential, the nasal
polyps and the distinctive pigmentation to one congen-
ital and familial syndrome, which he considered to be
a severe disorder.
A detailed description of the syndrome by Jeghers
and his colleagues [2]
In March and October, 1939, two female patients with
intestinal polyposis and ‘distinctive melanin pigmenta-
tion’ on the face, fingers, toes and oral mucosa visisted
Boston City Hospital, where Jeghers was Associate
Professor of Medicine. Jeghers mentioned these cases
briefly in his extensive publication ‘Pigmentation of the
skin’ in the New England Journal of Medicine in 1944
[9]. Several other cases of intestinal polyposis and pig-
mentation had also been reported, some of which were
reviewed in a French publication by Tourraine & Couder
in 1945, entitled ‘Syndrome de Peutz’ [10]. However,
the combination of polyposis and pigmentation of the
skin and mucous membranes was not established as a
distinct entity until 1949, when the syndrome was
described in detail by Jeghers, then Head of the
Department of Medicine at Georgetown University,
together with Dr. Victor McKusick from the Department
of Medicine at Johns Hopkins University,1 and Dr.
Kermit Katz of the Boston City Hospital [2]. During his
Boston years, Jeghers had collected information about
several patients with the syndrome in collaboration with
Katz. McKusick, who had also collected several patients
with the stigma during his residency at Johns Hopkins,
182
Figure 1.  Jan Peutz, 1951. Figure 2.  Harold Jeghers, 1988.
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Figure 2. Jan Peutz (1951) and Harold Jeghers (1988) (adapted from: Keller et al. [9]).
Today, the clinical diagnosis of PJS is defined by diagnostic criteria of the World Health 
Organisation (WHO) (Box 1) [6]. The syndrome is r re, with a  incidence stimated b tween 1 
in 50,000 to 1 in 200,000 live births [7]. At present, in the Netherlands there are approximately 
100 living PJS patients originating from over 60 families, including the original “Peutz-family”.
Box 1. Diagno tic criteria for Peutz-J ghers syndrome (PJS) recommended by the World Health 
Organ sation [6].
A. Positive family history of PJS, and
1. Any number of i tologically confirmed PJS polyps*, or
2. Characteristic, prominent, mucocutaneous pigmentation.
B. Negative family history of PJS, and
1. Three or more histologically confirmed PJS polyps, or
2. Any number of histologically confirmed PJS polyps and characteristic,prominent, mucocutaneous pigmentation.
 *Histology of PJS polyps: a central c re of smooth muscle that shows tree-like branching,
covered with normal epithelium.
Ge etic background
PJS is caused by a germline mutation in the liver kinase B1 (LKB1, also known as serine/
threo ine kinas  11; STK11) tumour suppressor gene, located n chromosome 19p13.3 of 
the human genome [10,11]. The syndrome inherits in an autosomal dominant way, and in 
approximately 25% of cases a de novo mutation is present. With the currently available tech-
13
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niques, a germline mutation is found in 80-94% of clinically affected patients, of which more 
than 60% is a point mutation [12-14]. Around 150 different germline LKB1 mutations, mainly 
located in the kinase domain of the gene, have been associated with PJS [15]. The majority 
of the mutations carried by PJS patients result either in truncation or in abnormal splicing of 
the protein product, and cause inactivation of LKB1. The clinical features of PJS vary among 
patients and affected families. Despite several studies, no convincing genotype-phenotype 
correlation has been demonstrated [16-18].
Clinical features
Mucocutaneous pigmentations are seen in around 95% of PJS patients, and can be the first 
clinical sign before any gastrointestinal symptoms occur. The pigmentations develop already 
in infancy and fade during adolescence in most patients. They are mostly seen in the perioral 
region, especially on the vermilion border of the lips (Figure 3), but can also be found on the 
buccal mucosa, around the nostrils, at the hands and feet, and in the peri-anal region. The 
lesions are flat, have a blue-greyish colour, and vary in size between 1 to 5 mm. Although the 
pigmentations do not have malignant potential, the cosmetic effect can be burdensome.
Figure 3. Characteristic pigmentations at and around the lips of a Peutz-Jeghers syndrome patient.
The polyps seen in PJS can develop throughout the gastrointestinal tract, but are mainly 
located in the proximal small bowel [19,20]. Number and size of gastrointestinal polyps differ 
per patient. PJS polyps have a typical macroscopic and microscopic appearance. They are 
referred to as hamartomas. They are often pedunculated and consist of a branched, tree-like 
smooth muscle core covered with normal epithelium (Figure 4) [21]. Hamartomas can develop 
already in the first decade of life and may cause complaints of abdominal pain, blood loss, or 
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acute intestinal obstruction, resulting from intussusception of a small bowel segment carrying 
a large hamartoma. The latter often requires acute surgical intervention. By the age of 10 
years, one-third of patients experience polyp-related symptoms [22]. The cumulative risk of 
intussusception by the age of 20 years is 50% [20].
A B
Figure 4. A. Endoscopic picture of a pedunculated small bowel polyp of a Peutz-Jeghers syndrome 
patient. B. H&E stained tissue of a Peutz-Jeghers syndrome hamartoma, showing the branched smooth 
muscle core.
PEUTZ-JEGHERS SYNDROME AND CANCER
During the second half of the 20th century, epidemiological and molecular genetic studies 
revealed that PJS is also associated with an increased cancer risk. A lifetime risk for any 
cancer between 37% and 93%, and relative risks ranging from 10 to 18 in comparison with 
the general population have been reported [23]. A substantial part of this elevated cancer risk 
is attributed to an increased risk for gastrointestinal tumours (mainly colorectal, small bowel, 
gastric and pancreatic cancer). A cohort study of 133 Dutch PJS patients showed a cumula-
tive cancer risk of 76% at age 70 years, with a gastrointestinal cancer risk of 51% at this age 
[24]. Female patients are at even higher risk than male patients, because of the additional risk 
of breast cancer and gynaecological cancers in women.
Predominantly due to the elevated cancer risk, mortality in PJS patients is significantly 
increased compared to the general population. In the study of van Lier et al. 42 of the 133 
patients had died at a median age of 45 years, including 28 cancer related deaths (67%) [24].
In addition to malignant gynaecological tumours, female PJS patients of reproductive 
age can also develop small, asymptomatic, bilateral ovarian tumours, known as “sex-cord” 
tumours with annular tubules (SCTATs) at a young age [25]. PJS-associated SCTATs have 
a low malignant potential and a good prognosis. These tumours are often associated with 
signs of hyperestrogenism, causing precocious puberty. Male PJS patients have an increased 
incidence of Sertoli cell testicular tumours [26,27]. These lesions are often hormonally active 
and patients can present with testicular enlargement or gynaecomastia.
15
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Surveillance and treatment
Because of the risk of hamartoma-related complications and the increased cancer risk in PJS 
and due to the lack of effective methods for chemoprophylaxis to prevent the formation of 
hamartomas and malignancies, patient management should focus on prevention by surveil-
lance. Over the years, several surveillance recommendations have been proposed, including 
the recommendations of the Dutch PJS working group in 2010 (Box 2) [7,23,28-30]. It should 
be noted that all these recommendations are based on clinical experience and expert opinion. 
In fact, no evidence-based surveillance strategy for PJS is available since no controlled trials 
on the effectiveness of such a program have been published.
In view of the morbidity caused by the hamartomas, it is generally accepted that surveil-
lance of the gastrointestinal tract should start already at a young age (8-10 years). At later age, 
surveillance of the gastrointestinal tract should also address detection of precursor lesions 
or malignancies at an early, asymptomatic stage. Furthermore, female PJS patients should 
undergo regular surveillance of the breasts and genital tract.
Currently, PJS patients with cancer are treated according to standard protocols. More 
insight in the pathophysiology of PJS-associated cancer might lead to personalized treatment 
for patients with PJS. This topic is further discussed in chapter 2 of this thesis.
Box 2. Dutch surveillance recommendations for Peutz-Jeghers syndrome patients [23].
Examination1 Starting age Interval
History, physical examination (including 
testicular palpation), and hemoglobin 
analysis
10 years 1 year (paediatrician)
VCE and/or MRI enteroclysis2 10 years 2-3 years
Gastroduodenoscopy 20 years 2-5 years (depending on findings)
Colonoscopy 25-30 years 2-5 years (depending on findings)
MRI and EUS pancreas 30 years 1 year, only in a prospective ongoing trial
Breast exam and breast MRI 25 years 1 year
Mammography and breast MRI 30 years 1 year3
Pelvic exam, cervical smear, transvaginal 
ultrasonography, and CA-125
25-30 years 1 year
EUS: endoscopic ultrasound; MRI: magnetic resonance imaging; VCE: video capsule endoscopy.
1Earlier and/or more frequently in symptomatic patients or if clinically indicated.
2If VCE shows polyps, it is recommended to perform an MRI enteroclysis to determine the exact 
localization and size of the polyps. Polyps >10-15 mm in diameter are an indication for double-balloon 
enteroscopy with polypectomy. In addition, we recommend intra-operative enteroscopy with polyp 
removal in each case that a laparotomy is indicated, to avoid re-laparotomies. If surgery is indicated a 
laparoscopic approach is preferred when possible.
3Mammography and MRI alternately performed every 6 months.
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LKB1 AND CANCER
The LKB1 tumour suppressor gene codes for the LKB1-kinase. The function of this kinase is 
complex and not completely unravelled yet. It is considered a “master-kinase”, involved in a 
range of cellular processes, including energy metabolism, cell polarity and cell growth. LKB1 
regulates these processes partly via the AMP-activated protein kinase/mammalian target of 
rapamycin (AMPK/mTOR) signalling pathway. Inactivation of LKB1 can lead to disruption 
of this cascade, resulting in upregulation of mTOR activity. This oncogenic protein triggers 
multiple cellular responses involved in uncontrolled proliferation and tumour growth [31-33].
Altered LKB1/AMPK/mTOR signalling is associated with a wide variety of cancers and 
hereditary hamartoma syndromes including PJS. Yet, the exact tumour suppressor functions 
of LKB1, both in sporadic as in PJS-associated carcinogenesis, remain elusive. The lack of a 
genotype-phenotype correlation in PJS patients reflects the involvement of additional genetic 
modifiers participating in carcinogenesis. Loss of heterozygosity of LKB1 is found in hamar-
tomas, but it is more frequently detected in carcinomas of PJS patients [34,35]. This might 
suggest that LKB1 acts as a haplo-insufficient tumour suppressor gene. Current knowledge 
of the LKB1/AMPK/mTOR signalling pathway and its role in disease will be further discussed 
in chapter 2.
AIM Of THIS THESIS
As pointed out in this introduction, the link between PJS and cancer is indisputable, but ques-
tions remain. The aim of this thesis is to investigate 1) the role of LKB1 signalling in cancer 
development and treatment, and 2) the prevalence and prevention of cancer in PJS.
OUTLINE Of THIS THESIS
In continuation of the general introduction, in chapter 2 the function and regulation of the 
LKB1/AMPK/mTOR signalling pathway is further explained. In addition, we describe how ab-
errant signalling of this cascade can cause disease, and in particular cancer. Finally, we reflect 
on the design and use of rational treatment targeting LKB1/AMPK/mTOR-associated disease.
Despite the strong association between germline LKB1 mutations and an increased risk for 
colorectal cancer (CRC), the role of altered LKB1/AMPK/mTOR signalling in sporadic CRC 
is unclear. Somatic LKB1 mutations have been rarely detected, but loss of heterozygosity of 
the LKB1 locus is found in 15-53% of CRC cases. Previous studies have shown that loss of 
LKB1 increases cell migration and invasion in breast, lung and oesophageal cancer in vitro. In 
chapter 3, we aimed to identify the role of LKB1 signalling in sporadic gastrointestinal cancer 
by investigating the effect of reduced LKB1 expression on human colon cancer cells.
The pathogenesis and molecular mechanisms underlying PJS-associated gastrointestinal 
cancer development are still poorly understood. Although a hamartoma-carcinoma sequence 
has been described by some, this is still debated. If LKB1 acts as a haplo-insufficient tumour 
suppressor gene, which additional oncogenic triggers are involved in carcinogenesis in PJS? 
In chapter 4 and 5 we analysed tissue of both gastrointestinal carcinomas and dysplastic 
hamartomas of PJS patients to identify molecular alterations underlying PJS-associated 
gastrointestinal carcinogenesis.
To prevent complications of hamartomas and, at a later age, to detect (pre)malignant le-
sions, surveillance of the gastrointestinal tract of PJS patients, including the small bowel, is 
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indicated. However, visualization of the small bowel is technically challenging and the optimal 
strategy for surveillance has not been determined yet. Chapter 6 of this thesis gives an over-
view of the currently available techniques to examine the small bowel in PJS patients, and 
proposes a step-up approach for surveillance.
Although PJS is known to be associated with an increased cancer risk, risk estimates and 
data about median age of onset differ widely in literature. This hampers counselling and care 
of patients and interferes with the implementation of surveillance strategies. Given the poor 
prognosis of pancreatic cancer, surveillance of the pancreas could be beneficial for high-risk 
populations. Do PJS patients belong to such a high-risk population? We address this question 
in chapter 7, by determining a reliable risk estimate for pancreatic cancer in a large cohort 
of Dutch PJS patients. Uncertainty also remains around breast cancer surveillance in PJS. It 
is believed that breast cancer risk in PJS patients approaches that of patients with BRCA1/2 
mutations, but no solid studies have been performed to confirm this. In chapter 8, we assess 
the breast cancer risk and clinicopathological features of breast cancer cases in the Dutch 
PJS cohort. Based on these data, we aim to provide a breast cancer surveillance recom-
mendation for female PJS patients.
Both the physical and psychological disease burden associated with PJS might influence 
family planning of patients. Genetic testing before birth could be considered as an extreme 
prevention method. In case of a known LKB1 mutation, two methods for genetic testing of 
an unborn child are available in the Netherlands, i.e. prenatal diagnosis and pre-implantation 
genetic diagnosis. In chapter 9, we investigated the desire to have children in PJS patients 
and their attitudes towards antenatal genetic testing.
Finally, in chapter 10, the results and conclusions of the studies reported in this thesis are 
summarized and discussed.

Chapter 2
Targeting LKB1 signalling 
in hereditary and sporadic 
cancer 
Adapted from:
The long and winding road to rational treatment of cancer associated with LKB1/AMPK/
TSC/mTORC1 signaling
Wendy van Veelen, Susanne E. Korsse, Lianne van de Laar, Maikel P. Peppelenbosch
Oncogene. 2011;30(20):2289-303.
Targeting LKB1 signaling in cancer
S.E. Korsse, M.P. Peppelenbosch, W. van Veelen
Biochim Biophys Acta. 2013;1835(2):194-210
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ABSTRACT
The serine/threonine kinase LKB1 is a master kinase involved in cellular responses such 
as energy metabolism, cell polarity and cell growth. LKB1 regulates these crucial cellular 
responses mainly via AMPK/mTOR signalling. Alterations in this signalling pathway are 
associated with a wide variety of cancers and hereditary hamartoma syndromes. Germline 
mutations in LKB1 cause Peutz-Jeghers syndrome, in which patients develop gastrointestinal 
hamartomas and have an enormously increased risk for developing gastrointestinal, breast 
and gynaecological cancers. In addition, somatic inactivation of LKB1 has been associated 
with sporadic cancers such as lung cancer. The exact mechanisms of LKB1-mediated tumour 
suppression remain so far unidentified, however, the inability to activate AMPK and the result-
ing mTOR hyperactivation have been detected in PJS-associated lesions. Therefore, targeting 
LKB1 in cancer is now mainly focusing on the activation of AMPK and inactivation of mTOR. 
Preclinical in vitro and in vivo studies show encouraging results regarding these approaches, 
which have even progressed to the initiation of a few clinical trials. In this review, we describe 
the functions, regulation and downstream signalling of LKB1, and its role in hereditary and 
sporadic cancers. In addition, we provide an overview of several AMPK activators, mTOR 
inhibitors and additional mechanisms to target LKB1 signalling, and describe the effect of 
these compounds on cancer cells. Overall, we will explain the current strategies attempting to 
find a way of treating LKB1-associated cancer.
21
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LKB1 SIGNALLING AND fUNCTION
The LKB1 protein
The liver kinase B1 (LKB1, also known as serine/threonine kinase 11, STK11) gene encodes 
a 48kDa protein, LKB1, which is ubiquitously expressed in adult as well as foetal tissues, 
particularly in pancreas, liver, testes and skeletal muscle [10,11]. It contains an evolutionary 
conserved serine/threonine kinase domain and a C-terminal region, where some posttrans-
lational modification sites have been identified (Figure 1) [11,36-38]. First, four autophos-
phorylation sites have been described, i.e. threonine (Thr) 185, Thr189, Thr336 and Thr402 
[39,40]. Autophosphorylation of Thr336 seems not to affect its catalytic activity nor its cellular 
localization, however, it may inhibit the cell growth suppressive capacity of LKB1 [40]. In 
addition, four phosphorylation sites have been identified, i.e. serine (Ser) 31, Ser325, Thr363 
(mouse Thr366) and Ser428 (mouse Ser431) [40-42]. Thr363 is phosphorylated by ATM in 
response to ionizing radiation [43]. Phosphorylation of Ser428 by cAMP-dependent kinase 
(PKA), p90RSK, and protein kinase Czeta (PKCζ) is not affecting its catalytic activity, but is 
essential for LKB1 to inhibit cell growth [41,42,44]. The kinases for Ser31 and Ser325 have 
so far not been identified. Finally, a prenylation site, i.e. Cys430 (mouse Cys433), has been 
identified [42]. Since it has been shown that farnesylation at Cys430 is not essential for LKB1 
to suppress cell growth, the functional relevance of this prenylation is not yet understood [41].
kinase domain1 433
49 309
Ser31 Ser325 Thr363
Thr402
Thr185
Thr189 Thr336
Ser428
Cys430
? ? ATM
PKA
p90RSK
PKC
38-43
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P P P
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P
F
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Figure 1. Schematic diagram of human LKB1.
The human LKB1 protein constitutes 433 amino acids. Amino acids 38-43 form a nuclear localization 
signal domain. Amino acids 49-309 form the serine/threonine kinase domain. Four autophosphorylation 
sites have been identified, i.e. Thr185, Thr189, Thr336 and Thr402. Four phosphorylation sites for other 
kinases have been identified, i.e. Ser31, Ser325, Thr363 and Ser428. Cys430 is a farnesylation site.
LKB1 activation
LKB1 contains a nuclear localization signal domain which is likely to be the reason that LKB1 
is normally localized in the nucleus (Figure 1 and 2) [45]. Because LKB1 lacks a nuclear export 
domain of its own, it needs interaction with other proteins in order to be actively exported 
out of the nucleus. Activation of LKB1 is therefore associated with its translocation to the 
cytoplasm which is induced upon formation of a heterotrimer with the STE20-related adaptor 
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(STRADα) and scaffolding mouse 25 (MO25) proteins (Figure 2) [36,39]. By facilitating the 
binding of exportins to LKB1 and acting as a competitor for importin-α/b, STRADα prevents 
nuclear re-localization of LKB1. MO25 merely serves as a stabilizer of the LKB1-STRAD in-
teraction [36]. When in complex with STRADα and MO25 and located in the cytoplasm, LKB1 
phosphorylates and activates kinases of the AMP-activated kinase (AMPK) family (Figure 2) 
[46-48]. Via AMPK and several other downstream mediators, LKB1 regulates crucial cellular 
processes involved in cell polarity, energy metabolism and cell growth (Figure 3).
AMPK1, AMPK2
MARK1, MARK2, MARK3, MARK4
BRSK1, BRSK2
SIK1, SIK2 NUAK1, NUAK2
QSK
SNRK
cytoplasmnucleus
STRAD
LKB1
STRAD
MO25
P
LKB1
Figure 2. LKB1 activation.
Lacking a nuclear export signal of its own, LKB1 resides in the nucleus. Upon binding to STRADα and 
MO25, LKB1 is exported to the cytoplasm and becomes catalytically active. In the cytoplasm, LKB1 has 
been shown to phosphorylate the 14 serine/threonine kinases of the AMPK family.
MARK
BRSK
AMPK
mTOR
p70S6K/4E-BPs
HIF-1/VEGF
ATG13/ULK1/2
P21
P27
P53
HMGCR
ACC
GS PI3K/AKT
PTEN
Isoprenoid synthesis
Fatty acid synthesis
Glycogen synthesis
Energy metabolism
Epithelial and 
neuronal polarity
Polarized cell migration
Asymmetric cell division
Cell polarity
Protein synthesis
Angiogenesis
Autophagy
Cell cycle
Apoptosis/survival
Cell growth
STRAD
LKB1
Figure 3. LKB1 signalling and function.
Via several downstream mediators, LKB1 regulates crucial cellular processes involved in cell polarity, 
energy metabolism and cell growth. In addition, LKB1 regulates hematopoietic stem cell homeostasis. 
Since this seems to be independent of AMPK/mTOR signalling, the underlying molecular mechanisms 
are yet to be identified.
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LKB1 in cell polarity
Originally, the Caenorhabditi elegans and Drosophila melanogaster counterparts of LKB1, 
Par-4 and dLkb1 respectively, have been shown to play major roles in cellular polarity [49,50]. 
LKB1 induces epithelial-cell polarization through sorting of apical and basolateral membrane 
proteins, formation of epithelial junctions and reorganisation of the actin cytoskeleton, which 
is at least in part mediated via activation of AMPKα [51-56]. In addition to activation of AMPKα, 
LKB1 regulates polarization through the activation of MARK isoforms (mammalian counter-
parts of C. Elegans and D. melanogaster Par-1), which play a remarkable role in microtubule 
skeleton organisation [57,58]. Through activation of BRSK (or SAD) proteins, LKB1 regulates 
neuronal migration and axonal outgrowth [59,60]. A role for C. elegans and D. melanogaster 
Par-4/dLkb1 in asymmetric positioning of the mitotic spindle and cytoplasmic determinants 
during mitosis has been established [61]. In mammalian cells, LKB1 has recently been 
shown to be involved in epithelial polarization by controlling Rho GTPases, primary cilium, 
phosphoinositide and Wnt/GSK3β signalling [62-65]. More specifically, LKB1 is involved in 
centrosome positioning, lumen initiation and brush border formation during epithelial morpho-
genesis [63,64]. Together, this shows that LKB1 acts as a master kinase regulating neuronal 
and epithelial polarization, polarized cell migration and asymmetric cell division (Figure 3). 
Given the role of LKB1 in these attributions, normal LKB1 function is required for proper 
function and proliferation of epithelial tissues.
LKB1 in energy metabolism
In addition to the regulation of cellular polarity, AMPK signalling controls lipid and glucose me-
tabolism (Figure 3). In circumstances of energy stress due to either excessive ATP consumption, 
or reduced aerobic ATP production, e.g. in the case of hypoxia, cellular AMP/ATP ratios increase. 
This is sensed by AMPKγ which binds AMP, leading to the complex formation of AMPKα, -β and 
–γ subunits [66-68]. Threonine residue 172 in the activation loop of AMPKα is now accessible 
to be phosphorylated by LKB1 [69-71]. Activated AMPK controls metabolic processes such 
as isoprenoid, fatty acid and glycogen synthesis via regulation of downstream targets such 
as HMG-CoA reductase, acetyl CoA carboxylase (ACC) and glycogen synthase [72-74]. Thus, 
by suppressing energy-consuming processes on the one hand, and enhancing energy gaining 
pathways on the other, AMPK activation by LKB1 aids in restoration of the cellular energy status.
LKB1 in cell growth
Moreover, LKB1 has been associated with cell growth control via multiple different signalling 
pathways (Figure 3). One such major downstream pathway of LKB1/AMPK is TSC/mTOR 
signalling [75]. Activated AMPK phosphorylates TSC2, thereby activating the TSC1:TSC2 
complex [76], which in turn regulates the activity of the mTORC1, a complex consisting of 
mTOR, raptor and mLST8. The activated TSC1:TSC2 complex, which expresses GTPase 
activity towards Rheb, a small G-protein that promotes mTORC1 activity when GTP-bound, 
induces conversion of active GTP-bound Rheb to inactive GDP-bound Rheb which subse-
quently results in inhibition of mTORC1 [77]. In addition to inhibiting mTORC1 via phosphory-
lation of TSC2, AMPK directly phosphorylates raptor resulting in the inhibition of mTORC1 
[78]. mTORC1 plays a key role in protein translation by phosphorylating and activating the 
ribosomal protein S6 kinase (S6K), and through the inhibition of eukaryotic initiation factor 4E 
Chapter 2
24
binding proteins (4E-BPs) [79]. In addition, mTORC1 activation stimulates angiogenesis by 
stabilizing hypoxia-inducible factor 1α (HIF-1α) in conditions of hypoxia [80].
Furthermore, mTORC1 activity inhibits autophagy via phosphorylation of ATG13 and 
ULK1/2 [81,82]. Thus, LKB1 regulates mTOR signalling to control cell growth via different 
pathways and cellular responses. However, recently it has been shown that LKB1 is necessary 
to maintain hematopoietic stem cell (HSC) homeostasis mainly independent of AMPK and 
mTOR [83-85], indicating that also other molecular pathways are involved in LKB1-regulated 
cell growth (Figure 3).
LKB1 is also involved in cell cycle regulation and apoptosis. Reintroduction of LKB1 expres-
sion in cells lacking LKB1 induces cell cycle arrest in G1 [86-92], while knocking down LKB1 
expression triggers cell cycle progression from G1 to S phase [93]. Notably, reintroduction 
of LKB1 catalytic deficient mutants in colorectal cancer (CRC) cells could not induce cell 
cycle arrest, but caused even upregulated expression of the cell cycle inducer cyclin D [92]. 
LKB1-induced cell cycle arrest is mediated by upregulation of the cell cycle inhibitors p21 
and/or p27 [86-90,92,94]. In addition, Lkb1-mediated tumour promotion has been shown to 
be mediated by suppression of p21-dependent growth arrest in vivo [95].
LKB1-mediated cell cycle regulation has been shown to be regulated via p53-dependent 
and p53-independent mechanisms [86,87,91,92,94,96]. Additionally, LKB1 has been shown 
to interact with and phosphorylate p53, and mediate p53-induced apoptosis [86,97,98], while 
in Drosophila dLkb1 induces p53-independent apoptosis via activation of the JNK pathway 
[99]. In mice, compound loss of p53 and Lkb1 accelerates onset and increased incidence 
of polyps, indicating that Lkb1 and p53 cooperate in tumour development [100,101]. LKB1 
mutants have been shown to diminish p53 activity [102]. Thus, LKB1 suppresses cell cycle 
progression and induces apoptosis most likely via suppression of p21, though the role of p53 
in these processes remains contradictory (Figure 3).
Several studies in cells and in mice have shown that LKB1 acts upstream of PTEN (Figure 3). 
In fact, LKB1 has been shown to interact with and phosphorylate PTEN, which was disrupted 
by introducing mutations in LKB1 [103,104]. In addition, LKB1 induces expression and nuclear 
export of PTEN resulting in reduced PI3K/AKT signalling and apoptosis [89,104,105]. This LKB1-
mediated nuclear export of PTEN has been shown to be independent of AMPK/mTOR signalling 
[105]. In vivo, loss of Lkb1 cooperates with Pten loss to accelerate tumourigenesis [106,107]. 
The tumourigenesis in these compound mutant mice was shown to be, at least in part, mediated 
by mTOR signalling since treatment with mTOR inhibitors reduced tumour formation [107,108].
These studies reveal a pleiotropic role for LKB1 in cell polarity, energy metabolism, and 
cell growth, processes that are deregulated in cancer. Most of these processes are mediated 
via AMPK/mTOR signalling, suggesting that this major downstream pathway is a suitable 
candidate to target for therapy against LKB1-associated cancer. However, other responses 
induced by loss of LKB1 have been shown to be independent of AMPK and/or mTOR signal-
ling, suggesting that the tumour suppression functions of LKB1 are, at least in part, also 
mediated via other downstream effectors.
LKB1 IN DISEASE
Through specific genetic alterations in different components of the LKB1/AMPK/mTORC1 
signalling pathway, this metabolic pathway is associated with disease (Figure 4). Germline 
inactivation of the tumour suppressor genes PTEN, NF1, LKB1, TSC1 and TSC2 predisposes 
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to a group of rare autosomal dominant inherited hamartoma syndromes, including Peutz-
Jeghers syndrome (PJS). These hereditary disorders are characterized by the development 
of hamartomas in multiple tissues (Table 1). Hamartomatous polyps have a relatively benign 
appearance, but with a markedly disturbed architecture of cells present in the area in which 
they normally occur, i.e. mesenchymal, stromal, endodermal, and ectodermal [109]. Despite 
the fact that these hamartomas follow a relatively benign course, they can cause e.g. bowel 
obstruction, seizures or haemorrhage which may lead to severe complications and even death 
[109]. In addition to the development of multiple hamartomas, these polyposis syndromes are 
associated with the development of a variety of cancers as well.
TSC2
TSC1
mTOR
raptor
Peutz-Jeghers
Syndrome
Tuberous Sclerosis
Complex
Neurofibromatosis
Type 1
PTEN Hamartoma
Tumor Syndromes
PKB
PI3K PTEN
PIP3
ERK
RSK
RAS
AMPK
AMPKAMPK
NF1
STRAD
LKB1
Figure 4. LKB1/AMPK/mTOR signalling in hamartomas sydromes.
Genetic alterations in the LKB1/AMPK/mTOR pathway are involved in several hereditary hamartomas 
syndromes. Germline inactivation of the tumour suppressor PTEN, which normally inhibits PI3K/PKB 
signalling, predisposes to a variety of hamartomas syndromes grouped as PTEN hamartomas tumour 
syndromes. Germline inactivation of the tumour suppressor NF1, an inhibitor of the RAS/ERK pathway, 
predisposes to NF1. Germline inactivation of the tumour suppressor LKB1, the activator of AMPK, 
predisposes to PJS. Germline inactivation of the tumour suppressors TSC1 or TSC2 both predispose to 
TSC. Tumour suppressors are indicated in white.
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Peutz-Jeghers syndrome
Peutz-Jeghers syndrome (PJS) is a rare autosomal dominant disorder. PJS is characterized 
by mucocutaneous hyperpigmentation, gastrointestinal hamartomatous polyposis and a 
highly increased cancer risk. All PJS patients develop early-onset hamartomatous polyposis 
throughout the entire gastrointestinal (GI) tract. PJS polyps are clearly distinct from the more 
common adenomatous polyps, which are premalignant lesions characterized by a dysplastic 
epithelium (‘adenoma-to-carcinoma sequence’). In contrast, the overlying epithelium in ham-
artomatous polyps is usually well differentiated but can be hyperplastic [110]. Adenomatous 
and carcinomatous changes in PJS-hamartomas have been reported, though rarely [111-
113]. Therefore, the gastrointestinal hamartomas and carcinomas developed in PJS patients 
are believed to be two distinct entities, though this is still debated. PJS patients are also at 
increased risk for developing cancer at a relatively young age, and at an age of 70 years a 
cumulative risk of 37-93% have been determined for these patients [24,114]. A wide spectrum 
of malignancies has been described, with the highest cumulative risks attributed to cancers 
of gastrointestinal (38-93%), breast (32-54%) or gynaecological (13-18%) origin [114]. The 
most frequently observed gastrointestinal cancers constitute CRC, but also small intestinal, 
gastric and pancreatic are observed more frequently compared to the general population 
[24,114,115]. In addition, rare tumours such as testicular or ovarian sex cord tumours, Sertoli-
cell tumours and adenoma malignum of the uterine cervix have been associated with PJS.
The tumour suppressor gene LKB1
In 1997, the PJS susceptibility locus was mapped to chromosome 19p13 [116]. One year 
later, inactivating germline mutations in LKB1 were detected to cause predisposition for PJS 
[10,11]. With the currently available techniques, an LKB1 germline mutation can be detected in 
approximately 80-94% of clinically affected PJS families. Around 25% of cases are sporadic, 
thought to be due to de novo germline LKB1 mutations.
Around 150 different mutations without a hotspot in LKB1 have been associated with PJS, 
without a clear genotype-phenotype correlation [117]. The majority of mutations result in 
truncation or abnormal splicing, although in approximately 20% of the cases a missense 
mutation in the kinase domain of LKB1 is detected. It has been suggested that truncating 
mutations tend to associate with an earlier age of onset of disease as compared to PJS 
cases associated with missense mutations in LKB1 [16]. The vast majority of PJS-associated 
missense mutations are located in the serine/threonine kinase domain, resulting in impaired 
kinase activity and cell growth suppressive capacity [11,36-38]. In addition, a substantial 
proportion of PJS-associated mutations are located in the C-terminus of LKB1. These muta-
tions have been shown to impair cellular polarity but not LKB1 kinase activity or its ability to 
promote growth arrest [118]. For several PJS-associated mutations, it has been shown that 
the resulting LKB1 mutants are retained in the nucleus [11,36-38].
LKB1 is classified as a tumour suppressor gene, implying that both alleles need to be inac-
tivated to contribute to tumour development. Loss of heterozygosity (LOH) of the remaining 
LKB1 allele has been detected in PJS-hamartomas, but it is observed more frequently in 
carcinomas [119,120]. This suggests that bi-allelic loss of LKB1 is not necessary for ham-
artomatous polyp development, but favours progression to carcinoma. Therefore, LKB1 is 
suggested to act as a haplo-insufficient tumour suppressor gene. Because LOH does not 
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necessarily take place in the invading epithelial cancer cells, there is still some controversy 
about where LKB1 loss contributes to carcinogenesis in PJS patients.
To investigate the tumour suppressor function of LKB1, mouse models have been gener-
ated and characterized. The original studies characterizing Lkb1 function in mice showed 
that Lkb1-/- mice die at embryonic stage, highlighting a crucial role during early development 
[121]. Mice with a heterozygous deletion are tumour prone, showing an increased incidence 
of spontaneous tumour formation as well as increased susceptibility to toxicity-induced 
carcinogenesis [35,91,121,122]. Moreover, Lkb1+/- mice develop hamartomatous polyps in 
the stomach and intestines, but, similar to their human counterparts, these polyps appear to 
lack or have only low malignant potential [34,35,122]. Finally, conditional Lkb1 loss in various 
tissues is also associated with the development of cancer [123-126]. The interesting conclu-
sion from these studies is that LKB1 is not likely to be a driver mutation in cancer, but as a 
secondary mutation it might enhance tumourigenesis.
LKB1 haplo-insufficiency
LKB1 is classified as a tumour suppressor gene, implying that both alleles need to be inac-
tivated to contribute to tumour development. Loss of heterozygosity (LOH) of the remaining 
LKB1 allele has been detected in PJS-hamartomas, but it is observed more frequently in 
carcinomas [119,120]. This suggests that bi-allelic loss of LKB1 is not necessary for ham-
artomatous polyp development, but favours progression to carcinoma. Therefore, LKB1 is 
suggested to act as a haplo-insufficient tumour suppressor gene. The haplo-insufficiency of 
Lkb1 has been confirmed in mice, where neither loss of the wild-type Lkb1 allele nor loss of 
expression of Lkb1 could be detected in most gastrointestinal polyps of heterozygous Lkb1 
knockout mice [34,35,122]. These results suggest that partial loss of Lkb1 is sufficient for 
tumour development. Haplo-insufficient tumour suppressor genes usually evoke their role 
in tumourigenesis in the context of additional oncogenic triggers. In the case of Lkb1, it has 
been shown that additional loss of Pten or p53, or additional oncogenic activation of Kras 
synergizes with Lkb1 loss in order to promote tumour formation [95,100,101,106]. In a subset 
of gastrointestinal hamartomas of heterozygous Lkb1 knockout mice loss of the wildtype 
Lkb1 allele or Lkb1 expression could be detected specifically in the epithelial compartment, 
suggesting that Lkb1 exerts its tumour suppressive functions mainly in the epithelium [34]. 
However, myofibroblast-specific loss of Lkb1 in mice has been shown to be sufficient for 
gastrointestinal hamartoma development, indicating that Lkb1 suppresses tumour formation 
through signalling in mesenchymal cells [127]. No phenotypical differences were observed 
between polyps of mice with mono-allelic or bi-allelic Lkb1 deletion, suggesting that also 
in stromal cells Lkb1 acts as a haplo-insufficient tumour suppressor [127]. Lkb1-deficient 
mesenchymal cells stop producing TGFβ, which is a crucial factor suppressing tumour initia-
tion and progression. Interestingly, LKB1 has recently been shown to inhibit Smad4-mediated 
transcriptional activation of TGFβ targets in epithelial cells [128], which might indicate that 
LKB1 controls TGFβ signalling at both ends. However no strategies for the moment have 
been devised for targeting the TGFβ pathway, likely due to its more complex role in cancer 
late progression.
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Table 2. Frequencies of LKB1 mutations/deletions and of LOH of 19p13.3 reported in sporadic 
carcinomas.
Type of sporadic cancer Mutation/
Deletion
LOH 19p13.3 Reference
Gastrointestinal
CRC 0/20 (0%) 13/50 (26%) 143
0/72 (0%) 144
7/13 (54%) 10/19 (53%) 131
1/71 (1%) 10/52 (19%) 145
1/80 (1%) 146
0/50 (0%) 15
5/38 (13%) 147
5/23 (22%) 148
3/8 (38%)1 149
Small intestinal 0/6 (0%) 146
Gastric 3/28 (11%) 150
0/8 (0%) 151
0/40 (0%) 146
Pancreatic 1/12 (8%) 151
3/103 (3%) 8/23 (35%) 152
1/20 (5%)2 5/20 (25%)2 153
0/5 (0%)3 154
Breast and gynaecological
Breast 0/62 (0%) 3/40 (8%) 155
5/30 (17%) 148
9/16 (56%)1 149
Ovarian 0/45 (0%) 12/49 (24%) 156
SCTAT 0/12 (0%)4 151
1/12 (8%)4 156
0/5 (0%) 0/2 (0%) 157
0/12 (0%) 12/29 (41%) 158
Cervical 1/26 (4%) 151
0/8 (0%)5 2/8 (25%)5 157
Testicular 1/28 (4%) 143
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Table 2. Frequencies of LKB1 mutations/deletions and of LOH of 19p13.3 reported in sporadic 
carcinomas.
Type of sporadic cancer Mutation/
Deletion
LOH 19p13.3 Reference
Lung
7/12 (58%)1 149
NSCLC adenocarcinoma 1/12 (8%) 151
5/20 (25%) 21/30 (70%) 159
7/155 (5%) 140
27/80 (34%) 142
3/81 (4%) 141
13/207 (6%) 160
0/51 (0%) 161
4/7 (57%)6 162
NSCLC squamous cell 0/12 (0%) 151
8/42 (19%) 142
0/14 (0%) 141
5/92 (5%) 160
6/67 (9%) 161
NSCLC large cell 0/3 (0%) 151
1/7 (14%) 142
0/2 (0%) 141
3/11 (27%) 161
SCLC 0/1 (0%) 151
0/1 (0%) 141
Additional
Melanoma 0/6 (0%) 151
1/15 (7%) 163
2/35 (6%) 164
2/8 (25%)1 149
Soft tissue 0/24 (0%) 151
Renal 0/19 (0%) 151
2/8 (25%)1 149
Brain 31/248 (13%)7 149
CRC: colorectal carcinoma; LOH: loss of heterozygosity; NSCLC: non-small cell lung cancer; SCLC: 
small cell lung cancer; SCTAT: sex-cord stromal tumours of the ovary.
1Brain metastases from this cancer type
2Intraductal papillary mucinous neoplasms
3Pancreatic acinar cell carcinomas
4Ovarian granulosa cell tumours
5Adenoma malignum of uterine cervix
6Mucinous bronchioloalveolar carcinomas
7Various histological subtypes of which LOH was most frequently observed in gliomas (17%) and 
pituitary adenomas (19%).
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LKB1 IN SPORADIC CANCER
Despite the strong association between LKB1 mutations and increased risk for carcinogen-
esis in PJS, LKB1 is not commonly mutated somatically in sporadic cancers, except for lung 
cancer (Table 2). In contrast, allelic loss, LKB1 promoter hypermethylation or reduced LKB1 
expression is observed in a wide variety of sporadic cancers (reviewed in [129,130]) (Table 2). 
Because of the suggested haplo-insufficiency of LKB1, this could indicate that loss of LKB1, 
probably in combination with additional oncogenic events, is involved in the development 
and/or progression of these sporadic cancer types.
Colorectal cancer
Since PJS patients have an increased risk for developing CRC [24], LKB1 mutation analyses 
have been set-up for sporadic CRC as well. However, somatic LKB1 mutations have been 
detected sparsely in these carcinomas (Table 2). In contrast, one study reported a mutation 
frequency of 54% in carcinomas in the left-sided colon [131]. Therefore it was suggested that 
LKB1 plays an important role in left-sided colon cancer carcinogenesis, however, in a later study 
no somatic LKB1 mutations could be detected in 50 left-sided colon carcinomas [15] (Table 2). 
LOH of 19p13.3 has been detected more frequently in sporadic CRC with frequencies ranging 
from 13% to 53% (Table 2). This suggests that reduced levels of LKB1 may contribute to the 
development of sporadic CRC, though not through mutational inactivation. Lkb1-deficient mice 
did not develop intestinal carcinomas, nor did the hamartomatous polyps progress to a more 
malignant histological phenotype when p53 was additionally deleted [100,101]. Therefore, it 
remains elusive how loss of LKB1 contributes to colorectal carcinogenesis.
Pancreatic cancer
PJS patients have an increased risk for developing pancreatic cancer, but somatic LKB1 
mutations have been detected only in a small proportion of sporadic pancreatic carcinomas 
(Table 2). In addition, a low frequency of reduced LKB1 expression has been observed in these 
carcinomas [132]. However, reintroduction of LKB1 expression in LKB1-silenced pancreatic 
cancer cells induced apoptosis, suggesting that LKB1 suppresses pancreatic cancer cell 
survival in vitro [133]. Deletion of Lkb1 in murine pancreatic epithelial cells of the islets, ducts, 
and acini resulted in the development of ductal metaplasia and cystadenomas, but no forma-
tion of pancreatic intraepithelial neoplasia (PanIN) or adenocarcinomas [95,124]. Introduction 
of an oncogenic Kras mutation in heterozygous Lkb1 knockout mice resulted in formation 
of pancreatic ductal adenocarcinomas, indicating that Lkb1 is a haplo-insufficient tumour 
suppressor and cooperates with Kras in the development of pancreatic cancer in mice [95].
Breast cancer
Somatic mutations in LKB1 and LOH of 19p13 is not observed frequently in primary sporadic 
breast carcinomas, however, LOH was frequently detected in brain metastases from breast 
carcinomas (Table 2). In addition, it has been shown that LOH of the LKB1 locus in primary 
breast carcinomas increased significantly as the tumours progressed to poorer histological 
grade, and that low LKB1 expression in breast carcinomas is associated with poorer histologi-
cal grade, presence of lymph node metastasis and a shorter overall survival [88,134,135]. In 
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line with these observations, it has been shown that LKB1 suppresses breast cancer cell 
migration and invasion in vitro, and tumour growth, microvessel density and lung metastasis 
in vivo [136,137]. Together, this suggests that loss of LKB1 is a late event in breast cancer and 
promotes breast cancer progression.
Lung cancer
Despite the fact that lung cancer is not clearly associated with PJS, LKB1 is the third most 
frequently mutated gene in sporadic non-small cell lung carcinomas (NSCLC). Though the 
proportion of missense mutations seems to be higher among the somatic mutations in spo-
radic cancer (45%) than among the germline mutations in PJS patients (21%), the mutations 
detected in NSCLC comprise mainly nonsense mutations or a combination of indels or large 
intragenic deletions on one LKB1 allele - resulting in truncation of the protein - plus large chro-
mosomal deletions on the other allele [130,138]. Somatic LKB1 mutations are most frequently 
detected in adenocarcinomas, but also in other histological subtypes of NSCLC (Table 2). 
Notably, LKB1 mutations are more frequently observed in NSCLC of Caucasians compared 
to East Asian populations (reviewed in [139]). In addition, LKB1 mutations frequently coincide 
with KRAS mutations. NSCLC patients with LKB1;KRAS compound mutations tend to have 
a poorer prognosis compared to patients with KRAS-mutated NSCLC without a concomitant 
LKB1 mutation, suggesting that loss of LKB1 induces more aggressive tumour phenotypes 
[140,141]. This is also shown in mice where double mutant Lkb1;Kras mice develop more 
aggressive tumours with higher tumour multiplicity, multiple NSCLC histologies and more 
frequent metastasis [142].
Overall, loss of LKB1 is involved in cancers associated with PJS as well as with a variety of 
sporadic malignancies, where it is associated with tumour progression. Therefore, LKB1 and 
its downstream signalling pathways suit a perfect target for therapeutic intervention of these 
cancers.
TARGETING LKB1 SIGNALLING IN CANCER
Since various cancers have been associated with impaired AMPK activation and/or mTOR inhi-
bition, whether or not triggered by loss of LKB1, AMPK/mTOR signalling has been suggested to 
serve a suitable target for cancer treatment. Both pharmacological AMPK activators (metformin) 
and mTOR inhibitors (rapamycin and its analogs sirolimus, everolimus and temsirolimus) are 
available and used in clinical settings. In addition to these clinically approved drugs, additional 
compounds affecting LKB1 signalling have been identified and are being tested in preclinical 
settings for their efficacy as anti-cancer agents. Since the discovery of LKB1 as the causative 
gene for PJS, and its signalling routes regulating cell growth, several studies have been focusing 
on targeting LKB1/AMPK/mTOR signalling in order to treat PJS-associated tumours.
Metformin
In the 1970s, metformin, a biguanide (Figure 5A), was approved by the Food and Drugs 
Administration (FDA) for the treatment of Diabetes Mellitus type 2 (DM2) in Europe, and in 
1995 in the USA. Since then, millions of persons are using metformin, which has been shown 
to increase overall survival and prevent macrovascular complications in DM2 patients [165]. 
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Metformin is also used successfully in polycystic ovarian syndrome (PCOS) and the man-
agement of the metabolic syndrome [166,167]. The efficacy of metformin in these metabolic 
disorders is attributed to the potential of metformin to reduce hepatic gluconeogenesis and 
improve insulin sensitivity [168]. Metformin has been shown to be an activator of AMPK, which 
is one of the master regulators of these metabolic processes (Figure 5C) [169]. The interest in 
metformin as an anti-cancer drug arose when population studies showed that metformin use 
is associated with a significant reduction of neoplasms in general, and of breast, pancreatic 
and prostate cancer in particular [168,170,171]. Therefore, metformin might also serve as an 
anti-tumour agent in cancer prevention and treatment.
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Figure 5. Metformin and rapamycin target LKB1 signalling.
A. Chemical structure metformin. B. Chemical structure rapamycin (sirolimus). C. Both metformin 
and rapamycin target the LKB1/AMPK/mTOR pathway. Metformin induces activation of AMPK via 
upregulation of cellular AMP:ATP ratios, resulting in inhibition of mTOR. Rapamycin is a direct mTOR 
inhibitor. By binding to FKBP12 it induces dissociation of the mTOR complex c (mTORC1) consisting of 
mTOR, raptor, and mLST8.
The anti-tumoural effect of metformin could partly be explained by its action in improving 
blood glucose and insulin levels [172]. However, metformin induces more direct anti-tumour 
responses in cancer cells as well. Several in vitro studies have shown that metformin treat-
ment inhibits cell growth, induces apoptosis, and reduces migration and invasion in a variety 
of human cancer cell lines (Table 3). The anti-proliferative effects have been shown to be 
mediated via inhibition of insulin-like growth factor-1 (IGF-1) signalling [173-176], but also via 
suppression of genes inducing cell cycle S- and M-phases [177-179]. The apoptosis-inducing 
effects of metformin have been reported to be p53-dependent, mediated by downregulation 
of the Bcl-2 protein family, targeting ERK and STAT3 signalling, and through activation of the 
JNK/p38MAPK pathway [180-184].
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Table 3. Metformin treatment-induced cellular responses in cancer cell lines.
Cancer cell type Inhibiting
cell growth
Inducing
apoptosis
Inhibiting
migration/invasion
Reference
Breast1    174, 178, 179, 181, 184-188
Pancreas    175, 176, 189, 190
Colon2  191, 192
Stomach  193
Lung3   173, 180
Ovary  183
Prostate   182, 191
Endometrium  194
Leukemia4  195
1Part of the actions have been detected in triple-negative breast cancer cells.
2These actions have been detected in P53-deficient colon cancer cells specifically.
3Non-small cell lung cancer cells
4BCR-ABL-positive chronic myeloid leukemia cells
In addition to these anti-proliferative and pro-apoptotic effects of metformin in vitro, metfor-
min treatment reduces growth of various tumour types and/or delays tumour onset in animal 
models (Table 4). Contradictory effects on angiogenesis and metastasis have been reported in 
xenograft mouse models (Table 4). Metformin treatment reduced tumour growth, microvessel 
density and metastasis in ovarian cancer cell tumours, while it promoted tumour growth and 
the angiogenic phenotype in ERα-negative breast cancer cell tumours (Table 4) [196,197]. 
In another high-energy diet fed xenograft mouse model, metformin did reduce growth of 
primary triple-negative breast cancer cell tumours, but did not affect metastasis (Table 4) 
[198]. These results suggest that the effects of metformin on tumour progression depend on 
the tumour type and/or additional circumstances such as hormonal and metabolic status. 
Notably, metformin potentiates the effects of chemotherapeutic agents, such as cisplatin, pa-
clitaxel, doxorubicin and gemcitabine, suggesting that metformin serves a potential adjuvant 
in conventional chemotherapy [196,199-204].
Most of the in vitro and in vivo anti-tumoural actions of metformin have been associated 
with AMPK activation and/or reduction in mTOR activity [182,191,214-216]. However, other 
studies specifically report AMPK-independent mechanisms of action of metformin as well 
[213,217,218]. Even though AMPK is activated upon metformin treatment, AMPK is not the 
direct target of metformin. Metformin is suggested to directly target complex I of the mito-
chondrial respiratory chain which evokes a rise in cellular AMP:ATP ratios [219,220]. This 
subsequently potentiates AMPK to be phosphorylated and activated by LKB1. Interestingly, 
metformin has been shown to induce LKB1 cytosolic translocation [102,221]. Contradictory 
results are reported about the requirement of LKB1 in metformin-induced AMPK activation 
and subsequent effects on metabolism in cells [106,217,221-225]. However, in women with 
PCOS single nucleotide polymorphisms in LKB1 were associated with a significantly reduced 
response to metformin treatment [226]. Moreover, metformin failed to inhibit cell growth in 
cells lacking LKB1, indicating that LKB1 is required for metformin-induced growth inhibitory 
effects [106,217]. Therefore, it is proposed that metformin is not a suitable drug for the treat-
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ment of tumours showing bi-allelic loss of LKB1 and/or loss of LKB1 expression, as is often 
the case in PJS patients. In these patients, metformin might, however, be a useful drug to 
prevent hamartoma and carcinoma development and outgrowth, although studies testing this 
in Lkb1-mouse models and in PJS patients have not yet been performed.
Although scarce, clinical evidence for anti-cancer effects of metformin have been reported 
for sporadic cancer. Metformin use suppressed colonic epithelial proliferation and formation 
of rectal aberrant crypt foci, an early feature of CRC, in non-diabetic patients [214]. More re-
Table 4. Metformin treatment in animal models.
Tumour type Model Effect of metformin treatment Reference
Pancreas Nu/nu mice xenograft
MiaPaca-2 cells, Panc-1 cells
Reduced tumour growth 176
Nu/nu mice xenograft
LNCaP cells
Reduced tumour growth 205
Syrian golden hamsters + BOP
+ high-fat diet
Reduced tumour incidence 206
Colon/Intestinal Nu/nu mice xenograft
HCT116 cells1
Reduced tumour growth 192
C57/BL6 mice xenograft
MC38 cells + high-energy diet
Reduced tumour growth 207
Balb/c mice + AOM Reduced tumour growth (mild) 208
Apc(Min/+) mice Decreased incidence of large (>2mm) 
adenomas
209
Breast Nu/nu mice xenograft
MDA-MB-231 cells2
Reduced tumour growth 185
Nu/nu mice xenograft
MDA-MB-435 cells3
Increased tumour growth, increased 
angiogenesis
197
Balb/c mice xenograft
66cl4 cells2 + high-energy diet
Reduced primary tumour growth, no effect 
on metastasis
198
Sprague-Dawley rats + NMU Delayed tumour onset 210
HER2/neu transgenic mice Decreased tumour incidence and size, 
delayed tumour onset
211
Ovarian Nu/nu mice xenograft
A2780 cells
Reduced tumour growth, and microvessel 
density, and metastatic nodules
196
Gastric Nu/nu mice xenograft
MKN74 cells
Reduced tumour growth 193
Lung A/J mice + NKK Reduced tumour growth 212
Melanoma C57/BL6 mice xenograft
B16 cells
Reduced tumour growth 213
Various4 Lkb1fl/+;Pten+/- mice Delayed tumour onset 106
AOM: azoxymethane; BOP: N-nitrosobis-(2-oxopropyl)amine; NKK: 4-(methylnitrosamino)-1-(3-pyridyl)-
1-butanone (tobacco carcinogen); NMU: N-methyl-N-nitrosourea.
1P53-deficient
2Triple-negative
3ERα-negative
4Intestinal polyps, lymphomas, pheochromocytomas, prostate -, breast - , pancreatic carcinomas
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cently, anti-proliferative effects of metformin use in non-diabetic women with operable invasive 
breast cancer have been described [227]. All epidemiologic, preclinical and clinical evidence 
has led to the design of a number of prospective clinical trials investigating metformin therapy 
for cancer in the neoadjuvant and adjuvant (in combination with standard chemotherapy or 
hormone therapy) settings (www.clinicaltrials.gov). The majority of studies concern breast, 
prostate, and pancreatic cancer, in line with previous observations of population studies. Two 
phase II trials investigate the use of metformin as chemopreventive agent in pre-malignant 
conditions, i.e. Barrett oesophagus (NCT01447927) and colorectal adenomas (NCT01312467). 
In addition, one phase III trial is currently recruiting participants (NCT01101438), evaluating 
the effects of metformin on early-stage breast cancer outcomes, including recurrence and 
death. Results of these trials are awaited.
In addition to metformin, other compounds such as TZDs [228], statins [229] and D942 [230] 
have been shown to activate AMPK indirectly by inhibiting mitochondrial ATP production, 
thereby increasing the cellular AMP/ATP ratio. Also natural polyphenols such as berberine and 
resveratrol have been identified as indirect activators of AMPK [231,232]. AICAR is another 
indirect AMPK activator which, after uptake by the cells, is converted to ZMP, an AMP mimetic 
that binds to the AMPKγ subunit [233,234]. Novel direct AMPK activators such as A-769662 
[235] and PT1 [236] have been identified, of which A-769662 has been shown to target AMPK 
subunit β1 [237] while PT1 activates both α1 and α2 subunits by reducing its auto-inhibition. 
Preclinical studies have shown that these AMPK activators can inhibit tumour cell growth 
[106,238-244].
Rapamycin
In 1999, rapamycin (sirolimus), a macrolide (Figure 5B) was approved as an immuno-
suppressant by the FDA, and used in organ transplantation to prevent allograft rejection 
[245]. Rapamycin specifically inhibits mTOR signalling by binding to the cytosolic FK-binding 
protein-12 (FKBP-12). This rapamycin-FKBP-12 complex binds to the mTOR protein resulting 
in the dissociation of mTORC1 (Figure 5C) [246]. Because of the discovery of hyperactivated 
mTOR signalling in a variety of human cancers, rapamycin got attention for its putative ef-
ficacy in inhibiting cancer cell growth. Numerous studies have revealed that rapamycin 
inhibits growth of several cancer cell types such as breast, pancreas, prostate, kidney and 
lung in vitro, and reduces tumour growth and formation of metastases in tumour xenograft 
animal models [247-251]. Notably, rapamycin has been shown to increase the sensitivity for 
chemotherapy (gemcitabine) and radiotherapy in vitro and in vivo [252-255]. Additional in 
vivo studies demonstrated that treatment with rapamycin reduces tumour growth in differ-
ent genetically engineered mouse models that spontaneously develop tumours (Table 5). In 
these models, mTOR signalling was activated by deletion of e.g. Lkb1, Tsc1 or Tsc2, Nf1, or 
Pten, but also by overexpression of Akt or Neu/ErbB2 (Table 5). Since these genetic events 
are common events in sporadic cancers as well as in cancers associated with hereditary 
hamartoma syndromes such as PJS, tuberous sclerosis complex (TSC), neurofibromatosis 
(NF) and Cowden’s Disease, rapamycin has been suggested to serve an effective anti-tumour 
drug in those disorders [256].
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Table 5. Genetically engineered tumour mouse models in which rapamycin treatment reduced tumour 
growth.
Model Tumour type Reference
Lkb1+/- mice PJS-like gastrointestinal polyps 257-260
ApcD716 mice Intestinal polyps 261
Apc(Min/+) mice Intestinal polyps 262
Basal colonic crypt cell-specific Apc-/- mice
(Adeno-Cre)1
Distal colon tumours 263
cis-Nf1+/−:p53−/− mice Malignant peripheral nerve sheath tumours 264
Tsc2+/- mice Renal cystadenomas and liver hemangiomas 265, 266
ENU-treated Tsc2+/- mice Renal cystadenomas 267
Pten+/- mice Pheochromocytomas and endometrial 
hyperplasia
268
Endometrial-specific Lkb1-/- mice (Sprr2f-Cre) Invasive endometrial carcinomas 269
MISIIR-TAg transgenic mice Ovarian tumours 270
Ovarian-specific Apc-/-;Pten-/- mice (Adeno-Cre)2 Ovarian endometrioid adenocarcinomas 271
Pten+/-;TRβPV/PV mice Follicular thyroid carcinomas 272
Bladder-specific Pten-/-;p53-/- mice (Adeno-Cre)3 Invasive bladder carcinomas 273
Prostate-specific Pten-/- mice (Pb-Cre4) Prostate tumours 274
Pb-Akt1 transgenic mice Prostate tumours 275
MMTV-NeuYD transgenic mice Mammary tumours 276
MMTV-NeuYD;VEGF transgenic mice Mammary tumours 276
MMTV-c-Neu/ErbB2 transgenic mice Mammary tumours 277
MMTV-PyMT transgenic mice Mammary tumours 278
BK5-ErbB2 transgenic mice Gallbladder tumours 279
ENU: N-ethyl-N-nitrosourea; PJS: Peutz-Jeghers syndrome.
1Adeno-Cre delivery in distal colon
2Adeno-Cre delivery in ovarian bursae
3Adeno-Cre delivery in bladder lumen
Clinical trials have been set-up to test the efficacy of rapamycin in cancer patients, and 
in particular for patients with renal cell carcinoma (RCC), TSC or pancreatic neuroendocrine 
tumours (NETs). In an international randomized phase III trial, the efficacy of temsirolimus to 
treat RCC has been compared to conventional interferon (IFN)α treatment (NCT00065468). 
Temsirolimus superiorly improved progression-free and overall survival in these patients [280]. 
A randomized placebo-controlled phase III trial documented that the use of everolimus in 
patients with advanced RCC after progression on sunitinib and/or sorafenib stabilized tumour 
progression, and improved progression-free survival with acceptable tolerability (RECORD-1, 
NCT00410124) [281,282]. In two non-randomized, open-label trials (NCT00457808 and 
NCT00490789), it has been shown that sirolimus treatment of patients with TSC or sporadic 
lymphangioleiomyomatosis (LAM) resulted in regression of angiomyolipomas, however, these 
tumours tended to increase in volume after the therapy was stopped [283-285]. In a prospec-
tive, open-label phase I/II trial (NCT00411619), everolimus treatment of patients with subep-
Chapter 2
38
endymal giant cell astrocytomas (SEGA) was associated with marked reduction in tumour 
volume and seizure frequency [286]. A multicentre phase II trial (NCT00126672), showed that 
sirolimus treatment of TSC patients induced regression of kidney and liver angiomyolipomas, 
and SEGAs [287]. Two phase II trials showed that everolimus, both alone and combined with 
octreotide long-acting release (LAR), improved disease control in patients with advanced NETs 
[288,289]. Two placebo-controlled phase III trials have been published investigating everoli-
mus plus octreotide LAR versus octreotide LAR alone in patients with advanced carcinoids 
(RADIANT-2, NCT00412061) and everolimus monotherapy for advanced pancreatic NET (RA-
DIANT-3, NCT00510068). In both studies everolimus improved progression-free survival with 
a low rate of severe adverse events [290,291]. Both temsirolimus (in May 2007) and everolimus 
(in March 2009) have been approved by the U.S. Food and Drug Administration (FDA) for the 
treatment of advanced RCC after failure of treatment with sunitinib or sorafenib. In October 
2010, the FDA approved the use of everolimus to treat subependymal giant cell astrocytomas 
in individuals with TSC who require treatment but are not candidates for surgery. In May 2011, 
everolimus has also been approved to treat patients with progressive NETs of the pancreas 
that are unresectable, locally advanced or metastatic.
Clinical studies to test the efficacy of mTOR inhibiting drugs in other cancers such as lung, 
breast, and CRC are currently ongoing. Besides the relatively high frequency of LKB1 muta-
tions in sporadic NSCLC, mutations in EGFR and activation of AKT are frequently detected in 
these tumours as well [292,293]. Though all these events result in increased mTOR activity, the 
results of clinically inhibiting mTOR in NSCLC are so far not promising. Combined everolimus/
gefitinib therapy in patients with advanced NSCLC led to a partial response in only 13% of the 
patients (8/62, of which two patients had mutations in KRAS) [294]. The LKB1 mutation status 
in these patients was not reported. As described in this review, loss of LKB1 is detected in 
breast carcinomas, however, loss of PTEN and mutations in PIK3CA has been detected more 
frequently. These genetic events all result in aberrant mTOR signalling, and are associated 
with resistance to hormonal therapy [295,296]. In a randomized placebo-controlled phase III 
trial (BOLERO-2, NCT00863655), postmenopausal women with hormone-receptor positive 
advanced breast tumours, resistant to endocrine therapy alone, were treated with everolimus 
and an aromatase inhibitor, which improved their progression-free survival [297]. This study 
indicates that inhibiting mTOR signalling sensitizes breast carcinomas to hormonal therapy 
in human patients. Also for advanced CRC, in which loss of LKB1 occurs infrequently but 
mTOR hyperactivation has been reported more commonly [298,299], inhibition of mTOR with 
rapamycin analogs has been proposed for reversion of chemotherapy resistance. Several 
phase I and phase II trials are currently investigating this hypothesis by adding everolimus 
or temsirolimus to chemotherapy treatment regimens (www.clinicaltrials.gov). Furthermore, 
results of a phase II trial for the treatment of refractory metastatic CRC in 50 patients with a 
combination of bevacizumab and sirolimus were published last year [300]. Unfortunately, the 
combination of drugs showed modest activity on the disease and considerable side effects.
In addition to the approved rapalogs sirolimus, temsirolimus and everolimus, the efficacy 
of a fourth rapalog, i.e. ridaforolimus, is currently being tested in phase III clinical trials. Be-
sides these mTORC1 inhibitors, dual mTORC1 and mTORC2 inhibitors such as AZD8055 
[108,301,302], PP242 [303]; OSI-027 [291]; WAY-600; WYE-687; WYE-354 [304]; WYE-132 
[305]; KU-0063794 [306]; X-387 [307] have been developed and are currently being tested for 
their efficacy as anti-tumour agent.
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Combining mTOR inhibitors with other specific pathway inhibitors
Rapamycin has been shown to be most effective in cells that rely on AKT signalling for their 
proliferation and tumour growth, whereas cells which depend on other signalling pathways 
for their growth are resistant to rapamycin [248,308,309]. Tumours that are responsive to 
rapamycin may develop resistance when alternative survival pathways, such as the mitogen-
activated extracellular kinase (MAPK/ERK) signalling pathway, become activated [263,308]. 
Combination of rapamycin with other specific pathway inhibitors could solve this problem of 
resistance. Notably, rapamycin has been shown to synergize with specific inhibitors of e.g. the 
EGFR/ErbB2, MEK/ERK and Hedgehog signalling in vitro and in vivo [310-319].
In rapamycin-sensitive as well as rapamycin-resistant tumours, inhibition of mTOR by 
rapamycin treatment induces a feedback loop resulting in upregulation of PI3K/AKT signalling 
[320,321]. Therefore, blocking of both PI3K/AKT signalling and mTOR signalling by combining 
rapamycin with specific PI3K inhibitors (LY294002, Wortmannin, ZSTK474) has been shown 
to be more effective in tumour-growth inhibition than rapamycin alone [321-324]. Recently, 
a new inhibitor has been identified targeting both mTOR and PI3K, i.e. NVP-BEZ235 [325]. 
NVP-BEZ235 is an imidazo-quinoline derivative, which can bind to the ATP-binding cleft of 
both PI3K and mTOR [325]. Several in vitro and in vivo studies have shown that this dual 
inhibitor induces apoptosis and cell cycle arrest in a wide variety of tumour-cell types, and 
in most of these cases, the anti-tumour efficacy of NVP-BEZ235 was greater compared 
to that of rapamycin (e.g. [322,325-332]). Even in chemo-resistant tumour cells, or tumour 
cells which have been shown difficult to treat, dual PI3K/mTOR inhibition by NVP-BEZ235 
efficiently inhibits tumour-cell growth, e.g. in KRAS-mutant NSCLC and in breast cancers 
resistant to ErbB2 inhibitors [333-338]. In addition, NVP-BEZ235 enhances sensitivity to 
chemo- and radiotherapy [339-342]. In some cases, combining NVP-BEZ235 with MEK or 
RAF inhibitors showed an increased efficacy in inhibiting tumour-cell growth, suggesting that 
some cancers require inhibition of both PI3K/mTOR and MEK/ERK signalling pathways for 
efficient anti-cancer treatment [320,343-346]. NVP-BEZ235 has entered phase I/II clinical 
studies for patients with advanced breast, renal, endometrial and other solid cancers (www.
clinicaltrials.gov).
In addition to the NVP-BEZ235 inhibitor, novel dual PI3K/mTOR inhibitors such as PI-
103 [347-349], PF-04691502 [350,351], GDC-0980 [352,353], NVP-BGT226 [354-356], 
GSK2126458 [357], and PKI-402 [358,359] have been developed and are currently under 
investigation for their anti-tumour activities.
Other options to treat PJS-associated tumours
Since germline LKB1 mutations predispose to PJS, LKB1/AMPK/mTOR signalling has been 
proposed as a suitable target for treatment of PJS-associated hamartomas and carcinomas. In 
addition to the preclinical studies using metformin and rapamycin to inhibit tumour cell growth 
in vitro and in vivo as described in this review, other options for targeted treatment have been 
suggested. In tumours of Lkb1+/- mice as well as in tumours of PJS patients, elevated levels 
of cyclooxygenase-2 (COX-2) have been detected [360,361]. Inhibition of COX-2 with cele-
coxib, a non-steroidal anti-inflammatory drug, in Lkb1+/- mice reduced tumour burden and 
was associated with decreased vascularity [362]. In addition, 2 of 6 PJS patients responded 
well to celecoxib treatment as they showed reduced gastric polyposis [362], suggesting that 
inhibition of COX-2 serves a suitable strategy to treat PJS-associated lesions.
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Recently, the SRC protein has been identified as a target of LKB1 in an integrative genomic 
and proteomic approach [363]. In this study, Src was shown to be activated in Lkb1-deficient 
Kras-mutated murine primary and metastatic lung tumours, which was validated in human 
lung carcinoma samples. Inhibition of Src by Dasatinib did not affect tumour growth, but 
restored the sensitivity to PI3K/mTOR/MEK inhibition using NVP-BEZ235 and AZD2644 [363]. 
These results suggest that inhibition of SRC, whether or not in combination with other specific 
inhibitors, might be a suitable approach for treatment of PJS patients as well, although the 
activity status of SRC in PJS-associated lesions has to be determined yet.
CONCLUSION
As described in this review, aberrant LKB1 signalling is involved in a variety of human cancers, 
both in sporadic cancers as well as in cancers associated with hamartoma syndromes like 
PJS. LKB1 signalling has been attributed to a wide diversity of biological processes, involving 
a multitude of downstream mediators. These biological processes are known to be essential 
and deregulated in tumours, indicating the relevance of LKB1 loss in cancer. However, since 
only little is known about the biological consequences of LKB1 loss in carcinomas and the 
molecular mechanisms underlying these biological consequences, the exact tumour suppres-
sor functions of LKB1 are yet to be elucidated. So far, most efforts to target LKB1 signalling in 
cancer have focused on activating AMPK and inhibiting mTOR.
However, since activation of AMPK might require intact LKB1, and since it has been shown 
that some molecular and cellular responses of LKB1 loss are independent of AMPK and/or 
mTOR activity, targeting these two mediators might not be efficient in treating LKB1-associated 
cancer. More insight into the tumour suppressor functions and mediating molecular mecha-
nisms of LKB1 will likely uncover additional and/or novel proteins and pathways to target, in 
order to treat LKB1-associated cancer. Nevertheless, hyperactivation of mTOR downstream 
of LKB1 is also mediated via other major signalling pathways such as the PI3K/AKT survival 
pathway, which is frequently aberrantly activated in cancer. More insights into the genes and 
pathways deregulated in tumours and essential for their growth, will provide novel strategies 
in order to develop therapeutic agents specifically targeting these pathways. In particular, a 
combination of these specific agents, and/or a combination of these agents with conventional 
hormonal, chemotherapy and radiotherapy are most likely to result in efficient anti-cancer 
regimens without inducing therapy resistance.
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ABSTRACT
Cytoskeleton-stabilizing drugs, such as paclitaxel, have become an important component in 
the pharmacological battle against gastrointestinal cancer. However, no examples of genetic 
tumour suppression through cytoskeletal stabilization have been identified. The cell polarity 
kinase LKB1 is an important tumour suppressor in the gastrointestinal tract as evident from 
the high incidence of neoplastic lesions in patients harbouring germline haploinsufficiency of 
the encoding gene. The mechanisms by which LKB1 counteracts malignant disease remain 
however largely obscure. In an effort to obtain insight, we created a panel of LKB1 knock-
down clones from an established LKB1-proficient colon cancer cell line, i.e. HT29. Loss of 
LKB1 did not affect cell growth, but the LKB1-deficient cells displayed increased motility in 
migration assays. The increased cell migration coincided with downregulation of the epithelial 
marker E-cadherin, and upregulation of the cancer stem cell marker CD44. In addition, LKB1-
knockdown cells showed increased levels of phosphorylated PAK, an important effector of the 
Cdc42/Rac motility GTPases, which coincided with a shift in the actin cytoskeleton of LKB1-
inhibited cells. We conclude that LKB1 constitutes a tumour suppressor gene that acts on the 
cancerous process of cell migration through cytoskeletal rearrangement by PAK signalling.
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INTRODUCTION
The treatment of gastrointestinal cancers has been revolutionized by the introduction of cy-
toskeleton stabilizing drugs, such as paclitaxel. Pharmacological stabilization of cytoskeletal 
dynamics is generally considered an important rational avenue for gastrointestinal cancer 
treatment [364]. This has led to the notion that humans likely harbour similar genetic mecha-
nisms limiting cancer progression through cytoskeletal stabilization.
The hereditary Peutz-Jeghers syndrome (PJS) is characterized by the development of mu-
cocutaneous hyperpigmentation and gastrointestinal hamartomatous polyposis [28]. Patients 
afflicted with PJS are also at strongly increased risk for developing gastrointestinal cancer, in 
particular colorectal cancer (CRC) [24]. Predisposition for PJS is a result of inactivating germ-
line mutations in the serine/threonine kinase 11 (STK11) gene - from hereon referred to as the 
liver kinase B1 (LKB1) gene [28]. LKB1 contains an evolutionary conserved serine/threonine 
kinase domain. Activation of LKB1 is associated with its translocation to the cytoplasm upon 
trimerisation of LKB1 with the STE20-related adaptor (STRADα) and scaffolding mouse 25 
(MO25) proteins [36,39]. In the cytoplasm, complexed LKB1 phosphorylates and activates 
AMP-activated kinase (AMPK)α resulting in inhibition of mTOR. Via this canonical pathway, as 
well as via AMPK/mTOR-independent routes, LKB1 acts as a master kinase in regulating cell 
polarity, energy (glucose and lipid) metabolism and cell growth [256,365]. Although the link 
between LKB1 and PJS is undebated, the role of LKB1 in the pathogenesis of PJS-associated 
carcinogenesis is still unclear.
In addition to PJS, LKB1 is involved in sporadic cancers. For instance, LKB1 is the third 
most frequently mutated gene in sporadic non-small cell lung carcinomas (NSCLC) [141,160]. 
Notably, LKB1 mutations in NSCLC frequently coincide with KRAS mutations. NSCLC patients 
with LKB1;KRAS compound mutations tend to have a poorer prognosis compared to patients 
with KRAS-mutated NSCLC without a concomitant LKB1 mutation, suggesting that loss of 
LKB1 induces more aggressive tumour phenotypes [140,141]. This is also shown in mice, 
where lung-specific double mutant Lkb1;Kras mice develop more aggressive tumours with 
higher tumour multiplicity, multiple NSCLC histologies and more frequent metastasis [142].
Sporadic CRC development is usually initiated by activation of the Wnt signalling pathway 
due to mutations in either the Adenomatous Polyposis Coli (APC) gene or the gene encoding 
β-catenin (CTNNB1) [366]. Despite the strong association between germline LKB1 mutations 
and increased risk for developing CRC, LKB1 is rarely mutated somatically in sporadic CRC 
[143,145]. However, LOH of 19p13.3 has been detected in up to 50% of cases, suggesting 
that reduced levels of LKB1 might contribute to the development of sporadic CRC [143,145]. 
Thus, the exact tumour suppressor functions of LKB1 in sporadic and PJS-associated 
colorectal cancer development remain elusive. LKB1-null mouse embryonic fibroblasts es-
cape passage-induced senescence, suggesting a role for LKB1 in limitless replication [34]. 
In addition, in epithelial breast, lung and oesophageal cancer cells, loss of LKB1 increases 
migration and invasion, indicating that LKB1 plays a major role in epithelial cancer cell metas-
tasis [136,364,367-369].
We therefore studied the role of LKB1 in colon cancer by knocking down LKB1 expression 
in human colon cancer cells. We show that LKB1 suppresses colon cancer cell migration, as 
a result of cytoskeletal rearrangement.
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MATERIALS AND METHODS
Cell culture and treatments
The human colon cancer cell line HT29 was cultured in DMEM (Lonza), supplemented with 
5% foetal bovine serum (FBS, Sigma Aldrich) and 1% penicillin/streptomycin (p/s) (Gibco) 
at 37oC;5% CO2. Stable human LKB1-knockdown (iLKB1) and non-targeting control (iNT) 
HT29 cells were generated using Sigma Mission shRNA pLKO-puro lentiviral vectors; LKB1 
shRNA GCCAACGTGAAGAAGGAAATT and control non-targeting shRNA CAACAAGAT-
GAAGAGCACCAA. Cells were selected and maintained in DMEM 5% FBS;1% p/s and 2μg/
ml puromycin (Sigma) at 37oC;5% CO2.
Quantitative PCR and microarray analysis
Total RNA was isolated from cultured cells using TRIzol (Sigma-Aldrich). RNA (1μg) was 
reversely transcribed using an iScriptTM cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA). 
Quantitative PCRs (qPCRs) were performed using SensimixTM SYBR & Fluorescein Kit 
(Quantace, London, UK) and an IQ5 iCycler PCR machine (Bio-Rad). Expression levels were 
corrected for expression of GAPDH, averaged and presented as fold changes. Assay was 
performed three times in duplicate and p values were calculated using the Student t-test. The 
primers used are described in Supplementary Table 1.
For microarray analysis, RNA was isolated from four independent monoclonal HT29-iLKB1 
and four independent monoclonal HT29-iNT lines. RNA quality and quantity controls and gene 
expression profiling (Affymetrix, GeneAtlas 2.0/U133) was performed at the department of 
Biomics (Erasmus MC, Rotterdam, the Netherlands). Raw intensity values of all samples were 
normalized by Robust Multichip Analysis normalization (background correction and quantile 
normalization) using Partek version 6.5 (Partek Inc., St. Louis,MO). The normalized datafile 
was transposed and imported into OmniViz version 6.0.1 (BioWisdom Ltd., Cambridge, UK) 
for further analysis. For each probe set, the geometric mean of the hybridization intensity of 
all samples was calculated. The level of expression of each probe set was determined rela-
tive to this geometric mean and 2log-transformed. The geometric mean of the hybridization 
signal of all samples was used to ascribe equal weight to gene expression levels with similar 
relative distances to the geometric mean. Differentially expressed genes were identified using 
statistical analysis of microarrays. Cutoff values for significantly expressed genes were a false 
discovery rate (FDR) of 0.05 or less and a fold change of 1.5. Functional annotation of the 
statistical analysis of microarrays results was done using Ingenuity Pathway Analysis (Ingenu-
ity, Mountain View, CA).
Quantitative Western blot analysis
Subconfluent cells were lysed in Laemmli sample buffer containing 0.1M DTT, and incubated 
5 min at 95°C. Immunoblotting was performed using fluorescent Odyssey immunoblotting 
(LI-COR Biosciences, Lincoln, NE, USA) [370]. Quantification was performed using Odyssey 
LI-COR software. Primary antibodies employed for immunoblotting are depicted in Supple-
mentary Table 2.
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PepChip analysis
Recombinant active LKB1 (LKB1/STRADα/MO25 complex; Upstate Millipore) was incubated 
with 2μl of filter-cleared activation mix (50% glycerol, 70mM MgCl2, 70mM MnCl2, 400μg/ml 
BSA, 400μg/ml PEG800 [-33P]ATP (1000kBq)) on PepChip arrays (PepScan, Lelystad, The 
Netherlands) for 90 min in a humidified incubator at 37°C, and washed in 1% Tween-20;PBS 
(PBST). Subsequent washes in 2M NaCl;1% Tween-20 followed by PBST were conducted un-
der continuous agitation at 50°C. After air-drying, chips were exposed to a phosphor-imager 
screen for 72 h and the intensity of the spots was analysed by ScanAlyze software.
The PepChip array contains 1024 sequences, spotted in triplicate. PepChip analyses were 
performed twice. The mean intensity of each of the 6 spots was calculated for each sequence, 
and spots deviating more than two times standard-deviation were excluded. Peptides of 
which the average phosphorylation minus 1.96 times the standard deviation was higher than 
the value expected from describing the background distribution were considered to represent 
true phosphorylation events. A list of peptides was generated by ranking-ordering the spots 
and curve-fitting analysis, resulting in an “On” or “Off”-call for each peptide. PepChip peptides 
were annotated in the following signalling pathways/functions: PI3K-PKB-mTOR, Mitogenic, 
G-protein, Nutrient, Cytoskeletal, Mitosis/DNA damage, Immunity and Stemness.
MTT cell viability assay
HT29 cells were seeded 6*104 cells per M24 well and measured at indicated time-points by 
adding 100μl 5mg/ml MTT per well, 30 min incubation at 37°C and replacement of the medium 
by 100μl DMSO. Absorbance (550nm) was measured and averaged. Assays were performed 
three times in duplicate.
Scratch wound-healing assay
Cells were seeded (5*105 cells per M6 well) and incubated at 37oC;5% CO2. At 100% con-
fluence, a scratch was made across the plates using a pipette’s tip. Cells were cultured in 
complete medium and images were taken every 24 h to monitor the wound healing process.
Transwell migration assay
Cells (2*104) were seeded in DMEM;1% FBS;1% p/s in 24-well Transwell inserts (8μm pore 
size; BD Falcon). The inserts were placed in M24 wells containing DMEM;10% FBS;1% p/s. 
After incubation for 72 h at 37oC;5% CO2, the cells remaining at the top of the insert mem-
brane were physically removed by cloth-swaps. The migrated cells attached at the underside 
of the insert membranes were fixed in methanol and stained using 5% Giemsa/PBS (Merck). 
Migrated cells were counted using a light microscope.
Collagen adhesion assay
Cells (2*104) were seeded in M96 wells coated with 0.02% collagen (Collagen R Solution, 
Serva Electrophoresis). After incubation for 30 min at 37oC; 5% CO2, adherent cells were fixed 
in methanol and stained using 5% Giemsa/PBS (Merck). The adherent cells were counted 
using a light microscope.
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β-catenin reporter assay
β-catenin reporter assays were performed as previously described [370]. Luciferase activi-
ties were measured using the dual-luciferase reporter assay system (Promega). Assays were 
performed three times in triplicate.
Immunofluorescence microscopy
Cells were cultured on sterile glass coverslips at 80% confluence and fixed in 2% PFA for 
10 min. The cells were incubated in 1% BSA;0.1% Triton-X100/PBS (PBSAT) for 10 min, and 
subsequently with the primary antibody E-cadherin or β-catenin, or rhodamine conjugated 
phalloidin (#PHDR1 Cytoskeleton, Inc.) diluted in PBST for 1.5 h at room temperature. The 
cells were washed and incubated with the secondary antibody Alexa Fluor 488 Goat anti-
mouse (A11296, Invitrogen) or Alexa Fluor 594 Goat anti-rabbit (A11037, Invitrogen), for 1 
h at room temperature. The nuclei were visualized by incubating the cells in 67ug/ml DAPI 
(Sigma-Aldrich) in PBS for 5min. After washing, the cells were mounted with Vectashield 
(Vector Labs). The stainings were analyzed using the 63x oil objective of the Leica TCS SP5 
Confocal microscrope.
Statistical analysis
All statistical analyses were performed with the use of Microsoft Office Excel 2003 (Microsoft 
Corporation, USA) and GraphPad Prism 5 software (GraphPad Software, La Jolla, CA, USA). 
Data were presented as means ± standard deviation (SD), unless otherwise stated in the 
figure legend. Before statistical analysis, values were normalized to the control iNT-A6. For 
comparison to the control group the two-tailed independent student t test was used. Two-
sided P values < 0.05 were considered statistically significant.
RESULTS
Reduced LKB1 expression does not affect cell growth in colon cancer cells
To dissect the mechanisms through which loss of LKB1 might contribute to colon cancer, we 
generated stable LKB1 knockdown HT29 colon cancer cells. Monoclonal LKB1-knockdown 
cell lines (iLKB1-E4 and E5) and monoclonal non-targeting control cell lines (iNT-A6 and D8) 
were selected. Significant knockdown of endogenous LKB1 was verified on protein and RNA 
level in these two independent clones (Figure 1A). LKB1 knockdown resulted in reduced 
phosphorylated levels of its direct target AMPK, whereas phosphorylated S6K (a target of 
mTOR) levels were unaltered (Figure 1A).
Colon cancer cell growth is largely dependent on its Wnt/β-catenin signalling activity, and 
LKB1 has been suggested to inhibit the canonical Wnt signalling pathway [371]. Therefore, 
the effect of LKB1-knockdown on β-catenin transcriptional activity was determined. HT29 
cells harbour an APC mutation that activates β-catenin signalling. Transcriptional levels of 
AXIN2, a β-catenin target gene and negative modulator of β-catenin signalling, were reduced 
in LKB1-knockdown cells (Figure 1B). However, constitutive as well as Wnt3A-stimulated 
β-catenin transcriptional activity as measured in a luciferase reporter assay, were slightly, 
but not significantly elevated in LKB1-knockdown cells (Figure 1B). These data suggest that 
49
LKB1 counteracts colon cancer cell motility
knockdown of LKB1 does not strongly alter intrinsic Wnt/β-catenin signalling of HT29 colon 
cancer cells.
In line with this, cell viability as determined by MTT assays revealed no differences in the 
growth curves of LKB1-expressing and LKB1-knockdown HT29 cells (Figure 1C). Together, 
these data suggest that LKB1 does not greatly influence growth-related properties of APC-
mutant colon cancer cells.
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Figure 1. Reduced LKB1 expression does not affect growth-related properties of APC-mutant colon 
cancer cells.
A. Generation of stable LKB1 knockdown in HT29 colon cancer cells (iLKB1) and non-targeting control 
cell lines (iNT). Significant knockdown of endogenous LKB1 on protein (left, centre) and RNA level (right) 
in iLKB1 cells compared to iNT cells. LKB1 knockdown results in reduced phosphorylation of its direct 
target AMPK, whereas phosphorylated levels of the further downstream target S6K are not affected. B. 
Transcriptional AXIN2 levels are significantly reduced in LKB1 knockdown cells (left). Luciferase reporter 
assays show that β-catenin-driven transcription is not significantly elevated in LKB1 knockdown cells, 
with or without stimulation with Wnt3A (right). C. MTT assays showing that LKB1 knockdown does not 
significantly affect HT29 cell viability. Error bars equal standard error of the mean. * and ** indicate p 
values of < 0.05 and < 0.005, respectively.
Reduced LKB1 expression induces migration of colon cancer cells
To investigate which cellular functions of colon cancer cells were affected by loss of LKB1 
expression, a genome-wide expression analysis approach was chosen using the high-
throughput Affymetrix GeneAtlas 2.0 platform. We compared the transcriptome signatures 
of four independent monoclonal iLKB1 lines to four independent monoclonal iNT lines using 
SAM analysis. This revealed 196 records, corresponding to a set of 142 genes, being differen-
tially expressed between these two groups (Figure 2A). Functional data analysis in Ingenuity 
identified ‘cellular movement’ and ‘lipid metabolism’ as the two most significantly affected 
cellular functions in HT29 cells lacking LKB1 (Figure 2A). Involvement of LKB1 signalling in 
lipid metabolism has already been shown and extensively studied [365]. However, a role for 
LKB1 in cellular movement of colon cancer cells has so far not been described. To investigate 
the effect of LKB1 knockdown on cellular movement of colon cancer cells, the migration 
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capacity of iLKB1 and iNT HT29 cell lines was determined using two different assays. Both the 
scratch wound-healing assay and transwell migration assay showed significantly increased 
migration of iLKB1 cells compared to iNT cells (Figure 2B,C). These functional assays con-
firmed the hypothesis obtained from the microarray analysis, indicating that LKB1 is involved 
in colon cancer cell migration. Interestingly, performing a pathway explore analysis with the 
26 molecules of the ‘cellular movement’-profile in Ingenuity, revealed the canonical pathway 
‘CRC metastasis signalling’ being most strongly associated with reduced LKB1 expression 
(not shown).
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Figure 2. Reduced LKB1 expression induces migration of colon cancer cells.
A. Genome-wide expression analysis, comparing four independent LKB1 knockdown cell lines (iLKB1) 
to four independent control cell lines (iNT), identify ‘cellular movement’ and ‘lipid metabolism’ as the two 
most significantly affected cellular functions in colon cancer cells lacking LKB1. Gene expression levels: 
red, upregulated genes compared with the geometric mean; blue, down-regulated genes compared 
with the geometric mean. The colour intensity correlates with the degree of change. B. and C. Both the 
scratch wound-healing assay (B.) and the transwell migration assay (C.) show significantly increased 
migration of iLKB1 cells compared to iNT cells. The error bars in figure 2B equal standard error of the 
mean. * and ** indicate p values of < 0.05 and < 0.005, respectively.
Effects on CRTC1 signalling
A recent microarray study in LKB1 knockout mice showed that loss of LKB1 in lung tumours 
enhances metastasis through enhancement of NEDD9 expression, as a result of increased ac-
tivity of the transcriptional co-activator CRTC1 [364]. We questioned whether this mechanism 
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was also active in human colorectal cancer cells with reduced LKB1 expression. However, 
in our microarray, these genes were not found to be upregulated in iLKB1 cells compared to 
iNT cells (not shown). In contrast, despite slightly increased protein levels of CRTC1 in iLKB1 
HT29 cells, NEDD9 mRNA levels were significantly reduced in LKB1-deficient colon cancer 
cells (Figure 3A,B). These data suggest that in human colon cancer cells, LKB1 suppresses 
migration through an alternative mechanism.
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Figure 3. Effects of LKB1 knockdown CRTC1 signalling in colon cancer cells.
A. Protein CRTC1 levels were slightly increased in LKB1 knockdown cells. B. Transcriptional expression 
of NEDD9 was significantly reduced in LKB1 knockdown cells. ** indicates p values of < 0.005.
Reduced LKB1 expression affects the epithelial phenotype and adhesion of colon 
cancer cells
The establishment of malignant behaviour requires tumour cells to acquire novel adhesion and 
migration properties, leading them to detach from their original sites and to localize to distant 
organs. Migration of epithelial cells usually involves epithelial-to-mesenchymal transition 
(EMT). In the LKB1 knockdown cells, expression of the epithelial marker E-cadherin was sig-
nificantly reduced (Figure 4A,B). However, expression of the mesenchymal markers Vimentin 
and N-cadherin could not be detected in LKB1-knockdown cells (Figure 4B). Despite the lack 
of mesenchymal induction, the cancer stem cell marker CD44, involved in EMT, cytoskeletal 
rearrangement and migration [372], was significantly increased (Figure 4A,B).
In epithelial cells, E-cadherin is typically located at the cellular membrane where it binds 
β-catenin to form adhesion junctions. In iLKB1 cells, reduced E-cadherin expression was 
associated with significantly reduced levels of β-catenin (Figure 4B). Immunofluorescence 
analysis showed diffuse expression of both E-cadherin and β-catenin at the site of the plasma 
membrane and cytoplasm of iLKB1 cells (Figure 4C). These data indicate that although a 
full EMT is not induced, the changes in epithelial phenotype of HT29 cells by reduced LKB1 
expression are indicative of impaired cell adhesion.
To confirm this hypothesis, we compared the adherence propensity of LKB1-knockdown 
cells and control cells. iLKB1 cells showed significantly reduced adherence to the extra-
cellular matrix (ECM) component collagen, compared to iNT controls (Figure 4D), indicating 
that loss of LKB1 in colon cancer cells impairs the interaction with the ECM.
Indirectly, this was also suggested by the observation that detaching cells from tissue cul-
ture plates using trypsin took longer for iNT cells than for iLKB1 cells (data not shown). These 
data suggest that reduced LKB1 expression induces colon cancer cell migration by inducing 
a partial EMT, and by altering the capacity of cells to adhere to the ECM.
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Figure 4. Reduced LKB1 expression affects the epithelial phenotype and adhesion of colon cancer cells.
A. Transcriptional levels of the epithelial marker E-cadherin are reduced in LKB1 knockdown cells, 
whereas transcriptional levels of the cancer stem cell marker CD44 are induced. B. In colon cancer 
cells lacking LKB1, E-cadherin and β-catenin protein levels are significantly reduced. Expression of the 
mesenchymal markers vimentin and N-cadherin are not detected in iNT cells, and are not induced in 
LKB1 knockdown cells. CD44 protein levels are induced. C. Immunofluorescence analysis demonstrates 
loss of both E-cadherin and β-catenin localization at cell-cell junctions in iLKB1 cells. D. LKB1 
knockdown cells show significantly reduced adherence to the extra-cellular matrix component collagen 
compared to control cell lines. * and ** indicate p values of < 0.05 and < 0.005, respectively. PC, positive 
control (mesenchymal cells).
Reduced LKB1 expression induces cytoskeletal rearrangements in colon cancer cells
Having observed a clear effect of LKB1 downregulation on cellular migration, we set out to 
further elucidate the molecular mechanisms through which this effect may be brought about. 
To this aim, we employed a kinome profiling approach, incubating recombinant active LKB1 
on PepChip kinome arrays to identify its peptide substrates. Using the top 10% of the identi-
fied LKB1 target peptide substrates, a pathway annotation analysis was performed which 
showed that proteins of the LKB1, AMPK and mTOR/S6K pathways are substrates for LKB1, 
thereby validating this technique and analysis (Figure 5A). Interestingly, in addition to these 
known downstream pathways of LKB1, the cytoskeletal RAC/PAK pathway was also shown 
to be within the substrate pathways of LKB1. To validate these results, we analysed PAK 
phosphorylation in iNT and iLKB1 cells. As shown in Figure 5B, PAK phosphorylation was 
significantly enhanced in LKB1-deficient cells. The main function of the PAK pathway is regu-
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lation of the actin cytoskeleton in order to promote migration. Indeed, immunofluorescence 
analysis showed rearranged actin filaments in LKB1-knockdown cells (Figure 5C). Actin fiber 
formation is carefully regulated by several actin binding proteins, amongst which cofilin. In 
line with enhanced migration and altered cytoskeletal rearrangement, we detected decreased 
protein levels of cofilin in iLKB1 cells (Figure 5B). In contrast, no differences in levels and 
protein phosphorylation of other cytoskeletal/migratory proteins (e.g. VASP, FAK, PAX) were 
observed (data not shown), indicating that LKB1-effects on the migratory phenotype of colon 
cancer cells is specifically regulated through PAK and cofilin. Together, these data suggest 
that loss of LKB1 in the colon cancer cell line HT29 induces changes in the cytoskeletal actin 
filaments, which enables cellular movement.
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Figure 5. Reduced LKB1 expression induces cytoskeletal rearrangements in colon cancer cells.
A. Results of the pathway annotation analysis of the PepChip array, using the top 10% of the identified 
LKB1 peptide substrates. In addition to the known downstream pathways of LKB1, e.g. LKB1, AMPK 
and mTOR/S6K pathways, the cytoskeletal RAC/PAK pathway is also shown to be within the substrate 
pathways of LKB1. B. Phosphorylated PAK protein levels are significantly increased in LKB1 knockdown 
cells, while cofilin expression was significantly reduced. C. Immunofluorescence analysis demonstrates 
rearranged actin filaments in LKB1 knockdown cells, suggesting changes in the cytoskeleton in these 
colon cancer cells. * and ** indicate p values of < 0.05 and < 0.005, respectively.
DISCUSSION
Germline mutations in LKB1 predispose PJS patients to the development of CRC and other 
gastrointestinal and extra- gastrointestinal cancers [24]. In sporadic CRC however, LKB1 is 
rarely somatically mutated [143,145]. This has led to the suggestion that LKB1 is not involved 
in the development of sporadic CRC. However, allelic loss has been observed frequently, 
suggesting that reduced levels of LKB1 do contribute to colorectal carcinogenesis. LKB1 is 
considered a master serine/threonine kinase regulating cell polarity, energy metabolism and 
cell growth [365]. Though the functions of LKB1 have been the subject of several investiga-
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tions over the past years, its tumour suppressor mechanisms in colorectal carcinogenesis 
remain largely obscure. This study shows that reduced levels of LKB1 enhance motility in 
human colon cancer HT29 cells by rearrangement of the actin cytoskeleton, suggesting that 
LKB1 suppresses sporadic CRC progression.
In sporadic lung and breast cancer, loss of LKB1 has been shown to associate with more 
aggressive tumour phenotypes and poor prognosis [88,134,135,140,141]. In addition, previous in 
vitro and in vivo studies showed that loss of LKB1 increases cell migration and invasion in epithe-
lial breast, lung and oesophageal cancer cells [136,137,364,373]. Our results are in line with these 
studies, providing evidence that loss of LKB1 induces a migratory phenotype in colon cancer 
cells, and suggesting that LKB1 suppresses sporadic epithelial cancer progression in general.
In breast cancer cells, LKB1 was required for adiponectin-mediated modulation of the 
AMPK-S6K axis to suppress migration and invasion [136]. Activation of CRTC1-mediated 
signalling was demonstrated to underlie LKB1-induced migration in epithelial lung and oe-
sophageal cancer cells [364,373]. In our study, we showed that these mechanisms are not 
involved in LKB1-induced colon cancer cell migration.
The effect of LKB1 knockdown on Wnt/β-catenin signalling, the major pathway underlying 
CRC initiation, seems to be complex. LKB1 is able to inhibit Wnt/β-catenin signalling through 
activation of GSK3, and the non-canonical Wnt5a is increased in Lkb1+/- mice as well as in 
PJS polyps [371,374]. Our results show that loss of LKB1 was not sufficient to significantly 
raise Wnt/β-catenin signalling in the context of an APC mutation. This is in line with our obser-
vations that LKB1 suppresses colon cancer cell migration rather than proliferation.
We identified reduced expression of the epithelial marker E-cadherin, though the ‘clas-
sical’ mesenchymal markers were not induced upon loss of LKB1. This indicates that loss 
of LKB1 in colon cancer cells does not induce a full EMT, as it has previously been shown 
for epithelial lung cancer cells [369]. Interestingly though, in our LKB1 knockdown cells we 
showed enhanced expression of CD44, a transmembrane glycoprotein associated with EMT, 
cytoskeletal rearrangement and migration [372]. CD44 is overexpressed and associated with 
metastases in several cancers including CRC [375-377]. The correlation between LKB1 and 
CD44 expression and the association with clinicopathological parameters in sporadic CRC 
needs further investigation.
Colon cancer is one of the most frequently observed cancers in the Western World and 
about half of the patients die due to metastatic disease. Tumour metastasis involves migration 
and invasion of primary tumour cells through tissue and through the ECM to distant sites, 
a process that requires cytoskeleton remodelling. PAKs are considered prime regulators of 
actin cytoskeleton dynamics and motility [378], and their expression has been associated 
with progression of CRC to metastasis [379]. Our data indicate that LKB1 suppresses cellular 
movement in colon cancer cells through actin cytoskeleton rearrangement mediated by PAK 
signalling. This important observation may indicate that recent pharmacologic cytoskeleton-
stabilizing drugs, such as paclitaxel may counteract the tumour cell responses induced by 
loss of LKB1.
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SUPPLEMENTARY MATERIAL
Supplementary table 1. Primers quantitative PCR
Gene forward sequence Reverse sequence
LKB1 5’-GCTCTTACGGCAAGGTGAAG 5’-TTTTGTGCCGTAACCTCCTC
Axin2 5’-tatccagtgatgcgctgacg 5’-ttactgcccacacgataagg
CD44 5’-TGGCACCCGCTATGTCCAG 5’-GTAGCAGGGATTCTGTCTG
E-cadherin 5’-AATTCCTGCCATTCTGGGGA 5’-TCTTCTCCGCCTCCTTCTTC
NEDD9 5’-GATTACGTCCACCTACAGGGTA 5’-TGTCATTCTCCACGGGCTTT
GAPDH 5’-AAGGTCGGAGTCAACGGATTT 5’-ACCAGAGTTAAAAGCAGCCCTG
Supplementary table 2. Antibodies immunoblotting and immunofluorescence
Antibody Dilution Company Catalog number
Primary antibodies
Rabbit-anti-LKB1 1:2000 Cell Signaling Technology 3047
Rabbit-anti-phospho-AMPK 1:1500 Cell Signaling Technology 2535
Rabbit-anti-phospho-S6K 1:1000 Cell Signaling Technology 5364
Rabbit-anti-E-cadherin 1:1000 Cell Signaling Technology 3195
Rabbit-anti-β-catenin 1:2000 Epitomics 1247-1
Mouse-anti-β-catenin 1:2000 BD Transduction Lab. 610154
Rabbit-anti-N-cadherin 1:1000 Cell Signaling Technology 4061
Rabbit-anti-vimentin 1:1000 Cell signaling Technology 5741
Rabbit-anti-cofilin 1:500 Signal Way 21164-1
Rabbit-anti-phospho-PAK 1:1000 Cell Signaling Technology 2607
Rabbit-anti-MECT1 (CRTC1) 1:1000 Rockland 600-401-936
Rabbit-anti-CD44 1:1000 Abcam ab41478
Mouse-anti-β-actin 1:2500 Santa Cruz sc-47778
Secundary antibodies
Goat-anti-mouse IgG IRDye 680LT 1:5000 LI-COR 926-68020
Goat-anti-rabbit IgG IRDye 800CW 1:5000 LI-COR 926-32211
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ABSTRACT
Peutz-Jeghers syndrome (PJS) is caused by mutations in the LKB1 gene. It is characterized 
by gastrointestinal polyposis and an increased cancer risk, mainly in the gastrointestinal tract. 
Mechanisms of PJS-associated carcinogenesis are unclear. We investigated the involvement 
of candidate genes and molecular pathways in PJS-associated gastrointestinal cancers and 
dysplastic hamartomas. Cases were selected from the Dutch PJS cohort. Available tissue 
was immunostained for phospho-S6, β-catenin, P53 and SMAD4. DNA was isolated from 
carcinoma tissue and dysplastic and non-dysplastic areas of hamartomas specifically. Muta-
tion analyses were done for BRAF, KRAS, and P53, and LOH analyses for LKB1 and P53. 
Twenty-four of 144 patients (17%) developed 26 gastrointestinal malignancies at a median 
age of 49 years (IQR 35-60). 11/792 hamartomas (1.4%) of nine patients were classified as 
dysplastic. LOH of LKB1 was detected in 3/6 (50%) carcinomas and in the dysplastic part of 
3/5 (60%) hamartomas. Aberrant P53 expression was observed in 8/15 (53%) carcinomas. Six 
carcinomas with P53 overexpression harboured a P53 mutation, with loss of the remaining 
wildtype allele in four. Two hamartomas showing P53 overexpression in high-grade dysplastic 
foci harboured a P53 mutation with LOH. Loss of nuclear SMAD4 was observed in high-grade 
dysplastic foci of 2/4 (50%) hamartomas, in contrast to low-grade dysplastic foci (0/4) and 
non-dysplastic epithelium. Our findings suggest a role for mutant P53 in PJS-associated gas-
trointestinal carcinogenesis. Inactivation of TGF-ß/BMP signalling and complete loss of LKB1 
might be involved in dysplastic transformation of gastrointestinal hamartomas specifically.
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INTRODUCTION
Peutz-Jeghers syndrome (PJS) is a rare, autosomal dominant inherited disorder. Incidence is 
estimated between 1 in 50,000 to 1 in 200,000 live births [7]. The syndrome is caused by an 
inactivating germline mutation in the LKB1 tumour suppressor gene (also known as STK11), 
located on chromosome 19p13.3 of the human genome [10,11]. A pathogenic germline muta-
tion in LKB1 is detected in 80-94% of families affected with PJS [13,14].
The typical PJS phenotype consists of mucocutaneous pigmentations and gastrointestinal 
polyposis. These polyps, histologically defined as hamartomas, can develop already in the 
first decade of life and may cause anaemia, bleeding, abdominal pain, and intestinal obstruc-
tion [20]. Furthermore, PJS patients are at increased risk for developing cancer at a young 
age [24,380]. Although a wide spectrum of malignancies has been described, patients are 
mostly affected by cancers in the gastrointestinal tract, including colorectal, pancreatic and 
gastric cancer. A cumulative risk of up to 57% at the age of 70 years has been described for 
gastrointestinal cancers [24].
At present, the pathogenesis and molecular mechanisms underlying PJS-associated 
gastrointestinal cancer development are unclear. Though adenomatous and carcinomatous 
changes are rarely observed in PJS hamartomas [111,112,381], a hamartoma-carcinoma 
sequence is debated. In addition to the initial germline mutation, several mechanisms for 
inactivation of the remaining wildtype LKB1 allele, such as loss of heterozygosity (LOH) and 
promoter hypermethylation, have been described of which LOH is observed most frequently. 
Interestingly however, although LOH is detected more frequently in carcinomas than in 
hamartomas, it is not detected in 100% of these carcinomas [119,120,382], suggesting that 
complete loss of functional LKB1 might not be required for the development of carcinomas 
in PJS. Coincidence of the proper secondary oncogenic hits in other genes in addition to this 
haploinsufficiency of LKB1 might be sufficient for carcinoma development in this syndrome 
[34,35].
The aim of this study was to get insight into the molecular pathways underlying PJS-asso-
ciated gastrointestinal carcinogenesis. To this aim, we collected a unique panel of 15 gastro-
intestinal carcinomas from a large cohort of Dutch PJS patients. The expression, activity and 
mutation status of genes and signalling pathways associated with sporadic gastrointestinal 
carcinogenesis as well as with gastrointestinal cancer related to other inherited disorders were 
studied by immunohistochemistry and DNA mutation analysis. To investigate whether there 
is an overlap between the molecular alterations in these carcinomas and in PJS hamartomas, 
specifically in dysplastic lesions of these hamartomas, we also analysed the affected genes 
and pathways in a unique set of nine dysplastic hamartomas from our patient cohort.
MATERIALS AND METHODS
Case selection and data collection
Cases were selected from the Dutch PJS cohort, initiated by two Dutch academic hospi-
tals. PJS patients throughout the Netherlands with a definite diagnosis of PJS – defined by 
diagnostic criteria recommended by the WHO (see chapter 1, Box 1, page 12), a proven 
LKB1 mutation, or both – were included in this cohort. Informed consent was obtained of all 
patients or of their next of kin if patients had passed away, and the study was approved by 
the Institutional Review Board of both participating hospitals. In total, 144 PJS patients from 
62 families were included in this cohort. Baseline characteristics of the cohort are shown in 
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Supplementary Table 1. Patients with a diagnosis of a primary malignancy of the gastroin-
testinal tract (i.e. oesophagus, stomach, small intestine (including duodenum), colorectum, 
pancreas, liver and biliary tract) were selected. Data were collected on the following variables: 
date of birth, date of death, gender, LKB1 germline mutation, date of diagnosis, tumour type 
and origin, tumour invasion, data on confirmation (medical record or histology) and treatment.
To select hamartomas with dysplastic changes, all available electronic pathology reports 
of hamartomas removed during endoscopy, intraoperative enteroscopy or surgery were 
screened. Two expert pathologists independently reviewed all haematoxylin and eosin-stained 
slides of hamartomas with some degree of dysplasia according to the original pathology re-
port. In case of disagreement, consensus was reached by consultation. Only cases with both 
hamartomatous characteristics and dysplastic changes were included in this study. Dysplasia 
was classified as low-grade dysplasia (LGD) or high-grade dysplasia (HGD).
Immunohistochemistry (IHC)
Formalin-fixed paraffin-embedded (FFPE) tissue of both carcinoma and dysplastic hamartoma 
cases was collected from pathology archives for further analysis.
Sections (4-5 μm) were cut and deparaffinised. Antigen retrieval was performed by boiling 
in 10mM Tris/1mM EDTA buffer pH9 (for β-catenin and SMAD4) or 10mM citric buffer pH6 
(for αSMA and pS6) for 10min. Non-specific binding sites were blocked in 3% H2O2 for 10min 
and 5% non-fat dry milk for 30min and in PBS with 10% normal goat serum for SMAD4. 
Primary antibodies used for IHC analysis included monoclonal mouse anti-human alpha 
smooth muscle actin (1:1000, DAKO clone 1A4), monoclonal mouse anti-β-catenin (1:1500, 
BD Biosciences 610154), monoclonal rabbit anti-phospho-S6 Ribosomal protein (1:250, Cell 
Signalling Technology #5364), p53 (1:400, DAKO clone DO-7), Mib-1 (1:100, DAKO clone 
MIB-1) and SMAD4 (1:400, Santa Cruz Biotechnology, Inc.). Incubations with primary antibod-
ies were carried out overnight at 4oC and for 1 hour at room temperature for SMAD4. Sections 
were washed 3 times with PBS containing 0.05% Tween-20 (PBST), and incubated with HRP-
labeled goat anti-rabbit IgG or goat anti-mouse IgG (EnVisionTM+, DAKO) for 30min. Sections 
were washed 3 times with PBST. After DAB precipitation, a haematoxylin counterstaining 
was performed. Slides were scored by two authors independently and final consensus was 
reached by consultation. αSMA was stained for confirmation of hamartomas. Proliferation 
rates were determined by the average percentage of Mib-1 positive cells in three microscopic 
fields (20x). Nuclear β-catenin and SMAD4 staining was considered positive when one or 
more positive nuclei were observed in a microscopic field (20x). P53 staining was scored on 
a scale ranging from - to +++ (-, negative; +, positive/normal; ++, moderate overexpression; 
+++, strong overexpression). Epithelial pS6 staining was scored on a scale ranging from - to 
++ (-, negative; +, positive; ++, overexpression).
DNA isolation
Tissue of gastrointestinal carcinomas was carefully dissociated from surrounding normal tis-
sue, resulting in samples containing >50% tumour cells. DNA of dysplastic hamartoma tissue 
was isolated from epithelial cells in the non-dysplastic area and epithelial cells in the dys-
plastic lesion specifically, using P.A.L.M. laser micro dissection. For DNA isolation, samples 
were incubated overnight at 56oC in lysis buffer (Cell Lysis Solution, Promega, cat # A7933) 
61
Molecular alterations in Peutz-Jeghers syndrome
containing 5% chelex (Chelex 100 resin (Bio-Rad) catalog # 143-2832) and 10% proteinase 
K. Samples were heated to 95oC for 10 minutes to inactivate the proteinase K and to denature 
the DNA.
DNA mutation analysis
DNA was amplified for mutational analysis. DNA of all tumours was sequenced and checked 
for mutations in KRAS codon 12 and 13 and BRAF codon 600. Mutation analysis of exon 3 
of ß-catenin was performed if nuclear expression of ß-catenin was observed with immuno-
histochemistry. P53 mutation analysis for exons 5-8 was performed for all gastrointestinal 
carcinomas. For the dysplastic hamartomas, P53 mutation analysis was only performed if 
aberrant P53 expression (i.e. strong overexpression or absence) was observed with immu-
nohistochemistry. In cases of a known germline LKB1 mutation or the detection of a P53 
mutation, loss of the wild-type LKB1 and P53 alleles, indicative for LOH, was determined 
from the nucleotide sequence analyses. PCRs were performed at an annealing temperature of 
58˚C, for 34 cycles using GoTaq® DNA Polymerase with 5x Buffer (Promega, Madison, Wis-
consin, USA). For most tumours a nested PCR was performed with 2 μL PCR product. DNA 
purification and sequencing reactions were performed by LGC Genomics (Berlin, Germany). 
Primers and nested primers used for amplification and sequences of the different genes are 
available upon request.
RESULTS
Clinical characteristics – Gastrointestinal carcinomas
Twenty-four of the 144 patients (17%, 67% male) from 18 families developed 26 gastrointes-
tinal malignancies (Table 1). Two patients were diagnosed with two primary tumours. Median 
age at diagnosis of the first tumour was 49 years (IQR 35-60). Two carcinomas were detected 
during surveillance endoscopies, in all the other cases patients presented with symptoms. 
Median survival after gastrointestinal cancer diagnosis was eight months (IQR 3-49 months). 
Twenty-one of these patients (88%) deceased at a median age of 55 years (IQR 38-61); 20 
of whom died as a direct cause of gastrointestinal cancer. Three patients are still alive at a 
median time of four years (IQR 3-15) after cancer diagnosis. These data suggest that PJS 
patients can develop aggressive gastrointestinal cancers at a relatively young age.
Clinical characteristics – Dysplastic hamartomas
A total of 792 hamartomas of 52 patients were histologically examined. Nineteen (2.4%) ham-
artomas of 15 patients were originally classified as dysplastic. Upon revision by two expert 
pathologists 11 (1.4%) hamartomas of nine patients (eights male) were classified as dysplastic 
and included in this study (Table 2), with a 100% consensus between the two pathologists. In 
the eight other cases the morphologic abnormalities were reclassified as reactive proliferation 
instead of dysplastic changes. This implies that gastrointestinal hamartomas of PJS patients 
are not precursor lesions, although malignant transformation does occur in sporadic cases.
Seven (64%) hamartomas contained foci of low grade dysplasia (LGD) and four showed foci 
of high grade dysplastic (HGD) changes (Table 2). Median size of the dysplastic hamartomas 
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was 30 mm (IQR 15-40). Dysplastic hamartomas were detected throughout the gastrointesti-
nal tract and five (45%) hamartomas were found during surveillance endoscopies.
Molecular alterations in gastrointestinal carcinomas
To investigate whether molecular alterations in genes known to be involved in sporadic and he-
reditary gastrointestinal cancer can also be identified in PJS-associated cancers, FFPE tissue 
of 15 available gastrointestinal carcinomas was selected (Table 3). Proliferation of tumour cells 
differed widely between the tissue samples. Loss of the wild-type allele of LKB1, indicative 
for LOH, was detected in 3/6 (50%) informative gastrointestinal carcinomas (Figure 1A), which 
is in line with previously reported frequencies. Inactivation of LKB1 impairs the inhibition of 
mammalian target of rapamycin (mTOR), resulting in phosphorylation of the ribosomal protein 
S6. All 15 carcinomas showed epithelial phospho-S6 expression, although in a heterogeneous 
manner. Phospho-S6 expression did not correlate with loss of wild-type LKB1. This suggests 
that complete loss of LKB1 occurs in PJS-associated gastrointestinal carcinomas, but is not 
required. Also, complete loss of LKB1 does not correlate with hyperactivation of mTOR in 
these tumours.
In 8/15 (53%) gastrointestinal carcinomas, aberrant P53 expression was observed. Six 
samples showed strong overexpression of P53 and two others showed total absence of P53 
expression, suggesting that in these carcinomas P53 was genetically altered (Figure 1B). In 
6/15 (40%) carcinomas, a mutation in P53 could be detected, which was accompanied by 
loss of the remaining wild-type allele in 4/6 (67%) cases (Figure 1C). These data suggest that 
genetically altered P53 is involved in gastrointestinal carcinogenesis in PJS.
In none of the gastrointestinal carcinoma samples a mutation in the BRAF gene was 
observed, and only one somatic KRAS mutation was found in a colon carcinoma. Nuclear 
ß-catenin, indicative for active Wnt-signalling, was detected in some tumour cells scattered 
throughout glandular structures of two colorectal carcinomas and one pancreatic carcinoma. 
A mutation in exon 3 of ß-catenin was found in one colorectal carcinoma. Loss of nuclear 
SMAD4, indicative for the inactivation of TGF-ß/BMP signalling, was observed in two pancre-
atic carcinomas. This might implicate that BRAF, KRAS, Wnt-signalling and the TGF-ß/BMP 
pathway, involved in sporadic and other hereditary gastrointestinal cancers, are not frequently 
altered in PJS-associated cancer of the digestive tract.
Molecular alterations in dysplastic hamartomas
To compare molecular alterations of PJS-associated carcinomas and dysplastic hamartomas 
of the gastrointestinal tract, we also collected FFPE tissue of nine dysplastic hamartomas 
(Table 4). In all hamartomas, the characteristic branching structure of smooth muscle cells 
could be observed by H&E and αSMA stainings (Figure 2A,B). As expected, Mib1 staining 
showed increased proliferation rates in all dysplastic foci compared to the non-dysplastic 
epithelial compartments of the same hamartomas (Figure 2C).
Loss of the wild-type allele could not be detected in the non-dysplastic areas of any of the 
hamartomas available for analysis. In contrast, loss of the wild-type LKB1 allele was detected 
in the dysplastic segments (2 LGD, 1 HGD) of 3/5 (60%) of these hamartomas (Figure 3A). 
Phospho-S6 expression was more abundant in the dysplastic epithelium of four hamartomas 
(three with HGD) (data not shown), and in two cases this correlated with loss of the wild-type 
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allele of LKB1 (Table 4). Stromal cells were also positive for phospho-S6 staining, but there 
was no difference in stromal expression between the non-dysplastic and the dysplastic parts. 
These results suggest that complete loss of LKB1 and activation of mTOR are involved in 
dysplastic degeneration of gastrointestinal hamartomas in PJS. However, loss of LKB1 did not 
correlate with mTOR hyperactivation.
Since we observed that P53 was frequently genetically altered in PJS-associated gas-
trointestinal carcinomas, we investigated P53 expression in the dysplastic gastrointestinal 
hamartomas. Aberrant expression of P53 was specifically observed in the HGD parts of 3/4 
(75%) hamartomas, of which two showed strong overexpression and one showed complete 
loss of P53 expression (Figure 3B). Aberrant expression of P53 could not be observed in 
Figure 1. Molecular alterations in gastrointestinal carcinomas of Peutz-Jeghers syndrome patients.
A. LKB1 nucleotide sequence analysis of a carcinoma, showing the known germline mutation in LKB1 
(Asp194Glu) with loss of the wild-type LKB1 allele (lower panel). B. Left (100x): carcinoma tissue 
showing P53 expression scored as +/++. Middle (100x): carcinoma tissue showing complete loss of P53 
expression scored as –. Right (100x): carcinoma tissue showing overexpression of P53 scored as +++. 
C. Left: P53 nucleotide sequence analysis showing a mutation in P53 (Pro190Leu) without loss of the 
wild-type P53 allele (lower panel). In upper panel the wild-type sequence is shown. Right: P53 nucleotide 
sequence analysis showing a mutation in P53 (Ile195Ser) with loss of the wild-type P53 allele (lower 
panel). In upper panel the wild-type sequence is shown.
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the LGD or non-dysplastic parts of the hamartomas. In the two HGD hamartomas showing 
strong overexpression of P53, a P53 mutation with loss of the wild-type allele was specifically 
detected in DNA isolated from the dysplastic cells (Figure 3C). This might indicate that geneti-
cally altered P53 is involved in HGD transformation of PJS-hamartomas. In contrast, no BRAF 
or KRAS mutations could be detected, suggesting that these oncogenes do not play a role in 
dysplastic transformation of hamartomas. In the low-grade dysplastic epithelium of 3/5 (60%) 
hamartomas with LGD, focal nuclear expression of β-catenin was detected, in contrast to the 
four hamartomas with HGD, where no nuclear expression of β-catenin was found (Figure 3B). 
However, the expression pattern was not abundant and no mutation in exon 3 of β-catenin 
was detected in DNA of these hamartomas. Notably, 2/4 (50%) HGD hamartomas showed 
absence of nuclear SMAD4 in the dysplastic foci, in contrast to the non-dysplastic epithelium 
of these hamartomas (Figure 3B). This was not observed in any of the LGD hamartomas. 
Therefore, loss of TGF-ß/BMP signalling might be involved in HGD transformation of gastro-
intestinal hamartomas in PJS.
Figure 2. Immunohistochemical staining of dysplastic Peutz-Jeghers syndrome hamartomas.
A. H&E staining of a PJS hamartoma (50x). B. α-SMA staining of a PJS hamartoma (50x), showing the 
characteristic branching smooth muscle bundles. C. 400x magnification of Mib1 staining, showing 
increased proliferation in the LGD area (~80%) (lower panel) compared to the non-dysplastic area (~40%) 
of the same hamartoma (upper panel), indicating increased cell proliferation in the dysplastic lesion of the 
hamartoma.
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Figure 3. Molecular alterations in dysplastic Peutz-Jeghers syndrome hamartomas.
A. Left: LKB1 nucleotide sequence analysis of a hamartoma with dysplasia, showing the known germline 
mutation in LKB1 (Tyr156Stop) as found in the non-dysplastic cells (upper panel) and loss of the wild-type 
LKB1 allele in the dysplastic LGD lesion of the hamartoma.
Right: LKB1 nucleotide sequence analysis of a hamartoma with HGD, showing the known germline 
mutation in LKB1 (Gln100Stop) without loss of the wild-type LKB1 allele in both the non-dysplastic 
(upper panel) and dysplastic (lower panel) cells of the hamartoma. B. Left (400x): P53 staining of 
hamartoma showing overexpression of P53 (scored as +++) in the HGD area (lower panel) in contrast to 
the non-dysplatic part (upper panel). Middle (400x): ß-catenin staining of a hamartoma with LGD, showing 
focal nuclear expression of ß-catenin in the LGD area (lower panel) but absence of nuclear ß-catenin in 
the non-dysplastic part (upper panel). Right (400x): SMAD4 staining of a hamartoma with HGD, showing 
nuclear expression of SMAD4 in the non-dysplastic hamartomatous cells (upper panel) but absence of 
nuclear SMAD4 in the HGD lesion of the same hamartoma. C. Left: P53 nucleotide sequence analysis 
of a hamartoma with HGD, showing a mutation in P53 (Gly279Arg) without loss of the wild-type P53 
allele in the HGD lesion (lower panel), while the mutation could not be detected in DNA isolated from the 
non-dysplastic area of the same hamartoma (upper panel). Right: P53 nucleotide sequence analysis of 
a hamartoma with HGD, showing a mutation in P53 (Ser127Phe) with loss of the wild-type P53 allele in 
the HGD lesion (lower panel), while the mutation could not be detected in the non-dysplastic area of the 
same hamartoma (upper panel). HGD; high-grade dysplasia, LGD; low-grade dysplasia.
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DISCUSSION
Patients with PJS are prone to develop cancer at a young age, especially in the gastroin-
testinal tract. In a large cohort of Dutch PJS patients, 17% of patients developed a primary 
malignancy in the gastrointestinal tract at a median age of 49 years. Although tumours devel-
oped throughout the digestive tract, they were mainly found in the colorectum and pancreas. 
Survival after gastrointestinal cancer diagnosis was strikingly short in our cohort, suggesting 
a more aggressive tumour phenotype in PJS. However, the pathogenesis of PJS-associated 
cancers remains unknown.
Inactivating germline mutations in the LKB1 tumour suppressor gene, causing PJS, were 
detected in the majority of patients or their affected family members of our cohort. Loss of the 
remaining wild-type allele of LKB1 was found in only three out of six gastrointestinal carcino-
mas, which is in line with previously reported frequencies [119,120,382]. In contrast, in three out 
of five hamartomas, loss of the wildtype LKB1 allele was detected in the dysplastic epithelium 
but not in the non-dysplastic epithelium of the same hamartomas. Therefore, complete loss of 
LKB1 might not be a prerequisite for gastrointestinal carcinogenesis in PJS, but is involved in 
dysplastic transformation of hamartomas. However, we cannot exclude loss of LKB1 protein 
expression since suitable antibodies for immunohistochemistry are not available. Furthermore, 
somatic inactivation by epigenetic silencing due to promoter methylation has been described 
for the LKB1 gene. LKB1-deficiency impairs the inhibition of mTOR, and it has been suggested 
that specific mTOR inhibitors (e.g. rapamycin) might be an effective therapy for treatment of 
both hamartomas and carcinomas in PJS patients [256,385]. However, activation of mTOR - 
by means of higher phospho-S6 protein levels - did not correlate with genetic loss of LKB1 in 
the majority of carcinomas and dysplastic hamartomas, indicating that alternative pathways 
(e.g. PI3K/AKT signalling) might be involved in mTOR activation in PJS tumours as well.
We detected mutations in the P53 tumour suppressor gene - in most cases with loss of the 
wildtype P53 allele and concomitant P53 overexpression - in both gastrointestinal cancers 
and hamartomas with high-grade dysplastic lesions. Because some of the P53 mutations 
were identified exclusively in the dysplastic parts of the hamartomas, and since our patients, 
although intensively monitored, do not show any signs of suffering from Li-Fraumeni syn-
drome, we strongly believe that these mutations are somatic rather than germline. These 
data suggest that mutant P53 is involved in gastrointestinal carcinogenesis and late stages 
of dysplastic transformation of hamartomas in PJS. In LKB1 mutant mice, additional loss 
of p53 increased and accelerated gastrointestinal hamartoma growth without changing the 
histological grade of these hamartomas [100,101]. Notably, additional loss of p53 could not 
induce intestinal carcinoma development in LKB1-deficient mice. Inactivation of LKB1 might 
collaborate with mutant P53 rather than with loss of P53 for PJS-associated carcinogenesis.
In sporadic colorectal cancer (CRC) cases, both activation of the Wnt/ß-catenin pathway 
and the oncogene KRAS are essential early events in development [386]. At a later stage in the 
adenoma-carcinoma sequence of sporadic CRC, mutations in the P53 tumour suppressor gene 
play an important role. In the present study, 2/4 (50%) of colorectal carcinomas showed nuclear 
ß-catenin, indicative for activation of the oncogenic Wnt/ß-catenin signalling pathway. How-
ever, nuclear ß-catenin was not as abundant as observed in sporadic CRC or in premalignant 
adenomas. Previously, ß-catenin mutations rather than mutations in APC have been detected 
in PJS tumours [120,387]. We observed no mutations in the ß-catenin gene in the carcinomas 
and dysplastic hamartomas showing nuclear ß-catenin. In one of four CRCs, a KRAS mutation 
was detected, which coincided with nuclear ß-catenin. In another CRC specimen, nuclear 
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ß-catenin coincided with a P53 mutation. These results suggest a synergism between active 
Wnt/ß-catenin signalling, KRAS and P53 in PJS-associated CRC formation, like in sporadic 
CRC. However, no KRAS mutations were observed in the other GI carcinomas and nuclear 
ß-catenin was observed in only one pancreatic cancer, while P53 mutations were abundant 
in the other carcinomas. Thus, although similar molecular mechanisms may be involved in 
PJS-associated CRC as well as in sporadic cases of CRC, our results indicate a strong link 
between LKB1 and P53 in other GI cancers, which may be specific for PJS-associated cancer.
Strikingly, in none of the investigated pancreatic carcinomas a KRAS mutation was detected, 
while mutations in this gene are found in more than 90% of sporadic pancreatic carcinomas 
[388]. This suggests that oncogenic activation of KRAS in addition to inactive LKB1 is not 
required for pancreatic carcinogenesis in PJS. This is also shown in mice, where specific 
loss of LKB1 in pancreatic epithelium is sufficient for pancreatic carcinoma formation [124]. 
In sporadic pancreatic cancers, the SMAD4 gene is inactivated in approximately 60% [389]. 
Here, we observed loss of nuclear SMAD4 in two out of five pancreatic cancers. Notably, 
nuclear SMAD4 was absent in the nuclei of dysplastic cells of two out of four HGD intestinal 
hamartomas, while it was present in all intestinal carcinomas. This might indicate involvement 
of inactive TGF-ß/BMP signalling in dysplastic transformation of PJS hamartomas, but not in 
intestinal carcinoma development, and suggest that these are two different entities of PJS.
Although dysplastic and carcinomatous changes do occur in hamartomas, it is rare. In the 
present study only about 1% of hamartomas showed some degree of dysplasia. Because 
not all hamartomas found in our patients were revised, this could be an underestimation. 
However, also in previous studies malignant transformation was found in a minority of PJS 
hamartomas (<1-9%) [111,112]. Furthermore, signs of hamartomatous tissue that could indi-
cate a hamartomatous origin were not observed in the PJS-associated carcinomas. Although 
the incidence of GI carcinomas is high in PJS patients, a much higher incidence would be 
expected if hamartomas were indeed precursor lesions, given the high polyp load in most 
PJS patients. In addition, the location of the gastrointestinal malignancies in PJS patients 
does not always correlate with the location of the hamartomatous polyps [381]. Also in the 
present study, most gastrointestinal cancers were found in the colorectum and pancreas, 
while dysplastic hamartomas were mainly found in the small bowel, in line with the preferred 
location of PJS hamartomas. Finally, although some molecular alterations were identified in 
both PJS-associated gastrointestinal carcinomas and dysplastic lesions of hamartomas, we 
mainly detected substantial differences. Based on these observations, we believe that an 
absolute hamartoma-carcinoma sequence in PJS patients is unlikely.
In conclusion, our findings suggest a role for mutant P53 in PJS-associated gastrointestinal 
carcinogenesis, in addition to a haploinsufficient function of the LKB1 tumour suppressor 
gene. Loss of nuclear SMAD4 and complete loss of LKB1 may be involved in dysplastic 
transformation of gastrointestinal hamartomas specifically.
Our conclusions are based on a small number of heterogeneous tumour samples, which is 
explained by the rarity of PJS. Though, to our knowledge, we describe the largest sample set 
of PJS-associated carcinomas of the gastrointestinal tract specifically. In addition, the set of 
gastrointestinal hamartomas with different grades of dysplasia used in this study is of amount 
not incorporated in such a study elsewhere. With these unique sample sets, we were able to 
identify molecular alterations associated with gastrointestinal tumour development in PJS. 
Whether these alterations contribute to the development of these PJS tumours is suggestive, 
but needs to be investigated further in functional studies.
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SUPPLEMENTARY MATERIAL
Supplementary Table 1. Baseline characteristics of the Dutch Peutz-Jeghers syndrome cohort.
Total 144
Gender
Male 70 (49%)
Female 74 (51%)
Families 62
Family history
Familial PJS 109 (76%)
Sporadic 24 (17%)
Family history unknown 11 (7%)
DNA mutation analysis 90 (63%)
LKB1 mutation carrier 83/89 (93%)
Deceased 48 (33%)
Median age at death 46 years (IQR 32-58 years)
Lost to follow up 6 (4%)
Cancer 48 (33%)
Median age at diagnosis of first cancer 46 years (IQR 35-55 years)
2 primary cancers 8
IQR: interquartile range; PJS: Peutz-Jeghers syndrome.
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ABSTRACT
Peutz-Jeghers syndrome (PJS), caused by germline mutations in LKB1, is characterized by 
the development of hamartomatous polyps in the gastrointestinal (GI) tract. McCune Albright 
syndrome (MAS) is caused by somatic activating mutations in GNAS and presents with cu-
taneous, skeletal, and endocrine manifestations. Recently, hamartomatous GI polyps with 
histological features similar to those in PJS were observed in MAS patients, suggesting a role 
for GNAS in the pathogenesis of PJS. This study reports the first somatic GNAS mutation 
analysis in GI tumours of PJS patients. No mutations were observed, suggesting that GNAS 
is not involved in the pathogenesis of GI tumours in PJS.
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GNAS is not involved in Peutz-Jeghers syndrome
Peutz-Jeghers syndrome (PJS) is a rare autosomal dominant inherited disorder caused by 
germline mutations in LKB1 (also known as STK11). PJS is clinically characterized by muco-
cutaneous pigmentations and the development of hamartomatous polyps, i.e. hamartomas, 
in the gastrointestinal (GI) tract [28]. Furthermore, PJS patients have a highly increased risk 
for developing cancer, mainly in the GI tract [28]. Although the genetic background of PJS 
is known, the pathogenesis of hamartomas and carcinomas in this syndrome is yet unclear.
McCune Albright syndrome (MAS), another rare genetic disorder, is characterized by café-
au-lait spots, polyostotic fibrous dysplasia, and endocrine hyperfunction. MAS is caused by 
postzygotic mutations in the GNAS gene [390]. GNAS encodes the α subunit of the stimula-
tory G protein (Gsα) involved in G-protein signalling. The most frequently observed mutations 
in MAS occur in exon 8, resulting in amino acid substitutions in codon 201. These mutations, 
often mosaicisms, change the Gsα activity preventing downregulation of cAMP/PKA signalling 
[390]. It was recently reported that hamartomatous polyps were observed in the stomach and 
duodenum of four MAS patients [391]. The polyps were histologically similar to PJS polyps, 
showing prominent bundles of smooth muscle fibres in the stromal cores covered by well 
differentiated gastric and duodenal epithelium. Activating GNAS mutations were found in the 
polyps or adjacent mucosa in 3 of 4 subjects. The authors suggested a putative interaction 
between the LKB1 and GNAS genes in the pathogenesis of MAS and PJS.
To investigate this hypothesis, we performed a somatic GNAS mutation analysis on GI 
tumours of PJS patients. We obtained archive material of 6 GI hamartomas and 12 GI carcino-
mas of our Dutch PJS patient cohort. DNA was extracted from this macro-dissected (carcino-
mas) or laser capture micro-dissected (hamartomas) formalin-fixed paraffin-embedded tissue. 
We successfully amplified and sequenced exon 8 of GNAS. No mutations at codon 201 were 
detected in the PJS-associated hamartoma and carcinoma samples (Table 1). These results 
suggest that GNAS is not involved in the pathogenesis of PJS-associated tumours.
Activating mutations in GNAS have been identified in various endocrine tumours [390], but 
its function in GI tumours is unclear. Recently, activating GNAS mutations were found in 83% 
of villous adenomas, but in only 3% of the more common tubulovillous adenomas [392]. Only 
3% of colorectal adenocarcinomas contained a mutation in GNAS, consistent with previous 
findings (0.5-2%) [393,394]. In 8% of pancreatic intraepithelial neoplasms, the most common 
precursor of pancreatic ductal adenocarcinoma, the GNAS gene was mutated [395]. However, 
no GNAS mutations were detected in 32 pancreatic ductal adenocarcinomas [396]. Notably, in 
41% of 118 intraepithelial papillary mucinous neoplasms, another common form of pancreatic 
carcinomas, GNAS mutations were observed [396].
These data suggest that GNAS could be involved in the pathogenesis of specific subtypes 
of GI carcinomas or their precursor lesions. In our study, we did not detect any GNAS mutation 
in GI hamartomas and carcinomas of PJS patients. Although hamartomas are not considered 
premalignant lesions of GI carcinomas in PJS, and should therefore as yet be regarded as 
two distinct entities of this syndrome, our results suggest that GNAS is not involved in GI 
tumourigenesis in PJS.
Chapter 5
80
Table 1. GNAS (codon 201) mutation analysis in gastrointestinal hamartomas and carcinomas of PJS 
patients.
Tissue Origin LKB1 germline 
mutation
LKB1 GNAS mutation 
(codon 201)
Hamartomas Stomach c.290+1G>A Splice variant no
Small bowel c.156_157dupGG Frameshift no
Duodenum c.580G>A Asp194Asn no
Colon c.468C>G Tyr156Stop no
Colon c.298C>T Gln100Stop no
Rectum c.298C>T Gln100Stop no
Adenocarcinomas Stomach c.580G>A Asp194Asn no
Stomach1 c.910delC Frameshift no
Colon Unknown Unknown no
Colon c.464+1dupG Frameshift no
Colon Deletion exon 1 Unknown no
Colon2 c.468C>G Tyr156Stop no
Pancreas3 c.582C>A Asp194Glu no
Pancreas Unknown Unknown no
Pancreas c.991dupC Frameshift no
Distal bile duct Unknown Unknown no
Distal bile duct c.156_157dupGG Frameshift no
Ampulla Vateri c.291-2A>G Splice variant no
1Carcinoma in situ
2Adenocarcinoma derived from a villous adenoma
3Acinar cell type
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ABSTRACT
Peutz-Jeghers syndrome (PJS) is a rare, autosomal dominant inherited disease. It is clinically 
characterized by the development of gastrointestinal hamartomas, mainly located in the small 
bowel. These hamartomas are prone to complications such as intussusceptions, abdominal 
complaints and anaemia. Furthermore, patients are at increased risk for developing small 
bowel cancer. Therefore, regular surveillance of the small bowel is indicated. However, the 
optimal strategy for surveillance has not been determined yet. This review gives an overview 
of the different techniques that have been described to examine the small bowel of PJS pa-
tients. First, a number of radiologic and endoscopic imaging modalities with diagnostic value 
are discussed. Secondly, recently developed advanced endoscopy techniques are described 
that can serve both as a diagnostic and therapeutic tool in the surveillance of the small bowel. 
Finally, a recommendation is given how to apply these individual techniques for small bowel 
surveillance in a step-up approach.
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INTRODUCTION
Peutz-Jeghers syndrome (PJS) is an autosomal dominant inherited disorder, characterized by 
gastrointestinal (GI) polyposis and mucocutaneous pigmentations. The syndrome is rare and 
incidence has been estimated between 1:8,500 and 1:200,000 births [397]. PJS is caused by 
germline mutations in the serine threonine kinase 11 tumour suppressor gene (STK11 or LKB1 
gene), located on chromosome 19p13.3 [10,11].
The predominant clinical feature of PJS is GI polyposis. PJS polyps are often pedunculated 
and have typical histological features, consisting of a branched, tree-like smooth muscle core 
covered with normal epithelium (see chapter 1, Figure 4, page) [21]. They are referred to as 
hamartomas. Hamartomas can develop throughout the GI tract, but are mainly located in the 
small intestine, usually in the jejunum [19,20]. They may cause complaints of abdominal pain, 
blood loss, or acute intestinal obstruction, in particular resulting from intussusception of a 
small bowel segment carrying a large hamartoma (≥15mm) [20]. The risk of intussusception 
before reaching the age of 20 years up to 50% [20].
Apart from GI polyposis, PJS is also recognized as a cancer predisposition syndrome. 
Patients carry a high risk for the development of both gastrointestinal and extra-intestinal 
malignancies already at a young age [24,380]. For GI cancer, lifetime cumulative cancer risks 
of 38-66% have been reported [23]. For small bowel cancer in particular, a lifetime cumulative 
risk of 13%, and a highly increased relative risk compared to the general population (RR 520) 
has been described [380]. It should be pointed out however that these estimates are derived 
from one meta-analysis and no prospective studies are available to confirm this.
At present, the mechanism of carcinogenesis in PJS patients remains unknown. With regard 
to cancer development in the GI tract, there is controversy whether the malignancies originate 
from pre-existing hamartomas or from coexisting adenomas or normal mucosa. Although 
malignant transformation is found occasionally in PJS polyps and a hamartoma-adenoma-
carcinoma sequence has been described [112,120], hamartomas are currently not considered 
precancerous lesions.
The initial main purpose of surveillance is prevention of small bowel obstruction and in-
tussusception by removal of hamartomas of significant size (≥15 mm). With advancing age, 
this focus may shift to the early detection of small bowel cancer or precancerous lesions; 
however, the preventive effect of surveillance on development of small bowel cancer remains 
to be proven. Up till now, only one recently published paper described the yield of long-term 
GI surveillance in PJS patients [111]. In this retrospective study concerning 51 patients no 
luminal cancers were diagnosed during a median follow-up period of 10 years.
Currently, small bowel surveillance is recommended in patients with PJS every 2-3 years 
from the age of 8-10 years. However, because of its length and tortuous course, visualization 
of the small bowel is technically challenging and the optimal strategy for surveillance has 
not been determined yet. This review gives an overview of the different techniques that have 
been described to examine the small bowel of PJS patients. First, a number of radiologic 
and endoscopic imaging modalities with diagnostic value are discussed. In the second part, 
recently developed advanced endoscopy techniques are described that can serve both as a 
diagnostic and therapeutic tool in the surveillance of the small bowel.
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IMAGING Of THE SMALL BOwEL
Long before any enteroscopy technique was available, the small bowel was visualized by ra-
diological techniques. Small bowel follow-through (SBFT) has been the classic diagnostic tool 
for the assessment of small bowel polyps. However, studies have revealed that the sensitivity 
of SBFT for the detection of small bowel tumours is low (33%-61%) [398,399]. Enteroclysis 
is far more sensitive than SBFT for the detection of small bowel lesions [399]. Enteroclysis 
is a double-contrast radiographic study that is performed by passing a small tube into the 
proximal small intestine, followed by fast infusion of both barium and methylcellulose. The 
fluid infusion causes distension of the bowel lumen and improves the detection of mucosal 
pathologies. In a retrospective study, results of SBFT were abnormal in 11 of 18 patients 
while enteroclysis showed abnormalities in 19 of 20 patients [399]. However, the placement of 
the naso-enteric tube for contrast application can be burdensome. Enterography is a similar 
technique as enteroclysis, but the contrast fluid is ingested by the patient, thereby obviat-
ing naso-enteric intubation. However, distension of especially the proximal small bowel with 
enterography is more cumbersome in comparison with enteroclysis, thereby reducing the 
detection rate of proximally located lesions. Apart from the fact that both conventional entero-
clysis and enterography are associated with significant exposure to ionizing radiation, even to 
a greater extent than with SBFT, overlapping bowel loops on a two-dimensional X-ray image 
may interfere with the distinctive capacity of these techniques to detect mucosal lesions. 
To overcome this problem, enterography and enteroclysis have been combined with cross-
sectional imaging by means of computed tomography (CT) or magnetic resonance imaging 
(MRI). These techniques offer multiplanar imaging and transmural visualization and provide 
additional information of extraluminal structures. Although CT enteroclysis has high sensitivity 
and specificity rates for the detection of diverse small bowel pathology, including polyps [400], 
this technique is not advisable as surveillance tool due to high exposure to ionizing agents.
MR enterography and MR enteroclysis
The major advantage of using MRI is the absence of radiation exposure, except for very limited 
exposure for positioning the naso-enteric tube at Treitz in case of enteroclysis. High sensitivity 
(86%) and specificity (98%) rates are reported with MR enteroclysis for the identification of 
small bowel neoplasms, even for lesions as small as 8 mm [401,402]. Although no firm data 
are available concerning the diagnostic yield of MR enteroclysis in PJS patients, the use of 
MR enterography as surveillance method for PJS has been studied [403,404]. In a British 
prospective study of 19 patients, large PJS polyps (>15 mm) – even those within incompletely 
distended segments – were visible on MR enterography [403]. The authors postulate that poor 
luminal distension could reduce the sensitivity of MR enterography for smaller polyps (≤15 
mm). However, as only large sized polyps determine further therapeutic strategies in PJS, this 
may be of less clinical relevance. In another small retrospective study, a 73% concordance 
between MR enterography and enteroscopy (i.e. double balloon enteroscopy, laparoscopic 
endoscopy or surgery) for polyps <15 mm was found, and a 93% concordance for polyps 
>15 mm [404]. The authors suggest the use of MR enterography as a yearly surveillance tool 
in PJS patients.
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Video capsule endoscopy
With video capsule endoscopy (VCE) a pill-size capsule is swallowed and passes passively 
through the gastrointestinal tract via peristalsis. In an ambulatory setting, the device makes im-
ages of the mucosa without the use of ionizing radiation. Visualization of the entire small bowel 
is obtained in approximately 80% of patients [405] The major potential risk of this technique is 
capsule retention within a postsurgical stricture, adhesion, or by a large polyp occluding the small 
bowel lumen. However, this is a rare complication with a reported frequency of 1%-2% [406,407].
The diagnostic value of VCE has been studied in PJS patients (Table 1). In general it is safe, 
well tolerated and valuable for the detection of polyps in the small bowel. Although VCE is able 
to detect polyps smaller than 5 mm [408,409], it cannot accurately determine the location and 
the exact size of the polyps. Furthermore, VCE is not able to accurately visualize the proximal 
region of the small intestine, most probably due to rapid capsule transit and relatively poor 
luminal distension at this level. Moreover, false-negative results of VCE are frequently reported 
and there is increasing evidence that even large lesions may be missed by VCE [410,411]. 
A Portuguese study reported 20% (5/26) of polyps larger than 11 mm missed by VCE in 14 
PJS patients [410]. Another case report described a PJS patient with a 37-mm polyp in the 
proximal ileum, not detected by VCE [411].
The use of VCE has also been assessed in children with PJS [412,413]. It is considered a 
safe and sensitive method for small bowel polyp surveillance. Younger children may have dif-
ficulty swallowing the capsule which can be overcome by placing the capsule in the stomach.
Small bowel endoscopy techniques
All the above mentioned imaging techniques share the disadvantage of only having diagnostic 
value. When large polyps (≥15 mm) are detected, intervention is required to remove these 
polyps. Various techniques have been described for small intestinal polypectomy in PJS 
patients. For a long time, push enteroscopy (PE) was the most frequently used non-surgical 
technique. It uses a long endoscope to reach the small bowel beyond the ligament of Treitz by 
fairly standard endoscopic techniques. Although several studies have described successful 
small bowel investigation and polypectomy of hamartomas with PE in PJS [421-423], the 
use of the push method is limited. Deep insertion of the enteroscope is hampered by the 
tortuous small intestine, in which the applied force is inefficiently transferred to the distal 
part of the enteroscope. The depth of insertion is at most 160 cm beyond the ligament of 
Treitz while small bowel length can range from 2 to 6.5 metres [424,425]. For surveillance in 
PJS patients, examination of the entire small intestine is desirable. To achieve this, in 1985 a 
combined endoscopic-surgical approach in 5 PJS patients was described [426]. During open 
laparotomy, passage of a scope was assisted by the surgeon. This approach allows direct 
visualization of the whole length of the small bowel and removal of hamartomas at the same 
time. Though, the investigation is invasive. It requires general anaesthesia and laparotomy 
with its associated risks, and the possibility of adhesion formation. Although some improve-
ment has been made with laparoscopic assistance for insertion of the enteroscope, this still 
requires general anaesthesia and both a surgeon and an endoscopist.
In the last decade, several advanced endoscopic techniques have been developed that 
allow visualization of the entire small bowel and therapeutic interventions without the need 
for surgery. In the following section, two of these techniques are described; balloon assisted 
enteroscopy and spiral enteroscopy.
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Balloon-assisted enteroscopy
As a modification of the push method, Yamamoto described total enteroscopy with a double-
balloon method [427]. This technique uses two balloons, one attached to the tip of the endo-
scope and another at the distal end of an overtube. The balloons are used to grip the intestinal 
wall so that the endoscope can be inserted without forming redundant loops in the small 
bowel. In a series of push and pull steps, the small bowel is pleated over the enteroscope. 
In comparison with PE, the double-balloon endoscope (DBE) can be advanced much further 
into the small intestine. A combined oral and anal approach enables visualization of the entire 
small bowel with a success rate of 40%-80% [428]. However, the procedure takes more time 
to perform than a conventional push enteroscopy. Dependent on the indication, DBE has a 
diagnostic yield of at least 60% for small bowel disease, including neoplastic lesions [429].
Ohmiya et al. were the first to describe the use of DBE for the diagnosis and treatment 
of PJS polyps in the small intestine [430]. In two patients, multiple polyps (10-60 mm) were 
detected in the jejunum and ileum and resected without subsequent bleeding or perforation. 
Since then, various studies have described a high diagnostic yield of DBE in PJS patients with 
successful polypectomy (Table 2).
In general, the complication rate after diagnostic DBE is estimated at 0.8% [445]; the most 
severe being acute pancreatitis with a risk of approximately 0.2% to 0.3% after oral approach 
[446,447]. As in conventional endoscopy, the risk of severe complications is higher in therapeutic 
enteroscopy (4.3%), mainly attributable to bleeding (3%). The reported complication risk of DBE 
in PJS patients differ widely (Table 2). Dutch authors described 29 diagnostic and therapeutic 
DBE procedures in 13 patients with PJS, with removal of multiple polyps of ≥ 10 mm [440]. 
No complications occurred during the procedures and during follow-up. However, two other 
studies, concerning 15 and 18 PJS patients respectively, report a complication rate of up to 
6.8%, including acute pancreatitis (2.7%) [444] and post-polypectomy syndrome (5%) [419].
It should be noted that DBE might be challenging in patients with a history of abdominal 
surgery, due to altered anatomy and the presence of adhesions. Furthermore, it is speculated 
that, apart from the usual risks associated with DBE, PJS patients might be more prone to 
perforation after polypectomy. As the serosa invaginates the stalk of the polyp, removing a 
polyp near its base might cause a bowel perforation. However, this is only based on expert 
opinion and no studies are available to confirm this theory.
One study assessed the feasibility and utility of DBE in the management of small bowel 
diseases in children (median age 12.9 years), including 5 patients known with PJS and small 
bowel polyps [438]. In two of the 5 PJS patients complete enteroscopy was achieved and 
polypectomy was successful in all. No enteroscopy-related complications occurred; however, 
one patient who underwent a laparoscopic-assisted DBE developed a pelvic abscess without 
intestinal perforation, most likely as complication of the laparoscopy.
Apart from the double-balloon method, a similar system exists with a single balloon. In 
contrast to the DBE system, no balloon is attached to the tip of the overtube but stable 
positioning in the small bowel is achieved by angling the tip of the endoscope or by so-called 
power suction. A recent study showed that DBE and single-balloon enteroscopy (SBE) have 
a comparable performance and diagnostic yield for the evaluation of the small bowel [448].
One study described the experience with SBE in PJS patients [449]. In 7 patients, multiple 
polyps (4-20 polyps; 0.5-40 mm in diameter) were detected and removed or biopsied. No 
major complications occurred. According to the authors, the handling of SBE seems to be 
much easier compared to that of DBE.
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Spiral enteroscopy
Recently, spiral enteroscopy (SE) was introduced [450]. This method uses a special overtube 
with raised helices at the distal end. Clockwise rotations pleat the small bowel over the over-
tube. To perform interventions or take biopsies, the rotation of the overtube is discontinued 
and instruments are inserted through the accessory channel of the enteroscope. Because of 
the novelty of the technique, there is little experience with spiral enteroscopy in PJS patients 
yet. In 2010, the efficacy of the technique was described in a study of 11 patients, including 1 
PJS patient [451]. This 35-year-old woman had previously undergone a small bowel resection 
because of an intussusception. During the procedure many small polyps and several large 
pedunculated polyps (20-30 mm) in the jejunum and ileum were detected and removed. The 
duration of the procedure was 30 minutes and the insertion depth was 240 cm. No major com-
plications occurred. More recently, a case of a small bowel perforation after therapeutic SE in 
a PJS patient was reported [452]. Given this scarce experience, further prospective studies 
with SE are needed for a reliable assessment of the use of this technique in PJS patients.
SUMMARY
Small bowel surveillance is indicated every 2-3 years for patients with PJS from the age of 
8-10 years. Removal of large small bowel hamartomas reduces the need for elective and 
emergency laparotomy. There are no firm data yet that surveillance of the small bowel reduces 
the risk of small bowel cancer.
Various radiologic and endoscopic techniques are available to examine the small intestine 
(Table 3). However, a golden standard is lacking. Currently, it is recommended to use a step-
up approach for surveillance, making complementary use of the different techniques. As a 
first step, MRI enteroclysis is a sensitive method for visualisation of the small bowel lumen 
and the detection of polyps. In children, VCE might be a feasible procedure for the first step 
of surveillance, although large polyps may be missed.
When significant polyps are detected (>10-15 mm), balloon-assisted enteroscopy (BAE) 
should be the preferred method for polypectomy as a second step. BAE could be considered 
the first surveillance step in patients known to have a high polyp load. In case a polyp is too 
large for safe removal with BAE or when a polyp cannot be reached with BAE, (laparoscopic) 
intraoperative enteroscopy could be considered for polypectomy or enterotomy. However, 
elective surgical interventions should be avoided in PJS patients because of the risk of adhe-
sions.
For patient convenience, one investigation for both detection and removal of significant 
lesions is preferable. This may be feasible with double balloon enteroscopy, although it is 
not known yet whether the diagnostic yield of DBE for the detection of PJS hamartomas is 
sufficient to serve as a diagnostic tool alone. Future research should clarify the diagnostic 
value of DBE in PJS patients.
Chapter 6
98
Ta
b
le
 3
. P
ro
s 
an
d
 c
on
s 
of
 d
iff
er
en
t 
ra
d
io
lo
gi
c 
an
d
 e
nd
os
co
p
ic
 t
ec
hn
iq
ue
s 
fo
r 
sm
al
l b
ow
el
 s
ur
ve
ill
an
ce
 in
 P
eu
tz
-J
eg
he
rs
 s
yn
d
ro
m
e.
Sm
al
l b
ow
el
 
fo
llo
w
-t
hr
ou
gh
M
R
I e
nt
er
oc
ly
si
s 
/ 
en
te
ro
gr
ap
hy
Vi
de
o 
C
ap
su
le
 
En
do
sc
op
y
In
tr
ao
pe
ra
tiv
e 
En
do
sc
op
y
P
us
h 
En
te
ro
sc
op
y
B
al
lo
on
 A
ss
is
te
d 
En
te
ro
sc
op
y
P
ro
s
- 
Fa
st
 p
ro
ce
du
re
- 
N
ot
 in
va
si
ve
- 
N
o 
se
da
tio
n 
re
qu
ire
d
- 
N
ot
 in
va
si
ve
- 
N
o 
ra
di
at
io
n 
ex
po
su
re
- 
N
o 
se
da
tio
n 
re
qu
ire
d
- 
M
in
im
al
ly
 
in
va
si
ve
- 
N
o 
ra
di
at
io
n 
ex
po
su
re
- 
N
o 
se
da
tio
n 
re
qu
ire
d
- 
O
n 
ou
tp
at
ie
nt
 
ba
si
s
- 
S
in
gl
e-
pr
oc
ed
ur
e
- 
In
sp
ec
tio
n 
an
d 
to
ta
l c
le
ar
an
ce
 o
f 
th
e 
en
tir
e 
sm
al
l b
ow
el
- 
M
od
er
at
el
y 
in
va
si
ve
- 
B
io
ps
ie
s 
an
d 
th
er
ap
eu
tic
 
in
te
rv
en
tio
ns
 
po
ss
ib
le
- 
M
od
er
at
el
y 
in
va
si
ve
- 
B
io
ps
ie
s 
an
d 
th
er
ap
eu
tic
 in
te
rv
en
tio
ns
 
po
ss
ib
le
- 
To
ta
l e
nt
er
os
co
py
 p
os
si
bl
e
C
on
s
- 
R
ad
ia
tio
n 
ex
po
su
re
- 
N
o 
in
te
rv
en
tio
ns
 
po
ss
ib
le
- 
Lo
w
 s
en
si
tiv
ity
- 
N
o 
in
te
rv
en
tio
ns
 
po
ss
ib
le
- 
S
iz
e 
es
tim
at
io
n 
an
d 
ex
ac
t 
lo
ca
liz
at
io
n 
of
 
po
ly
ps
 in
ac
cu
ra
te
- 
P
la
ce
m
en
t o
f 
na
so
-e
nt
er
ic
 tu
be
- 
N
o 
in
te
rv
en
tio
ns
 
po
ss
ib
le
- 
S
ig
ni
fic
an
t 
le
si
on
s 
m
ay
 b
e 
m
is
se
d,
 e
sp
ec
ia
lly
 
in
 th
e 
pr
ox
im
al
 
sm
al
l b
ow
el
- 
S
iz
e 
es
tim
at
io
n 
an
d 
ex
ac
t 
lo
ca
liz
at
io
n 
of
 
po
ly
ps
 in
ac
cu
ra
te
- 
C
ae
cu
m
 n
ot
 
al
w
ay
s 
re
ac
he
d
-L
ap
ar
ot
om
y/
la
pa
ro
sc
op
y 
re
qu
ire
d
- 
G
en
er
al
 a
ne
st
he
si
a 
re
qu
ire
d
- 
S
ur
ge
on
 a
nd
 g
as
tro
en
te
ro
lo
gi
st
 
re
qu
ire
d
- 
S
ed
at
io
n 
re
qu
ire
d
- 
Ti
m
e 
co
ns
um
in
g
- 
Li
m
ite
d 
to
 
du
od
en
um
 a
nd
 
pr
ox
im
al
 je
ju
nu
m
- 
B
ur
de
ns
om
e
- 
S
ed
at
io
n 
re
qu
ire
d
- 
Ti
m
e 
co
ns
um
in
g
- 
O
fte
n 
≥ 
2 
se
ss
io
ns
 re
qu
ire
d 
fo
r t
ot
al
 
en
te
ro
sc
op
y
- 
B
ur
de
ns
om
e


Chapter 7
Pancreatic cancer risk in 
Peutz-Jeghers syndrome 
patients; a large cohort 
study and implications for 
surveillance
Susanne E. Korsse, Femme Harinck, Margot G.F. van Lier, Katharina Biermann, 
G. Johan A. Offerhaus, Nanda Krak, Caspar W.N. Looman, Wendy van Veelen, 
Ernst J. Kuipers, Anja Wagner, Evelien Dekker, Elisabeth M.H. Mathus-Vliegen, 
Paul Fockens, Monique E. van Leerdam, Marco J. Bruno
Journal of Medical Genetics 2013;50(1):59-64.
Chapter 7
102
ABSTRACT
Background: Although Peutz-Jeghers syndrome (PJS) is known to be associated with pan-
creatic cancer (PC), estimates of this risk differ widely. This hampers counselling of patients 
and implementation of surveillance strategies. We therefore aimed to determine the PC risk in 
a large cohort of Dutch PJS patients.
Methods: PJS was defined by diagnostic criteria recommended by the WHO, a proven LKB1 
mutation, or both. All patients with a presumptive diagnosis of pancreatic, ampullary or distal 
bile duct cancer were identified. Cases were reviewed clinically, radiologically and immuno-
histochemically. Cumulative PC risks were calculated by Kaplan-Meier analysis and relative 
risks by Poisson regression analysis.
Results: We included 144 PJS patients (49% male) from 61 families (5640 person years 
follow-up). Seven (5%) patients developed PC at a median age of 54 years. Four patients 
(3%) were diagnosed with distal bile duct (n=2) or ampullary cancer (n=2) at a median age 
of 55 years. The cumulative risk for PC was 26% (95% CI 4% to 47%) at age 70 years and 
relative risk was 76 (95% CI 36 to 160; p<0.001). The cumulative risk for pancreatico-biliary 
cancer was 32% (95% CI 11% to 52%) at age 70, with a relative risk of 96 (95% CI 53 to 174; 
p<0.001).
Conclusions: PJS patients have a highly increased risk for pancreatico-biliary cancer. 
Therefore, patients are eligible for surveillance within well-defined research programmes to 
establish the benefit of such surveillance.
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INTRODUCTION
Despite the relative low incidence of pancreatic cancer (PC) (8-10 per 100 000 per year, with 
an approximate 1% life time risk in western populations [453]), PC is among the top five 
causes of cancer related deaths in both the USA and Europe [454,455]. The mean survival 
after diagnosis is less than 6 months and the overall 5-year survival is less than 5% [456]. 
This poor prognosis is mainly due to the late onset of symptoms and anatomic location of the 
disease. Consequently, less than 20% of all patients presents with localised disease and are 
therefore eligible for curative treatment. Unfortunately, this intended curative treatment proves 
only to be effective for the minority of patients with an overall 5-year survival after surgical 
resection of less than 10% [457]. Despite recent advantages in the field of surgery and oncol-
ogy, this dismal prognosis has not significantly changed over the past decades [458].
Detection of precursor lesions or malignancies at an early asymptomatic stage by sur-
veillance with endoscopic ultrasound (EUS) and/or MRI could offer a way to improve the 
prognosis [459]. In particular, when surveillance is directed towards populations of individuals 
that carry a high risk for developing PC, the potential health gain could be substantial.
One such high-risk population consists of patients with Peutz-Jeghers syndrome (PJS). 
PJS is an autosomal dominant inherited disorder, caused by germline mutations in the LKB1 
tumour suppressor gene (also known as STK11) [30]. It is characterised by gastrointestinal 
hamartomas and mucocutaneous pigmentations. Furthermore, patients with PJS are at risk 
for developing various types of cancer, including PC [24,115,380]. The actual risk of develop-
ing PC for PJS patients is currently unclear. Previous studies reported relative risks ranging 
from 0 to 132-fold increase and an average age of PC onset ranging from 41 to 60 years of age 
[115,380,460-462]. Consequently, this hampers counselling of PJS patients and implementa-
tion of surveillance strategies.
These disparate risk estimates were mainly derived from heterogeneous multicentre 
populations, small single centre cohort studies, and meta-analyses of these same studies. 
It is therefore key to perform such a study in a large homogenous population. In 2011, our 
research group reported on the high overall cancer risk in a unique, large pedigree based 
homogenous cohort of Dutch PJS patients with a substantial prospective period of follow-up 
[24]. For the present study, we performed a thorough re-evaluation of all reported cancers in 
the pancreatico-biliary region in this patient cohort, including 2 years of extended follow-up. 
Thus, we aimed to conclude the ongoing debate regarding the true PC risk in PJS, and to 
provide a more scientific rationale for the implementation of surveillance strategies.
MATERIALS AND METHODS
Peutz-Jeghers syndrome database
This nationwide cohort study was initiated by two Dutch academic hospitals. Between 1995 and 
July 2011, PJS patients throughout the Netherlands were included without selection for medical 
history. All patients had a definite diagnosis of PJS, defined by diagnostic criteria recommended 
by the WHO (see chapter 1, Box 1, page 12), a proven LKB1 mutation, or both. Informed consent 
was obtained from all patients and the study was approved by the Institutional Review Board 
of both participating hospitals. Patients were followed prospectively between January 1995 
and July 2011. Patient information at baseline and during follow-up was obtained by interview 
and chart review. Clinical data from the period before 1995 as well as data of deceased family 
members fulfilling the diagnostic criteria for PJS were collected retrospectively.
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Case selection and data collection
PC cases were identified from the PJS database. PC was defined according to the most 
recent WHO classification of tumours of the digestive system [456]. In addition, patients with 
a diagnosis of distal bile duct cancer or ampullary cancer were included. Surveillance of the 
pancreas might also detect these malignancies and accurate distinction between these three 
tumours often proves difficult. From all selected cases, medical records were reviewed by two 
MDs (SEK and FH). The following data were collected: gender, date of birth, cancer diagnosis 
and death, mutation status and type of mutation, family history of PJS, and family history of 
PC. The recorded cancer characteristics included tumour type and origin, tumour invasion, 
data on confirmation (medical record or histology), and presentation (surveillance, accidentally 
or symptomatic). Radiological images were reviewed by an expert abdominal radiologist (NK). 
Available formalin-fixed and paraffin-embedded tissue was reviewed by two expert patholo-
gists independently (KB and GJAO). Immunohistochemical staining for SMAD4, CDX2 and 
cytokeratins was performed to ascertain the diagnosis [456]. Eventually, all available informa-
tion was re-assessed by an expert panel (KB, GJAO, NK, ED, EMHMV, MEvL and MJB) to 
determine a definite diagnosis of PC, distal bile duct cancer or ampullary cancer.
Statistical analysis
Data were analysed using the SPSS V.17.0 statistical software for Windows (IBM, Somers, 
New York, USA). All risks were calculated for two groups: (1) PC cases; (2) cases of cancer in 
the pancreatico-biliary region, including cases with PC, distal bile duct cancer or ampullary 
cancer. Cumulative risks were estimated as a function of time using the Kaplan-Meier method 
and the Cox regression model. For these cumulative risk analyses, all subjects of the cohort 
were included. For relative cancer risk calculation, the tumour specific cancer incidence 
observed in our study population was compared to the age specific and gender specific 
incidence rates of the Dutch general population from 1960 to 2011 by Poisson regression 
analysis (log linear analysis) using the package R [463]. Subjects were studied with respect 
to their risk of developing cancer from birth until the date of death, date of last contact or 
the closing date of the study (1 July 2011). Sociodemographic data and incidence rates of 
the Dutch general population were derived from the Eindhoven Cancer Registry (1960-2009). 
These data are representative for the Netherlands. Incidence rates for 2009 were assumed to 
be representative for 2010 and 2011.
RESULTS
Study population
In total, 144 PJS patients from 61 families were included in the cohort with a total of 5640 
person-years of follow-up (including 1757 person-years of prospective follow-up). Forty-nine 
per cent were male (3050 person-years). At the closing date of the study six patients had 
been lost to follow-up (4%), and 48 (33%) had died at a median age of 46 years (IQR 32-58 
years); the median age of the 90 patients still alive (63%) was 37 years (IQR 21-52 years). The 
baseline characteristics of the cohort are shown in Table 1.
105
Pancreatic cancer risk in Peutz-Jeghers syndrome patients
Table 1. Baseline characteristics of the Dutch Peutz-Jeghers syndrome cohort.
Total 144
Gender
Male 70 (49%)
Female 74 (51%)
Families 61
Family history
Familial PJS 109 (76%)
Sporadic 24 (17%)
Family history unknown 11 (7%)
Fulfilling WHO criteria1 142 (99%)
DNA mutation analysis 92 (64%)
LKB1 mutation carrier 82/92 (89%)
Deceased 48 (33%)
Median age at death 46 years (IQR 32-58 years)
Lost to follow up 6 (4%)
Cancer 48 (33%)
Median age at diagnosis of first cancer 46 years (IQR 35-55 years)
2 primary cancers 8
IQR: interquartile range; PJS: Peutz-Jeghers syndrome; WHO: World Health Organisation.
1Two patients not fulfilling the WHO-criteria carry a proven LKB1 germline mutation.
Pancreatic cancer cases
The case selection process is shown in Figure 1. During follow-up, seven (4.9%) PJS patients 
from seven families developed PC, six male and one female. None of the cases was detected 
within the framework of a PC screening/surveillance programme. Adenocarcinoma of the pan-
creas was found in 6 patients and acinar cell carcinoma in one. Six cases were confirmed by 
revision of histology, and no histological material was available for the seventh case. Median 
age at diagnosis was 54 years (IQR 37-62 years). Six patients presented with symptoms. 
In one patient a tumour mass was incidentally found during a laparotomy because of small 
bowel polyps. None of the patients could be treated curatively. Median survival of patients 
after diagnosis was 6 months (IQR 4-17 months). Mutation analysis for the LKB1 gene was 
performed in five patients, detecting a pathogenic mutation in four of them. For the other two 
cases, a pathogenic mutation in the LKB1 gene was detected in affected family members, 
but mutation analysis was not performed in the PC patients. Two of the patients had been 
treated curatively for another malignancy (colorectal cancer and liposarcoma) prior to the 
development of PC. Individual patient characteristics are shown in Table 2A.
Ampullary cancer and distal bile duct cancer cases
In addition to the patients with PC, distal bile duct cancer was diagnosed in a male patient 
at the age of 57 and in a female patient at the age of 73 years. Both patients only underwent 
palliative treatment; survival after diagnosis was 3 and 8 months, respectively. Furthermore, 
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ampullary cancer/cancer involving the ampulla was detected in two male patients at the age 
of 41 and 53 years. Both patients underwent a pylorus preserving pancreaticoduodenectomy 
as curative treatment. One patient died of metastasized disease 5 years after diagnosis; the 
other patient is still alive 11 years after diagnosis. Patient characteristics are shown in Table 
2B. The median age at diagnosis for the group of patients with pancreatic, distal bile duct or 
ampullary cancer (n=11) was 54 years (IQR 42-62).
 
Pancreatic cancer n=5 
Distal bile duct cancer n=2 
Ampullary cancer n=3 
Adenocarcinoma of the small intestine n=4 
Adenocarcinoma of the digestive tract not 
otherwise specified n=3        
N=17 
 
 
Peutz-Jeghers syndrome 
database 
N=144 
Revision of medical records: 
- Pseudo-invasion of small intestinal hamartoma n=2 
- Insufficient information n=2 (excluded) 
- Ampullary cancer  pancreatic cancer n=1 
  
Pancreatic cancer n=6 
Distal bile duct cancer n=2 
Ampullary cancer n=2 
Adenocarcinoma of the small intestine n=1 
Adenocarcinoma of the digestive tract not  
otherwise specified n=2 
N=13 
Expert opinion after revision of histology and/or 
radiology: 
- Adenocarcinoma of the digestive tract not otherwise 
specified  pancreatic cancer n=2 
- Pancreatic cancer  adenocarcinoma of the 
digestive tract (stomach/small bowel) n=1 
 
 
 
 
Pancreatic cancer n=7 
Distal bile duct cancer n=2 
Ampullary cancer n=2 
Figure 1. Case selection
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Cumulative cancer risk
Pancreatic cancer (n=7)
The Kaplan-Meier estimate for the cumulative PC risk was 2.4% (SE 1.7%; 95% CI -0.9% to 
5.7%) at age 40; 3.9% (SE 2.2%; 95% CI -0.4% to 8.2%) at age 50; 11.1% (SE 5.3%; 95% CI 
0.7% to 21.5%) at age 60; and 25.6% (SE 10.8%; 95% CI 4.4% to 46.8%) at age 70 (Figure 
2, left). There was no significant difference in risk between males and females (p = 0.272).
Total number of patients at risk: 
 144 
 
114 
 
72 
 
21 
 
Total number of patients at risk: 
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114 
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21 
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Figure 2. Cumulative cancer risk in Peutz-Jeghers syndrome patients according to age.
Pancreatic, ampullary or distal bile duct cancer (n=11)
For pancreatic, distal bile duct or ampullary cancer the cumulative risk was 2.4% (SE 1.7%; 
95% CI -0.9% to 5.7%) at age 40; 5.2% (SE 2.6%; 95% CI 0.1% to 10.3%) at age 50; 18.2% 
(SE 6.5%; 95% CI 5.5% to 30.9%) at age 60; and 31.6% (SE 10.6%; 95% CI 10.8% to 52.4%) 
at age 70 (Figure 2, right). There was no significant difference in risk for these malignancies 
between males and females (p = 0.248)
Relative cancer risk
From 1960, 131 patients contributed to 4430 person-years at risk (males 2259 person-years, 
females 2171 person-years). Poisson regression analysis showed that the relative risk for PC 
(HR 76.2, 95% CI 36.3 to 160.0) as well as for pancreatic, ampullary or distal bile duct cancer 
(HR 95.8, 95% CI 52.8 to 173.7) was significantly higher in PJS patients than in the general 
population (p<0.001).
DISCUSSION
This nationwide, long term follow-up cohort study shows that patients with PJS have a highly 
increased PC risk. We found a cumulative cancer risk of more than 25% at the age of 70 
years and a 76-fold increased risk compared to the general population. The cumulative risk 
for developing any type of malignancy in the pancreatico-biliary region, including pancreatic, 
distal bile duct, or ampullary cancer, is as high as 29% at the age of 70 years and the relative 
risk for these cancers is 96. These data emphasise the relevance and clinical potential of 
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surveillance of the pancreas for PJS patients, provided a suitable and effective surveillance 
program is available.
Estimates on the risk of PC in patients with PJS vary widely within the literature. Our data are 
most in line with those from Giardiello et al. [380]. In a meta-analysis in which 210 PJS patients 
from six American and European studies were included, six cases of PC were identified which 
amounted to a cumulative risk of 36% by the age of 64 years and a relative risk of 132. The 
mean age at PC onset was 40.8 years (SD 16.2). Because the source data were contributed 
by multiple centres worldwide, the authors were not able to give extensive information about 
the intricacies of case selection or confirmation of the cancer diagnosis, including revision of 
pathology specimens and potential confounding issues relating to the problematic distinction 
between pancreatic, distal bile duct, and ampullary cancer. Furthermore, incidence rates of 
the US population were used for relative risk calculation, while the study population consisted 
of both US and European (UK and Dutch) patients. This might have led to biased relative 
cancer risks, as differences in cancer risk between PJS and control populations could exist 
due to variations in geography, race, culture and diet.
The extremely elevated risk found by Giardiello et al. has not been reproduced by more 
recent studies. An international collaborative study concerning 419 PJS patients from eight 
centres worldwide found a cumulative risk for developing PC of 11% by the age of 70 [460]. 
Relative risk was not reported. Another collaborative study found no PC in a total of 149 PJS 
cases [461]. Interpretation of the results of these two series is difficult, since no information is 
provided on the average age of the cohort or follow-up period. Albeit speculative, the lower 
risk found in these series could be the result of the participants being too young or the lack 
of sufficient follow-up time. The same data on age and follow-up period is missing in most 
current nationwide or single centre studies, which are often limited by a small sample size.
To our knowledge this is the first study to investigate the PC risk within a large, nationwide 
PJS patient cohort with long term follow up. This cohort goes back to the original family 
described by Jan Peutz in 1921 [4], and encompasses a substantial period of prospective 
follow-up time amounting to 5640 person-years including 1757 person-years of prospective 
follow-up. Because it is well known that differentiation between pancreatic, distal bile duct 
and ampullary cancer is a diagnostic challenge, we attempted to address the issue of case 
selection by careful expert revision of clinical, radiological, and histological materials. This 
enabled us to provide reliable risk estimates for PC alone and for cancers of the pancreas 
and pancreatico-biliary region including distal bile duct and ampullary cancer. The latter are 
sometimes misclassified or impossible to differentiate from PC. As such, these numbers could 
be looked upon as absolute minimum and maximum risk estimates. Another important clini-
cal consideration when making such a separate risk assessment is that distal bile duct and 
ampullary cancer, just like PC, have a potential for early detection in surveillance programs of 
the pancreas.
A few limitations of our study warrant consideration. Firstly, because this PJS patient cohort 
was initiated by two tertiary referral centres, selection bias could potentially have led to an 
overestimated incidence of PC. Secondly, we were unable to gather reliable information about 
the smoking behaviour of our patients. This is unfortunate because smoking is one of the 
most important risk factors for the development of PC [464,465] and therefore a probable 
confounding factor between different PJS populations.
The evidence is slowly accumulating that surveillance of high risk individuals leads to 
the detection of high grade precursor lesions and asymptomatic early stage PC [466-474]. 
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However, we currently still lack definite evidence that surveillance has a net benefit in terms 
of mortality reduction of PC related mortality and gain in life years, and whether this benefit 
outweighs the potential negative side effects of overtreatment, including associated compli-
cations and costs. We and others therefore suggest that surveillance of PJS patients should 
only be performed within the framework of well-established research protocols [475,476]. 
Results of the international Cancer of the Pancreas screening (CAPS) summit meeting in 2011 
indicate that surveillance in high risk individuals should be regarded as a promising develop-
ment, though more evidence is needed to address its real value [477]. During this meeting, 49 
experts in the field of PC voted on statements with respect to PC surveillance. This resulted 
in a number of outstanding questions that still need to be addressed, including questions with 
respect to who to screen, when to start screening, the optimal frequency of screening, and 
particularly the optimal management of the asymptomatic pancreatic lesions detected.
Based on the results of our current study, we recommend that PJS patients should be 
offered surveillance regardless of family history for PC, since all subjects with PC in our series 
had a negative family history of PC. Although the median age of PC onset in our cohort was 
54 years, we propose that surveillance starts at the age of 30 years. This suggestion is based 
on the fact that two patients in our series developed cancer in the pancreatico-biliary region at 
a very young age. If screening had started 10 years earlier than the median age of PC onset, 
these cases would have been missed.
It has been noted that some patients with PJS develop intestinal-type intraductal papillary 
mucinous neoplasms (IPMNs) [153]. IPMNs are well defined premalignant lesions of PC. One 
pancreatic adenocarcinoma in our study showed histological indication for development out 
of an IPMN lesion. Future research should be directed towards unravelling the molecular 
pathway of PC development in PJS patients. Such knowledge may tailor surveillance recom-
mendations even more. Furthermore, the efficacy and cost effectiveness of PC surveillance 
must be further studied.
In conclusion, absolute and relative risks of developing pancreatic, distal bile duct and 
ampullary cancer are very high in patients with PJS. This observation, and the prospect that 
detection of these malignancies, or preferably their precursor lesions, might be possible at 
an early and potentially curable point in time, render PJS patients eligible for surveillance by 
yearly EUS and/or MRI within well-defined research protocols.
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ABSTRACT
Background: Female Peutz-Jeghers syndrome (PJS) patients have a highly increased cancer 
risk, including breast cancer (BC). Risk estimates for BC in these patients vary, while informa-
tion on clinical and histological characteristics is scarce. In the present study, we assessed the 
BC risk and clinicopathological features of BC in a large PJS cohort, and sought to formulate 
a present-day BC surveillance recommendation.
Methods: Cases were identified from the Dutch PJS cohort. PJS was diagnosed according to 
international criteria. Clinical data were collected and radiological and histological data were 
reviewed. Cumulative BC risks were calculated by Kaplan-Meier analysis and relative risk by 
Poisson regression analysis.
Results: Of 145 PJS patients, 75 (52%) were female. Nine women from 8 families were di-
agnosed with BC at a median age of 50 years (range 34-61). Mammography allowed good 
visibility of all but one BC. The majority was of good or intermediate differentiation grade. All 
BCs were oestrogen-receptor positive and Her2-negative. Cumulative BC risk was 62% (95% 
CI 31%-93%) at age 65, and relative risk was 6 (95% CI 3 to 13, p<0.001) compared to the 
general population.
Conclusions: BC risk for female PJS patients is highly increased, approaching that of BRCA-
mutation carriers, while PJS associated BC seem to have a later onset and more favourable 
clinicopathological characteristics. We propose to start annual BC surveillance with mam-
mography in female PJS patients as of 30 years, with additional MRI in patients with dense 
breast tissue. Prospective evaluation of this schedule is required to determine its effectiveness.
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INTRODUCTION
Peutz-Jeghers syndrome (PJS) is a rare, autosomal dominant inherited disorder caused by 
a germline mutation in the LKB1 (also known as STK11) tumour suppressor gene. Clinical 
features include mucocutaneous pigmentations and gastrointestinal hamartomas. In addition, 
PJS patients have an increased risk for developing cancer in adult life, including gastrointestinal 
cancers (colorectum, stomach, and pancreas) and extra-gastrointestinal malignancies (lung, 
breast and gynaecological organs). A cumulative lifetime risk (CLTR) for developing cancer of 
up to 76% has been described [24]. Consequently, mortality in PJS patients is significantly 
increased compared to the general population [24]. Assuming that detection of precursor 
lesions or malignancies at an early and asymptomatic stage might decrease cancer-related 
mortality, cancer surveillance of various organs is recommended for this patient group [30].
Due to the additional risk of breast cancer and gynaecological malignancies, female PJS 
patients carry a higher CLTR for developing cancer than male patients [24]. Several studies 
reported on the risk of breast cancer (BC) in PJS (Table 1), describing CLTRs for BC of 29-54% 
at age 65 years, and relative risks (RR) of 6-15 [17,380,460,478]. However, these risk estimates 
were mainly derived from heterogeneous multicentre populations, small cohort studies, or 
meta-analyses of these studies. Furthermore, important clinical and histological information of 
PJS-associated BC cases and data on the method of detection is currently lacking.
In the present study, we assessed the BC risk for female PJS patients and investigated 
the features of PJS-associated BC by revision of clinical, pathological and radiological data 
of the Dutch PJS cohort. Based hereon, we propose a present-day recommendation for BC 
surveillance for female PJS patients.
MATERIALS AND METHODS
Peutz-Jeghers syndrome database
Between 1995 and July 2012, Dutch PJS patients were included in a nationwide cohort study, 
initiated by two academic hospitals (Academic Medical Centre in Amsterdam and Erasmus 
MC University Medical Centre in Rotterdam). The diagnosis of PJS was defined by diagnostic 
criteria as recommended by the World Health Organisation (WHO) (see chapter 1, Box 1, page 
12) and/or a proven LKB1 mutation. Patients were included without selection for medical 
history. Informed consent was obtained from all patients or from their next of kin if patients 
had passed away. Patient information was obtained by interview and chart review. Clinical 
data from the period before 1995 as well as data of deceased family members fulfilling the di-
agnostic criteria for PJS were collected retrospectively from hospital files. Institutional Review 
Boards of both coordinating hospitals approved the study.
At the closing date of the current analysis, 145 PJS patients from 62 families were included 
in this cohort study. Baseline characteristics are shown in Table 2.
Case selection and data collection
BC cases (both invasive and ductal carcinoma in situ; DCIS) were identified from the PJS da-
tabase. The following data regarding BC patients were collected: dates of birth, BC diagnosis 
and death; tumour type (DCIS or invasive cancer); family history of BC and PJS; and LKB1 
mutation status and type of mutation.
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Radiological analysis
Available radiological images were reviewed by two expert breast radiologists (HMZ and IMO), 
being informed on clinical symptoms of the cases. Images consisted of mammographies 
and in one case an additional ultrasound was available. No magnetic resonance imaging 
(MRI) scans were performed. The radiologists assessed the overall breast composition using 
the following patterns: almost entirely fat (American College of Radiology score 1; ACR 1), 
scattered fibroglandular densities (ACR 2), heterogeneously dense (ACR 3) and extremely 
dense (ACR 4). Radiological findings were described and the level of suspicion for malignancy 
was assessed according to the Breast Imaging Reporting and Data System (BI-RADS): no 
abnormality (BI-RADS 1), normal finding (BI-RADS 2), probably benign finding (BI-RADS 3), 
suspicious abnormality (BI-RADS 4) or finding highly suggestive for malignancy (BI-RADS 5) 
[479].
Histological analysis
Available formalin-fixed and paraffin-embedded breast tissue was reviewed by an expert 
breast pathologist (CvD). Invasive carcinomas were classified according to the criteria of the 
WHO Classification, and graded according to the modified Bloom and Richardson grading 
system [480]. DCIS cases were graded based on cytonuclear characteristics. Slides stained 
for steroid receptors (oestrogen receptor (ER) and progesterone receptor (PR)) were scored 
as positive (≥ 10% tumour nuclei positive) or negative (< 10%) according to Dutch guidelines 
(available at www.oncoline.nl) [481]. Her2 status was determined according to the current 
guidelines.[482] Steroid receptors and Her2 status were only determined on invasive BCs.
Table 2. Baseline characteristics of the Dutch Peutz-Jeghers syndrome cohort.
Total Males females
Number of patients 145 70 (48%) 75 (52%)
Families 62 36/62 46/62
Family history
Familial PJS 110 (76%) 55 55
Sporadic 26 (18%) 9 17
Family history unknown 9 (6%) 6 3
DNA mutation analysis 91 (63%) 42 49
LKB1 mutation carrier 82/91(90%) 37 45
Deceased 50 (35%) 27 23
Median age in years at death (IQR) 46 (32-58) 54 (33-60) 45 (31-53)
Follow-up (person-years) 5796 3091 2705
Prospective follow-up (person-years) 1852 860 992
Lost to follow up 5 (3%) 3 2
IQR: interquartile range; PJS: Peutz-Jeghers syndrome.
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STATISTICAL ANALYSIS
Data were analysed using the SPSS 20.0 statistical software for Windows (IBM, Somers, 
New York, USA). Cumulative BC risks were estimated as a function of time using the Kaplan-
Meier method, including all females of the cohort. For relative cancer risk calculation, the BC 
incidence observed in the female study population was compared to the age-specific and 
gender-specific incidence rates of the Dutch general population from 1960 to 2011 by Poisson 
regression analysis (loglinear analysis) using the package R [463]. Patients were studied with 
respect to their risk of developing cancer from birth till date of BC diagnosis, death, date of last 
contact or closing date of the study (July 1, 2012), whichever came first. Socio-demographic 
data and incidence rates of the Dutch general population were derived from the Eindhoven 
Cancer Registry (1960-2011). These data were considered representative for 2012 as well.
RESULTS
Study population
In total, 75 female PJS patients of 46 families contributed to 2705 person-years of follow-up, 
including 992 person-years of prospective follow-up (64 patients). At the closing date of the 
current analysis, two patients had been lost to follow-up (2.7%) and 23 patients (31%) had 
died at a median age of 45 years (IQR 31-53 years). The median age of the 50 women (67%) 
still alive was 31 years (IQR 20-49 years). At the closing date of the study, 24 out of 30 patients 
being ≥ 25 years of age underwent some kind of BC surveillance.
Table 3. Clinical characteristics of Peutz-Jeghers syndrome patients with breast cancer.
Case 
number1
Age (year) at 
breast cancer 
diagnosis
Age at 
death
Type of breast 
cancer
family 
history 
of breast 
cancer
familial/ 
sporadic PJS
LKB1 germline 
mutation
I 34 (2000) - In situ carcinoma No Familial c.370 A>T
II 50 (2009) - Multifocal invasive 
carcinoma
Yes Familial c.752 G>A
III 34 (1997) - Invasive carcinoma No Sporadic Not tested
IV 55 (2009) 585 Invasive carcinoma Unknown Familial c.735-1 G>A6
V 49 (2009) - Invasive carcinoma No Sporadic Deletion exon 1
VI2 53 (1964) 69 Unknown Yes Familial c.921-12 G>A6
VII2 61 (2006) - Invasive carcinoma Yes Familial c.921-12 G>A
VIII 61 (1996) 625 In situ carcinoma No Familial c.991dupC
IX3,4 47 (1944) 475 Unknown No Familial codon 66insT, stop in 
codon 1626
1Case numbers correspond with the case numbers in Table 4 and Figure 1
2First-degree family members
3Malignancy confirmed by previous case-reports [383, 384]
4Case excluded from the relative risk analysis because of diagnosis before 1960
5Deceased because of breast cancer
6Mutation detected in affected first-degree relative
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Breast cancer cases
During follow-up, nine (12%) PJS patients from eight families developed BC at a median age 
of 50 years (range 34-61 years), including two cases of DCIS. No cases of bilateral BC were 
observed. Data on patient characteristics are depicted in Table 3. At the end of the study 
period, four BC patients had died, of which three died due to BC. One of these patients (case 
VIII) was diagnosed with DCIS (poorly differentiated) but presented with metastatic disease 5 
months after diagnosis. Mutation analysis for the LKB1 gene was performed in five patients, 
Pedigree case I
*
Pedigree case IV
*
Pedigree case III
3*
Pedigree case V
2*
?
Pedigree case VI and VII
2 2 4 3
2
*
*
Pedigree case II
*
?
??
Pedigree case VIII
*
4
2 3
Pedigree case IX
*
*
Figure 1. Pedigrees of breast cancer patients.
Breast cancer patients are marked with an asterisk. Case numbers are depicted in roman numerals 
according to Table 3 and 4.
Squares: males; circles: females; diamonds: unknown sex; solid symbols: PJS affected individual; open 
symbols: unaffected individual; symbol with question mark: unknown PJS status; symbol with slash: 
individual is deceased.
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detecting a pathogenic mutation in four. In three other patients fulfilling the diagnostic WHO 
criteria for PJS, a pathogenic mutation in the LKB1 gene was detected in affected first-degree 
relatives. Two BC patients belonged to the same family (case VI and VII). A first-degree family 
member of case II also suffered from BC, but the diagnosis of PJS in this affected family 
member was uncertain and this patient was therefore not included in the current analysis. 
Figure 1 shows the pedigrees of all patients.
Radiology of breast cancer cases
Radiological images of seven patients (78%) were available for revision. Results are shown 
in Table 4. Two patients underwent BC surveillance on a yearly basis, and three patients 
presented with a palpable mass. In five of the seven patients (71%), the mammographies 
showed a low breast density (ACR score 1 or 2). Of note, all cancers but one were identifiable 
on mammography; one BC was identified on additional ultrasound.
Histology of breast cancers
BC tissue of six patients (67%) was available for revision. Two tumours concerned DCIS, and 
four were invasive carcinomas, including a multifocal carcinoma in one patient. All five invasive 
carcinomas, with a median size of 12 mm, were classified as invasive ductal carcinoma not 
otherwise specified. Three of these invasive carcinomas showed adjacent DCIS. Results of 
grading, immunohistochemical staining for steroid receptors and Her2 status, and TNM stage 
at time of diagnosis are shown in Table 4.
Cumulative cancer risk
At age 35 years, the Kaplan-Meier estimate for the cumulative breast cancer risk was 5% (95% 
CI -1.7-11.7) (Figure 2). This BC risk increased from the age of 50 years on, with cumulative 
breast cancer risks being 13.7% (95% CI 0.8-26.6) at age 50 years; 25.9% (95% CI 6.3-45.5) 
at age 55 years; 36.5% (95% CI 11.0-62.0) at age 60 years; and 61.9% (95% CI 30.5-93.3) at 
age 65 years (Figure 2).
Relative cancer risk
From 1960 onwards, 69 patients contributed to 2239 person-years at risk. One BC case was 
excluded from the relative risk analysis because of diagnosis before 1960. Poisson regression 
analysis showed that the relative risk for BC in female PJS patients was 6.4 (95% CI 3.2 - 12.9) 
compared to the general Dutch female population (p<0.001).
DISCUSSION
The present study, performed in a homogenous, large cohort of Dutch PJS patients, shows a 
highly increased risk for developing BC in female patients. We found a cumulative risk of 62% 
at the age of 65 years, mainly rising from 50 years on, and a 6-fold increased risk compared 
to the general female population. These results confirm the very high breast cancer risk in 
women with PJS, in fact approaching the BC risk of patients with BRCA1/2-gene mutations 
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(relative risk 6-8) [483,484]. It has previously been proposed that PJS patients should be 
offered BC surveillance as applied for BRCA mutation carriers [23,30]. In the Netherlands, 
this encompasses annual MRI from the age of 25 years, with annual mammography added 
from 30 till 60 years, after which enrolment in the population based BC screening programme 
is advised. However, histological and radiological features of breast tumours could provide 
valuable information in view of surveillance recommendations. To our knowledge, data heron 
of PJS-associated breast tumours has not been systematically described before in literature. 
Based on our observations, important clinicopathological differences between BC cases in 
PJS patients and BRCA mutation carriers seem to exist, which in our opinion require adjust-
ment to provide a more tailor made BC surveillance regimen for female PJS patients.
First of all, age of BC onset in PJS patients is not as young as reported for BRCA mutation 
carriers. The median age at BC diagnosis in the present study was 50 years (range 34-61 
years), which is in line with the age distribution of BC in other studies concerning PJS patients 
(Table 1). Younger onset of disease has only been described in single case reports [485,486]. 
For BRCA1 and BRCA2 carriers, mean age at BC diagnosis is 43.7 years and 46.8 years, 
respectively [487]. Furthermore, the cumulative incidence of BC in BRCA mutation carriers 
rapidly increases as of young age, being 20-25% at the age of 40 years [487,488]. We ob-
served a cumulative BC incidence of 5% at 40 years in PJS patients, in line with the literature 
(Table 1), and this risk mainly increases from the age of 50 years on (Figure 2).
Secondly, our histological revision of PJS-associated breast cancers showed that the 
majority of carcinomas were of good or intermediate differentiation grade. Furthermore, all 
invasive carcinomas were steroid receptor positive, and Her2 negative. In contrast, most of 
the invasive BRCA-associated breast cancers are of poor differentiation grade and associated 
with a more rapid tumour growth, justifying intensive surveillance at young age [489-491]. 
Although we were not able to assess tumour growth rate in our sample of BC patients due to 
sample size and unavailability of serial imaging examinations, mammographies showed a low 
breast density (ACR score 1 or 2) in five of the seven PJS patients, allowing good visibility of 
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Figure 2. Cumulative breast cancer risk in female Peutz-Jeghers syndrome patients according to age.
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the suspicious lesions. Unfortunately, we were not able to compare our data with other data 
because of lack of reports.
Based on our observations, a panel of experts in the field of (hereditary) BC surveillance dis-
cussed the pros and cons of different surveillance recommendations for female PJS patients. 
In this panel, an oncologist, a pathologist, two radiologists, and a clinical geneticist were 
represented. Because of the highly increased RR of 6, we propose that BC surveillance should 
approach the annual surveillance recommendation of BRCA mutation carriers. Though, in 
view of the later age of BC onset, a later start of surveillance as of 30 years seems justifiable 
in female PJS patients. Furthermore, based on the finding of the radiological revision, it may 
be considered to only perform an MRI in patients with dense breast tissue (ACR 3 or 4), also to 
limit the amount of surveillance investigations in this patient group. After the age of 60 years, 
PJS patients can enrol in a population based BC screening programme. In the Netherlands, 
this encompasses mammography every two years till the age of 75 years.
It seems unlikely that the increased BC risk also affects male PJS patients. In our cohort no 
case of male BC occurred, and in previous literature only one male PJS patient with BC has 
been described [460]. Although this might be an underestimation, the BC risk will always be 
too low to justify surveillance in male PJS patients.
Several limitations of this study should be discussed. First of all, because two tertiary refer-
ral centres initiated this PJS patient cohort, selection bias could potentially have led to an 
overestimation of the incidence of BC. Second, three BC cases had a family history for both 
PJS and BC. Having a first-degree relative with BC is known to increase the risk for BC with 
a factor 1-4 [483,484,492]. This might have distorted the increased risk as described in the 
current study. Third, reliable information about important risk factors for BC, such as obesity, 
diet, the use of oral contraceptives, the age of menarche and first pregnancy, or null parity are 
missing [483,484,492,493]. These missing data, in addition to the small sample size, did not 
allow correcting for confounding factors possibly influencing the BC incidence.
Our results are in line with the results of other collaborative studies (Table 1) [17,460,461,478]. 
However, these studies showed extensive overlap in included patients, who were enrolled 
from specialised centres throughout the Western world. Furthermore, in these studies risk 
estimates for BC were not always complete, and lacked important information about clinical 
and histological characteristics. The extremely elevated risk found by Giardiello et al. [380] 
was based on a meta-analysis of available literature, including single case reports, and has 
not been reproduced by more recent and larger studies. The current study is the first to report 
on the occurrence of BC specifically in a large, pedigree-based nationwide cohort of PJS 
patients with a substantial period of prospective follow-up. None of the patients was included 
in this cohort because of cancer diagnosis, which refutes the possibility of ascertainment bias.
While the high relative risk estimate as described in this study justifies the proposed inten-
sive BC surveillance for PJS patients, we are aware that our recommendation solely reflects 
expert opinion and is not yet evidence based. The relevant findings on clinical and histological 
features of PJS-associated BCs indicate that adaptations to the surveillance scheme for 
BRCA mutation carriers may be relevant. We therefore emphasize that prospective evaluation 
of the proposed surveillance regimen is mandatory, and central registration of this patient 
group might facilitate this aim.
In conclusion, the current study shows a highly increased absolute and relative risk for 
developing BC in female PJS patients, approaching the risk for BRCA mutation carriers. At 
the same time, clinical, histological and radiological characteristics of PJS-associated breast 
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tumours substantially differ from BRCA tumours, in favour of the PJS group. Therefore, we 
propose to start annual BC surveillance with mammography in female PJS patients at the age 
of 30 years, with additional MRI in patients with dense breast tissue (ACR 3 and 4). After the 
age of 60 years, patients can enrol in a population based BC screening programme. Central 
registration of female PJS patients and prospective evaluation of BC surveillance regimens is 
warranted.
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ABSTRACT
Peutz-Jeghers syndrome (PJS) is a hereditary disorder caused by LKB1 gene mutations, and 
is associated with considerable morbidity and decreased life expectancy. This study was 
conducted to assess the attitude of PJS patients towards family planning, prenatal diagnosis 
(PND) and pregnancy termination and pre-implantation genetic diagnosis (PGD). In a cross-
sectional study, 61 adult PJS patients were asked to complete a questionnaire concerning 
genetic testing, family planning, PND and PGD. The questionnaire was completed by 52 
patients (85% response rate, 44% males) with a median age of 45 (range 18-74) years. Thirty-
seven (71%) respondents had undergone genetic testing. Twenty-four respondents (46%, 
75% males) had children. Fifteen (29%) respondents reported that their diagnosis of PJS had 
influenced their decisions regarding family planning, including 10 patients (19%, 9/10 females) 
who did not want to have children because of their disease. Termination of pregnancy after 
PND in case of a foetus with PJS was considered ‘acceptable’ for 15% of the respondents, 
whereas 52% considered PGD acceptable. In conclusion, the diagnosis of PJS influences the 
decisions regarding family planning in one third of PJS patients, especially in women. Most 
patients have a negative attitude towards pregnancy termination after PND, while PGD in case 
of PJS is judged more acceptable. These results emphasize the importance of discussing 
aspects regarding family planning with PJS patients, including PND and PGD.
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INTRODUCTION
Peutz-Jeghers syndrome (PJS) is a rare, autosomal dominant inherited disorder caused by 
germline mutations in the LKB1 gene [10,11]. The syndrome is clinically characterized by gas-
trointestinal hamartomas and mucocutaneous pigmentation [4,494]. Hamartomatous polyps 
can develop already in the first decade of life and may cause various complications, including 
anaemia, bleeding and acute intestinal obstruction [19,495]. Furthermore, PJS is associated 
with an increased cancer risk in adult life. Lifetime cumulative cancer risks as high as 93% 
have been described [23,380]. These clinical aspects of the disease affect the psychological 
condition and quality of life of PJS patients. They suffer from mild depression and experience 
a poorer mental quality of life, more limitations in daily functioning due to emotional problems, 
and a poorer general health perception compared to the general population [496,497].
Performing genetic testing might influence family planning of patients. Diagnostic muta-
tion analysis is available for patients clinically suspected of PJS. If a pathogenic mutation is 
confirmed, antenatal genetic testing of offspring is available through prenatal diagnosis (PND) 
(i.e. chorionic villus sampling and amniocentesis), which may result in the wish to terminate 
the pregnancy in case of an affected foetus. In addition, prei-mplantation genetic diagnosis 
(PGD) has become available. PGD involves in vitro fertilization (IVF). One or two cells of a 
3-day old embryo created in vitro are analysed for the genetic defect, and only embryos with 
an unaffected genotype are selected for transfer to the uterus [498]. Although PND and PGD 
are available for hereditary cancer syndromes in most European countries, the application of 
these techniques remains controversial in the social, ethical and political domain [499].
Data concerning family planning of patients with PJS are lacking. Therefore, the aim of 
this study was to investigate the desire to have children in PJS patients, and their attitudes 
towards PND with the implication of pregnancy termination and towards PGD.
MATERIALS AND METHODS
Patients
A total of 61 PJS patients from 39 families from two Dutch academic hospitals were invited to 
complete a questionnaire on genetic testing, family planning, PND, and PGD. The study was 
approved by the Institutional Review Boards of both participating hospitals. Patients were 
eligible if they were aged 18 years or older and fulfilled the diagnostic criteria for PJS recom-
mended by the World Health Organisation (see chapter 1, Box 1, page 12). The questionnaire, 
an information-folder, a consent form and a reply paid envelop were sent to all potential 
participants by mail. After 6 and 12 weeks a reminder was sent to non-respondents.
Measures
The questionnaire was earlier described in detail by van Lier et al. [497]. Briefly, it comprised 
a range of demographic variables including age, gender, and parenthood. As psychological 
determinants, concerns regarding cancer were assessed with the cancer worry scale (CWS) 
[500], and illness perceptions were evaluated by the Illness Perception Questionnaire-Revised 
(IPQ-R) [501]. Clinical variables including history of cancer and family history of PJS were 
derived from medical records.
In addition, respondents were asked whether or not they had undergone genetic testing 
and, if they had, what the result had been. Self-reported data regarding genetic testing were 
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confirmed by medical records where possible. Questions were posed about the current desire 
to have (more) children, and if the diagnosis of PJS had influenced the desire to have (more) 
children. Furthermore, after a short introductory text about PND and PGD, respondents were 
asked whether or not they considered termination of pregnancy after PND or the use of PGD 
acceptable; (1) in general, and (2) in case of PJS. Response categories were ‘yes’, ‘no’ or 
‘unsure’ [502].
Statistical analysis
Data were analysed using the SPSS 17.0 statistical software for Windows. Descriptive statistics 
were used to characterize the study sample. Continuous variables were reported by means 
(and standard deviation) and medians (and range). Univariate analyses (χ², Fisher’s exact test, 
independent t-test and Mann-Whitney U test) were used to evaluate which sociodemographic, 
clinical and psychological variables were related to attitudes towards genetic testing, PND and 
PGD. A two-sided p value < 0.05 was considered statistically significant. Multivariate logistic 
regression analyses using backward selection with a p value of 0.1 for removal of the variable 
was carried out to determine associations between possible confounders (sociodemographic, 
personal and family medical history, and psychosocial determinants) and three outcome mea-
sures: genetic testing (‘yes’ or ‘no’), termination of pregnancy after PND acceptable in case of 
PJS (‘yes’ or ‘no/unsure’) and PGD acceptable in case of PJS (‘yes’ or ‘no/unsure’).
RESULTS
Baseline characteristics
The questionnaire was completed by 52 PJS patients (response rate 85%) from 34 families. 
Median age of respondents was 44.5 (18-74) years and 23 (44%) were male. Baseline charac-
teristics of the respondents and non-respondents are shown in Table 1.
There were no significant differences in age (p = 0.056) or cancer incidence between male 
and female respondents (p = 0.144). However, women in our cohort scored significantly higher 
than men on the cancer worry scale (6.41 vs. 5.13, p = 0.038), and on the IPQ-R subscale 
emotional representations (16.21 vs. 12.87, p = 0.019). Scores on the other six IPQ-R sub-
scales did not differ significantly between male and female respondents.
Genetic testing
Of the 52 patients who completed the questionnaire, 37 patients had undergone genetic 
testing, of which 33 (89%) were actually carrier of a pathogenic LKB1 mutation. Multivariate 
logistic regression analysis showed female gender (p = 0.035) and parenthood (p = 0.016) as 
positive predictors for genetic test uptake (Table 2).
Parenthood and influence of PJS on family planning
Twenty-four respondents (46%; median age 50 years) had children. Female PJS patients less 
often had children than male patients (25% versus 75%, p<0.001).
Fifteen of the 52 respondents (29%, median age 44 years) reported that the diagnosis of 
PJS had influenced their desire to have children (i.e. less or no children). Ten of these 15 
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Table 1. Baseline characteristics of respondents and non-respondents.
Respondents
N (%)
Non-respondents
N (%)
Total number 52 9
Median age (range)1 44 (18-74) 34 (18-67)
≤ 45 yrs (childbearing age) 29 (56) 5 (56)
> 45 yrs 23 (44) 4 (44)
Gender1
Male 23 (44) 6 (67)
Female 29 (56) 3 (33)
Partner
Yes 36 (69) Unknown
No 16 (31) Unknown
Children
Yes 24 (46) 5 (56)
No 28 (54) 4 (44)
Educational level
Low 29 (56) Unknown
High 23 (44) Unknown
Genetic testing performed
Yes 37 (71) 9 (100)
No 15 (29) 0 (0)
Family history
Familial PJS 33 (63) 5 (56)
Sporadic PJS/family unknown 19 (37) 4 (44)
PJS: Peutz-Jeghers syndrome; yrs: years.
1Age (p = 0.86) and gender distribution (p = 0.29) did not differ between respondents and non-
respondents.
Table 2. Determinants of genetic testing (N=52).
 
Univariate analysis Multivariate logistic regression 
analysis
OR (95% CI) p value OR (95% CI) p value
Gender; male/female 1.676 (0.501;5.611) 0.402 11.344 (1.183;108.805) 0.035
Age 1.042 (0.995;1.092) 0.080 -
Children; yes/no 3.235 (0.869;12.043) 0.080 17.664 (1.726;180.818) 0.016
PJS familial; yes/no 1.333 (0.357;4.985) 0.669
Malignancy; yes/no 1.517 (0.277;8.310) 0.631
CWS score 0.962 (0.750;1.235) 0.763
OR: odds ratio; 95% CI: 95% confidence interval; CWS: cancer worry scale.
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respondents (19%; median age 45 years) stated that they had decided to have no children 
because of PJS, including 9 females and one male, the latter whom had adopted a child. 
Cancer incidence was higher in these 10 patients (56% vs. 44%, p = 0.011), and they scored 
higher on the cancer worry scale (8.0 vs. 5.2, p = 0.039) compared to the other respondents. 
Twenty-three of the respondents (44%, median age 45 years) indicated that PJS had not 
influenced their desire to have children.
In general, the majority of respondents considered termination of pregnancy after PND and 
the use of PGD as ‘acceptable’ (62% and 61%, respectively). The attitude of respondents 
regarding these two techniques in relation to PJS is shown in Figure 1. Fifteen per cent of 
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0
20
40
60
80 Yes
No
Don't know
15
73
10
2
52
17
21
10
Missing
%
Figure 1. Attitude of Peutz-Jeghers syndrome patients towards termination of pregnancy after PND, and 
towards pre-implantation genetic diagnosis in case of Peutz-Jeghers syndrome.
PND: acceptance of termination of pregnancy after PND in case of PJS.
PGD: acceptance of the use of pre-implantation genetics diagnosis in case of PJS.
Table 3. Determinants of the attitude towards termination of pregnancy in case of a foetus with PJS (N=51).
Univariate analysis Multivariate logistic 
regression analysis
OR (95% CI) p value OR (95% CI) p value
Gender; male/female 2.609 (0.472;14.406) 0.271 -
Age 0.936 (0.877;0.998) 0.042 -
Aware of mutation status; yes/no1 0.680 (0.149;3.099) 0.618
Children; yes/no 0.124 (0.014;1.098) 0.061 -
PJS familial; yes/no 0.655 (0.133;3.218) 0.602
Malignancy; yes/no 0.625 (0.067;5.822) 0.680
CWS score 1.165 (0.881;1.540) 0.283
OR: odds ratio; 95% CI: 95% confidence interval; CWS: cancer worry scale.
1Twenty-nine respondents were aware of their mutation status; 27 LKB1-mutation positive and 2 LKB1-
mutation negative.
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patients considered pregnancy termination after PND acceptable, while 52% accepted the 
use of PGD in case of PJS. Results of univariate and multivariate analyses are shown in Table 
3 and 4. No significant associations were found for the attitude towards pregnancy termina-
tion after PND or towards PGD.
Table 4. Determinants of the attitude towards preimplantation genetic diagnosis in case of PJS (N=47).
 
Univariate analysis Multivariate logistic regression 
analysis
OR (95% CI) p value OR (95% CI) p value
Gender; male/female 1.455 (0.454;4.664) 0.529 -
Age 1.021 (0.978;1.067) 0.341 -
Aware of mutation status; yes/no1 1.700 (0.525;5.500) 0.376
Children; yes/no 1.135 (0.356;3.621) 0.831
PJS familial; yes/no 0.343 (0.078;1.500) 0.155
Malignancy; yes/no 0.375 (0.078;1.803) 0.221
CWS score 1.187 (0.884;1.593) 0.254
OR: odds ratio; 95% CI: 95% confidence interval; CWS: cancer worry scale.
1Twenty-nine respondents were aware of their mutation status; 27 LKB1-mutation positive and 2 LKB1-
mutation negative.
DISCUSSION
This is the first survey among PJS patients that evaluated their decisions regarding family 
planning, and their attitude towards PND with possible pregnancy termination, and towards 
PGD. Twenty-four respondents (46%, 75% males) had children. Interestingly, there was a 
notable gender difference in our study population with respect to parenthood. Female patients 
less often had children than men with PJS. Furthermore, 90% of patients (9 / 10) who explicitly 
indicated that they did not want to have children because of PJS were female. The reason for 
this difference is not clear. As PJS is associated with an increased risk for the development of 
gynaecological tumours [23,460], disabilities (e.g. hysterectomy or oophorectomy) might have 
prevented female patients from having children. However, this was the case in only 2 females 
from our cohort (at the age of 36 and 39 years). In addition, there were no significant differ-
ences in age or cancer incidence between male and female respondents. One could postulate 
that psychosocial explanations for this difference exist. Women in our cohort did have more 
cancer worries than men, and had a higher emotional response to PJS. These findings could 
imply that women are more emotionally affected by their disease which can render to a higher 
sense of responsibility towards their offspring [503].
All respondents, irrespective of parenthood or not, were asked about their attitude towards 
termination of pregnancy after PND. More patients accepted the use of PGD in case of PJS 
than pregnancy termination after PND, suggesting a preference for PGD. This preference 
has been observed before in couples with different genetic disorders, including cancer 
susceptibility syndromes as hereditary breast and ovarian cancer, and familial adenomatous 
polyposis syndrome [504-508]. In a recent study among 210 couples with a broad spectrum 
of genetic disorders, the majority of couples preferred PGD over PND for diagnostic testing in 
a future pregnancy [509]. The preference for PGD can partly be explained by the fact that PGD 
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offers patients the possibility to have an unaffected genetically related child while termina-
tion of a pregnancy can be avoided. Furthermore, early reassurance is seen as an important 
advantage [504]. Though, many individuals with a hereditary condition for which PGD has 
been permitted, are unfamiliar with the technique or even unaware of its existence [509]. In 
practice, PGD is physically and psychologically burdensome [510]. Our questionnaire did not 
explore the knowledge of respondents about PND and PGD. Although both techniques were 
shortly described, the information might have been too limited. Furthermore, positive attitudes 
towards PND and PGD do not necessarily translate into actual use [511].
This study is hampered by some limitations. First of all, the cross-sectional study design 
makes evaluation of causal interactions impossible. Instead, we can only demonstrate 
statistical associations between determinants and the attitude towards genetic testing and 
reproductive decision making. Second, only affected individuals were asked to fill in the 
questionnaire, not their partners, yet it is likely that partners of PJS patients play an important 
role in the reproductive decision making and family planning. Third, the actual use of PND 
and subsequent pregnancy termination and PGD amongst PJS patients is not known and 
questions regarding religion were not included in our questionnaire, while religion can be of 
influence on the attitude towards both PND as well as PGD. Finally, in spite of the response 
rate of over 85%, our conclusions are drawn from a small sample size. Since PJS is a rare 
disorder it is difficult to assess a larger group. However, we managed to approach nearly all 
known Dutch PJS patients, thereby creating a heterogeneous cohort of patients enrolled in 
similar surveillance programs and with similar access to medical care. To our knowledge this 
is the first report concerning reproductive decision making and the attitude towards antenatal 
diagnostics amongst PJS patients.
In conclusion, this study demonstrates that the diagnosis of PJS influences decisions 
regarding family planning in approximately one third of PJS patients, especially in women. 
The majority of patients undergo genetic testing, and many PJS patients have a positive at-
titude towards PGD as an option to prevent transmission of PJS to their offspring. In contrast, 
the attitude of respondents was predominantly negative towards pregnancy termination after 
PND in case of a foetus affected with the syndrome. Our results emphasize not only the 
importance of accurate genetic counselling for these patients; it also indicates that medical 
specialists dealing with patients suffering from hereditary cancer syndromes, including PJS, 
should discuss aspects regarding family planning such as PND and PGD.
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A clear link exists between Peutz-Jeghers syndrome (PJS), the LKB1 tumour suppressor gene, 
and the development of cancer. Within this context, the focus of this thesis was to investigate 
1) the role of LKB1 signalling in cancer development and treatment, and 2) the prevalence and 
prevention of cancer in PJS. This final chapter discusses the novel insights obtained from our 
research projects and directions for future research.
THE ROLE Of LKB1 IN GASTROINTESTINAL CANCER
After the discovery of LKB1 as the gene carrying the causative mutation in PJS in 1998 [10,11], 
its function was gradually unravelled in the following years. LKB1 appears to play a crucial role 
during early embryonic development [121]. Additionally, LKB1 is involved in various processes in 
the cell, including cell polarity, energy metabolism, and cell growth (chapter 2). LKB1 is classified 
as a tumour suppressor gene, although its tumour suppressing functions are still largely unclear.
Despite the strong association between LKB1 germline mutations and the increased cancer 
risk in PJS patients, LKB1 is not commonly mutated in sporadic cancers, except for non-
small cell lung cancer (NSCLC) [141,160]. Also in sporadic colorectal cancer (CRC) somatic 
mutations in LKB1 are rarely detected, although CRC is one of the most commonly found 
cancer types in PJS patients. Loss of heterozygosity (LOH) of the LKB1 locus 19p13.3 has 
been detected in up to 50% of sporadic CRC cases [143,145], suggesting that reduced levels 
of LKB1 might contribute to the development of these cancers. However, the exact tumour 
suppressor functions of LKB1 in sporadic CRC development remain elusive. Therefore, in 
chapter 3, we investigated the role of LKB1 in colon cancer by knocking down LKB1 expres-
sion in human colon cancer cells. To this aim, we used HT29 cells, which are well differenti-
ated epithelial colon cancer cells with good adherent capacities. These cancer cells harbour 
a homozygous mutation in the tumour suppressor genes P53 and APC, and an oncogenic 
BRAF mutation. We observed that additional loss of LKB1 in these cells did not significantly 
affect Wnt/β-catenin signalling and cell growth, but rather affected cellular motility by rear-
ranging the actin cytoskeleton. This observation is in line with previous studies showing that 
loss of LKB1 increases migration and invasion in epithelial breast, lung and oesophageal 
cancer cells [136,369,373]. Together, these data suggest that LKB1 suppresses progression 
of sporadic CRC as well as of other cancers to a more invasive and thus more malignant phe-
notype. Overall, LKB1 might play a role in epithelial cancer cell metastasis rather than initiating 
sporadic cancer development. To further address this intriguing suggestion, the level of LKB1 
expression in human CRC tissue should be evaluated and correlated to clinicopathological 
parameters such as tumour stage and patient survival. However, such analyses require a 
suitable antibody detecting endogenous LKB1 in immunohistochemical stainings, which is 
currently lacking. Therefore, research should focus on the development of such an antibody.
LKB1 is considered a haploinsufficient tumour suppressor gene. Haploinsufficiency means 
that one functional allele of the gene is not sufficient to bring about the wild-type condition, 
in contrast to a classical tumour suppressor gene. The haploinsufficiency of LKB1 has been 
confirmed in mice. Lkb1+/- mice develop intestinal polyps identical to those seen in individu-
als affected with PJS (hamartomas), but neither loss of the wild-type Lkb1 allele nor loss of 
expression of Lkb1 could be detected in most gastrointestinal (GI) polyps of these mice, 
indicating that partial loss of Lkb1 is sufficient for hamartoma development [34,35].
Haploinsufficiency of a tumour suppressor gene could be more pronounced in combination 
with additional oncogenic triggers. For Lkb1, additional loss of tumour suppressor genes Pten 
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or p53, or additional oncogenic activation of Kras synergizes with Lkb1 loss for tumour forma-
tion [95,100,101,106]. In addition, because Lkb1-deficient mouse models did not develop GI 
carcinomas, and because of the lack of a genotype-phenotype correlation in PJS patients, 
additional oncogenic events seem to be required for LKB1-associated CRC development. It 
remains yet unknown which additional triggers, together with loss of LKB1, are needed for 
CRC development.
To answer this question, we investigated the involvement of candidate genes and molecular 
pathways in tissue of PJS-associated GI cancers and dysplastic hamartomas in chapter 4 
and 5. Firstly, we detected loss of the remaining wild-type allele of LKB1 more frequently in 
carcinomas than in hamartomas of PJS patients, which is in line with previous reports [119,120]. 
However, loss of the wild-type LKB1 allele was observed in dysplastic epithelium of a subset of 
the investigated hamartomas, but not in the non-dysplastic epithelium of the same hamartomas. 
This suggests that partial loss of LKB1 is sufficient for hamartoma development, and that com-
plete loss of LKB1 may induce dysplastic transformation in the epithelium of PJS hamartomas.
Next, our findings suggest that mutant P53, rather than complete loss of this tumour sup-
pressor gene, plays a major role in LKB1-associated GI carcinogenesis. It is remarkable that 
we did not find evidence for involvement of mutant KRAS in PJS-associated GI tumours, 
since previous research indicate that LKB1 cooperates with KRAS in the development of 
both pancreatic cancer in mice [95] and human NSCLC [140,141]. In fact, NSCLC tumours 
with LKB1:KRAS mutations have a more aggressive phenotype compared to LKB1 wild-type 
tumours [142]. This discrepancy might be explained by different oncogenic mechanisms that 
cause tumour growth in different organs. In addition, LKB1-associated carcinogenesis in PJS 
patients and patients without a hereditary cancer predisposition may differ substantially. Fur-
thermore, in the gastrointestinal tract, LKB1 has been suggested to act as a landscaper gene 
rather than being a tumour suppressor gene directly affecting the epithelium. Hamartomas as 
seen in PJS contain a prominent stromal component, raising the possibility of non-epithelial 
tissue origins in tumour growth. A previous study showed that heterozygous loss of Lkb1 
restricted to the smooth muscle lineage in mice was sufficient to induce gastrointestinal 
hamartoma formation [127]. Whether this so-called ‘landscaper mechanism’ is also associ-
ated with LKB1-associated GI carcinogenesis, and how this would cooperate with additional 
oncogenic events in the epithelial compartment of the GI tract, is yet unknown.
Because hamartomatous GI polyps with histological features similar to those in PJS were 
observed in patients with McCune Albright syndrome - MAS; caused by somatic activating mu-
tations in GNAS - [391], we also investigated the effect of loss of LKB1 in the GNAS signalling 
pathway (chapter 5). We did not find any evidence for an interaction between GNAS and LKB1. 
It should be noted that smooth muscle proliferation, upon which the hypothesis of overlap 
between MAS and PJS was based, is not a histopathological feature specific for the PJS polyp. 
It can develop secondary to mechanical insults due to intestinal peristalsis during polyp growth.
To investigate whether the observed molecular alterations described in chapter 4 truly 
cooperate with loss of LKB1 to induce GI cancer, mouse models are a useful research tool. 
By specific crossings, it is possible to generate Lkb1+/- mice that harbour intestinal epithelium-
specific p53 or Kras mutations, or Apc-deficiency; all mutations that also commonly occur in 
sporadic CRC. With such models, the additional role of Lkb1 loss in GI carcinogenesis can be 
investigated in vivo. In addition, these models will serve a valuable tool to investigate novel 
therapeutic strategies in the preclinical setting. Furthermore, it may clarify the controversy re-
garding the hamartoma-carcinoma sequence, similar to the well-known adenoma-carcinoma 
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sequence of sporadic CRC, as proposed for cancer growth in PJS [512]. Whether the carcino-
mas in the GI tract of PJS patients develop in sequence from hamartomas, or if they develop 
independently, remains one of the major questions within the PJS research field. Based on 
our own clinical experience and on available literature, we proclaim that GI hamartomas and 
carcinomas are two distinct entities of PJS. This opinion was strengthened by our study of 
molecular alterations in these two types of PJS lesions (chapter 4). Although there is some 
overlap in molecular alterations, particularly with regard to mutations in P53, substantial dif-
ferences remain. Most strikingly, nuclear SMAD was absent in high-grade dysplastic foci of 
intestinal hamartomas, while it was present in all intestinal carcinomas. This might indicate 
involvement of inactive TGF-β/BMP signalling in dysplastic transformation of PJS hamarto-
mas, but not in intestinal carcinoma development. Interestingly, Lkb1-deficient mesenchymal 
cells stop producing TGF-β, which is a crucial factor in suppressing tumour initiation and 
progression [127]. This resulted in the development of GI hamartomas, but not adenomas 
or carcinomas in the GI tract. Therefore, we suggest a role for aberrant TGF-β signalling in 
hamartoma development and transformation, which is not involved in PJS-associated CRC 
development.
TREATMENT Of LKB1-ASSOCIATED DISEASE
Up to now, PJS patients with cancer are treated according to standard treatment protocols 
for sporadic cancer. However, personalized treatment may avert the increased mortality in this 
patient group caused by the increased cancer risk. With the current molecular knowledge of 
LKB1-associated cancer, various treatment options have been suggested and investigated 
with variable success (reviewed in chapter 2). The usual suspect as a target for therapy is 
inhibiting mammalian target of rapamycin (mTOR). Inactivation of LKB1 impairs the inhibi-
tion of mTOR, resulting in phosphorylation of the ribosomal protein S6. However, despite 
phospho-S6 expression in tissue of GI carcinomas and hamartomas of PJS patients, we could 
not identify a correlation between genetic loss of LKB1 and increased levels of phospho-S6 
(chapter 4). This suggests that alternative pathways may be involved in mTOR activation, 
which could be targeted with other compounds (chapter 2). In 2010 however, a case report 
described the successful use of the mTOR inhibitor everolimus in a PJS patient with advanced 
pancreatic cancer [385]. This patient harboured a germline LKB1 mutation and loss of the 
wild-type allele was detected in tumour tissue. The mTOR pathway was activated in the 
primary tumour, as evident from strong cytoplasmic staining for phospho-S6. Targeting the 
activated mTOR pathway with everolimus resulted in a good initial response of the tumour. 
In addition, no new large colorectal polyps developed in this patient during the treatment 
period of 9 months. Interestingly however, phospho-S6 protein levels did not change during 
everolimus treatment and after 9 months of treatment, progressive disease was found.
Nevertheless, this promising result led to the initiation of a clinical pilot study to treat PJS 
patients with everolimus (EVAMP study, ClinicalTrials.gov identifier: NCT01178151). The 
EVAMP study consists of two treatment arms. In the one arm, PJS patients with advanced 
malignancies are included for everolimus treatment. In the other arm, patients with high-risk 
GI hamartomas (defined as fast growing, recurrent polyps >15 mm, not accessible for safe 
endoscopic resection) are included for chemopreventive treatment with everolimus. In both 
arms, treatment consists of 10 mg everolimus orally daily. At the time of this writing, one 
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PJS patient was included in the chemopreventive arm of the EVAMP study. The effect on 
hamartoma growth was not evaluated yet.
Metformin, an activator of AMP-activated kinase (AMPK), is suggested as another promis-
ing drug for targeted treatment of cancer associated with loss of LKB1, since LKB1 is a 
direct activator of AMPK (chapter 2). However, metformin failed to inhibit cell growth in cells 
completely lacking LKB1, indicating that LKB1 is required for metformin to sort a growth 
inhibitory effect [106,217]. Therefore, instead of being a curative therapy, metformin might 
be a suitable drug to prevent hamartoma and carcinoma development and outgrowth in PJS 
patients. Studies to assess this in Lkb1-mouse models and in PJS patients have not been 
performed yet, but there are plans in the near future to start a chemoprevention trial with 
metformin in PJS patients.
A new approach for the treatment of LKB1-associated cancer could be inhibition of p21-
activated kinases (PAKs, isoforms 1-6). PAKs are downstream effectors of the small G-proteins 
of the Rac and cdc42 family. They are involved in the regulation of cell survival, proliferation 
and migration. PAK overexpression and activation is reported in various types of cancer, 
including CRC [513]. Our in vitro data, described in chapter 3, also suggest that loss of LKB1 
in CRC results in cell migration through cytoskeletal rearrangement mediated by PAK signal-
ling. Specific PAK inhibitors could thus serve as potential therapeutics for cancer, including 
LKB1-associated cancer. To date, a handful of highly selective and potent small-molecule 
PAK inhibitors have been developed, including IPA-3 (PAK1 inhibitor) and PF-3758309 (PAK4 
inhibitor) [514,515]. The efficacy and applicability of these agents is still investigated. Re-
search showed that PF-3758309 blocked the growth of multiple human tumour xenografts 
in mice [516]. However, a phase I study investigating oral administration of PF-3758309 in 
patients with advanced solid tumours (ClinicalTrials.gov identifier: NCT009321126) was pre-
maturely terminated due to the undesirable pharmacokinetic characteristics and the lack of an 
observed dose-response relationship.
In conclusion, the molecular background of LKB1-associated tumour growth is slowly being 
unravelled, leading to targeted treatment options for LKB1-associated cancer. PJS is a perfect 
model to study the relationship between genetics and disease phenotype, and to design 
rational therapy strategies. However, given the high levels of complexity in biological systems, 
the road to the development of adequate personalized treatment of LKB1-associated disease 
is still long and winding.
SURVEILLANCE IN PJS
Early detection is still the best option to treat cancer. Therefore, care for PJS patients should 
focus on surveillance. Surveillance of the GI tract (e.g. stomach, small bowel, and colon) 
should start at a young age, to prevent complications of (large) hamartomas. At later age, 
the detection of precursor lesions or malignancies at an early stage becomes important 
and surveillance should also involve other organs, such as the breast, the pancreas and the 
gynaecological tract.
Small bowel surveillance
Surveillance of the stomach and the colon of PJS patients is possible with common endoscopic 
techniques, and is therefore quite feasible. PJS hamartomas however, are located in the small 
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intestine in >90% of patients, predominantly in the jejunum [8]. It is this part of the GI tract that 
is difficult to examine, because of its extensive length and tortuous course. The application of 
several non-surgical techniques to examine the small bowel of PJS patients was reviewed in 
chapter 6. The golden standard for small bowel surveillance in PJS patients does not exist. MRI 
combined with enterography or enteroclysis is a safe and sensitive method for the detection of 
especially large (>15 mm) hamartomas in the small bowel. Balloon-assisted enteroscopy (BAE) 
offers both diagnostic and therapeutic options for small bowel surveillance in PJS patients. 
Both techniques are available in various Dutch hospitals and thus are valuable tools for small 
bowel surveillance in PJS patients. But how do MRI enteroclysis and BAE relate to each other? 
Does one technique exclude the other, or are they complementary? A clinical trial is currently 
been carried out in two Dutch academic hospitals to answer these questions. This prospective 
trial compares the diagnostic accuracy of MRI enteroclysis (MRE) and proximal double balloon 
enteroscopy (DBE) for the detection of small bowel hamartomas in PJS patients. Included pa-
tients first undergo an MRE, followed by a DBE within two months. Diagnostic yield – number, 
location, and size of polyps in the small bowel – of both examinations are analysed and com-
pared. Furthermore, patient burden is investigated using questionnaires. Bowel preparation, 
duration of the examination, side effects of sedation, and pain during and after the examination 
are variables that should also be taken into account when establishing a surveillance examina-
tion that patients need to undergo regularly. Results of this trial are still awaited.
Although repeated abdominal surgery should be avoided as much as possible in PJS pa-
tients, the value of intraoperative enteroscopy for detection and removal of small bowel ham-
artomas should be noted. This combined endoscopic-surgical approach was first described 
in 1985 [426], and enables endoscopic inspection and clearance of the entire small bowel with 
surgical assistance if needed. Nowadays, advanced laparoscopic techniques minimize surgi-
cal invasiveness and duration of the procedure, and facilitate the intra-abdominal assistance of 
the endoscopist by the surgeon. Especially in PJS patients with a high polyp load, laparoscopic 
intraoperative enteroscopy seems to be the most elegant method for both patient and doctor.
Pancreatic cancer surveillance
Although the need for GI surveillance in PJS patients is established, this does not hold true 
for pancreatic cancer (PC) surveillance. Given the very poor prognosis of PC (5-year survival 
<5% [517], surveillance might be feasible in a selected group of individuals at high risk for 
developing PC, based on their family history or identifiable genetic predisposition. Whether 
PJS patients also belong to this high-risk group, and should be eligible for surveillance, was 
subject to debate since accurate risk estimates for PC in PJS were not available. We were 
now able to provide a reliable risk for PC in PJS, as described in chapter 7. This risk was 
calculated from data of the Dutch PJS cohort; a large, nationwide patient cohort with long-
term follow-up. We found a cumulative risk for PC of 26% (95% CI 4-47) at the age of 70 
years, and a relative risk of 76 (95% CI 36-160). The risk for pancreatico-biliary cancer (includ-
ing pancreatic, distal bile duct and ampullary cancer) was even higher, with a cumulative 
risk of 32% (95% CI 11-52) at age 70, and a relative risk of 96 (95% CI 53-174). Given this 
high risk, we recommend PJS patients to undergo PC surveillance from the age of 30 years, 
regardless of family history of PC, by yearly EUS and/or MRI. However, this should only be 
done in well-defined research protocols, since correct implementation of such a surveillance 
program is far from clear yet. Available evidence supporting screening and surveillance is 
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limited to observational studies, and many unanswered questions remain. Who should be 
screened? At what age should screening begin and end? Which screening test should be 
used? And, most challenging, what should be the management of asymptomatic pancreatic 
lesions detected with screening or surveillance? All these questions should be answered with 
careful consideration of the principles of screening and practice for disease as proposed by 
Wilson and Jungner and published by the World Health Organisation (Box 1) [368], as nicely 
explicated by Harinck and colleagues [459]. Although the International Cancer of the Pancreas 
Screening (CAPS) Consortium recently developed statements on these important matters 
[477], additional research and evidence is needed to optimize screening and subsequent 
management. Until then, PC surveillance for high-risk individuals including PJS patients, 
is performed only within a research setting. Such a trial has been conducted by four large 
hospitals in the Netherlands. High-risk individuals, defined as first-degree relatives of patients 
with familial PC or carriers of a PC-prone gene mutation (i.e. CDKN2A, LKB1, BRCA1/2 and 
P53), undergo yearly surveillance of the pancreas from the age of 45 years or from the age of 
at least 10 years younger than the age of the youngest relative with PC. Surveillance involves 
both endoscopic ultrasound and MRI. PJS patients were also included. The main objectives 
of this study are to determine whether surveillance results in the detection of early carcinomas 
and benign precursor lesions, and whether this early detection improves the prognosis of 
patients. In addition, advantages of such a surveillance program are outweighed against the 
disadvantages such as overtreatment, costs and psychological burden. Results of this trial are 
expected within the near future.
Box 1. Principles of screening by Wilson and Jungner [368].
1. The condition sought should be an important health problem.
2. There should be an accepted treatment for patients with recognized disease.
3. Facilities for diagnosis and treatment should be available.
4. There should be a recognized latent or early symptomatic stage.
5. There should be a suitable test or examination.
6. The test should be acceptable to the population.
7. The natural history of the condition, including development from latent to declared disease, should be 
adequately understood.
8. There should be an agreed upon policy on whom to treat as patients.
9. The cost of case-finding (including diagnosis and treatment of patients diagnosed) should be 
economically balanced in relationship to possible expenditure on medical care as a whole.
10. Case-finding should be a continuing process and not a ‘once and for all’ project.
Breast cancer and surveillance
In contrast to surveillance of the pancreas, breast cancer screening and surveillance is well 
established and seems beneficial, both in the general population as in high-risk individuals 
such as BRCA1/2 mutation carriers. Additionally, there is no doubt that the breast cancer risk 
is increased in female patients with PJS. The first PJS patient officially described in literature, 
one sister of the so-called ‘Hutchinson twins’, died of breast cancer [3]. But it remained 
unclear where PJS patients should be placed in the spectrum of high-risk individuals. Ac-
curate risk estimates for breast cancer in PJS were lacking and nothing was known about 
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tumour characteristics, which may influence the design of surveillance protocols. Therefore, 
we evaluated breast cancer cases detected in the Dutch PJS cohort and provide an accurate 
breast cancer risk estimate for female PJS patients in chapter 8. Although our study confirms 
that this risk is highly increased (relative risk 6, 95% CI 3-13), and even approaches that of 
BRCA1/2 mutation carriers, there are important considerations that refrain from following the 
surveillance recommendations as formulated for this latter patient group. However, given the 
very small number of PJS patients, it is desirable to implement a surveillance program for 
PJS patients in the current, well organized breast cancer surveillance care as exists in our 
country. Extensive multidisciplinary deliberation led us to the formulation of a breast cancer 
surveillance recommendation for PJS patients, as depicted in Box 2. This recommendation is 
derived from the surveillance guidelines for BRCA1/2 mutation carriers, as formulated in the 
Dutch breast cancer guidelines (available at www.oncoline.nl) Although extrapolating data can 
be misleading, sometimes one has to do with the means available. Though, future evaluation 
of the proposed recommendation for breast cancer surveillance in PJS patients is required.
Box 2. Adjusted Dutch surveillance recommendations for Peutz-Jeghers syndrome patients.
Examination1 Starting age Interval
History, physical examination (including testicular 
palpation), and hemoglobin analysis
10 years 1 year (paediatrician)
MRI enteroclysis2 10 years 2-3 years
(chapter 6)
Gastroduodenoscopy 20 years 2-5 years (depending on findings)
Colonoscopy 25-30 years 2-5 years (depending on findings)
MRI and EUS 30 years 1 year, only in a prospective ongoing trial
(chapter 7)
Mammography and breast MRI3 30 years 1 year
(chapter 8)
Pelvic exam, cervical smear, transvaginal 
ultrasonography, and CA-125
25-30 years 1 year
EUS: endoscopic ultrasound; MRI: magnetic resonance imaging.
1Earlier and/or more frequently in symptomatic patients or if clinically indicated.
2Polyps >10-15 mm in diameter are an indication for double-balloon enteroscopy with polypectomy. In 
addition, we recommend intra-operative enteroscopy with polyp removal in patients with a high-polyp 
load.
3If mammography provides a reliable assessment of the breast tissue, MRI can be omitted.
Family planning and prenatal testing
Testing an unborn child for PJS (prenatal diagnosis, PND), providing the causing germline 
mutation is known in the affected parent, and possibly terminating a pregnancy in case of an 
affected foetus could be seen as an extreme form of prevention. PND by means of chorionic 
villus sampling is widely available in the Netherlands. However, the effects of such a test, and 
especially the impact of the decision-making in case of an affected foetus, should not be un-
derestimated. In case of pre-implantation genetic diagnosis (PGD), the decision to terminate 
a pregnancy needs not to be made because only unaffected embryos are transferred into the 
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uterus. However, the PGD procedure is physically and psychologically burdensome [510], 
mainly because of the need for pregnancy by in vitro fertilization. In chapter 9 we describe 
that PJS seriously influences the desire to have children of patients because of the disease 
burden. Additionally, our results indicate that PJS patients consider PGD more acceptable 
than the use of PND with the probability of pregnancy termination.
The actual use of PND amongst PJS patients in the Netherlands is unknown, but data are 
available for the use of PGD. PGD has been performed in the Netherlands since 1995. Only 
one academic hospital (University Hospital Maastricht) is authorized to perform this treatment. 
In the period from 1995 until 2011, 3 couples were referred for PGD for the indication PJS, 
including 2 in 2011 [518]. This might indicate that the awareness of the possibility of antenatal 
genetic testing for PJS patients with a desire to have children increases in patients and doc-
tors, which is a step forward in the care for PJS patients.
GENERAL CONSIDERATIONS
As mentioned repeatedly in this discussion, care for PJS patients should focus on surveillance. 
Box 2 shows the slightly modified Dutch surveillance recommendation, as a result of the new 
insights provided by this thesis (see also chapter 1, Box 2, page 15). But this recommendation 
only reflects expert opinion; the lack of data from randomized controlled trials as well as 
comparative observational studies remains a major drawback. A systematic review assessed 
the current literature on the management of PJS [30]. This revealed 15 studies concerning PJS 
and surveillance, all with low or very low category of evidence (III; non-experimental descrip-
tive study or IV; expert opinion) and grading of recommendation (B or C). This highlights the 
paucity of good-quality data on which management recommendations are based.
It was attempted by colleagues in the UK to provide such data. In a retrospective study 
they aimed to assess the outcomes from GI surveillance in PJS patients [111]. Fifty-one young 
patients (median age at first contact 20 years) were followed for 683 patient years (median 
10 years). During follow-up, patients underwent enteroscopies or surgical procedures during 
which 2461 polypectomies were performed (of which only 6 hamartomas contained atypia 
or dysplasia). No luminal GI cancers were diagnosed in any of these patients. The authors 
conclude that, although evidence of benefit from GI tract surveillance in terms of cancer 
detection or prevention is not robust, surveillance is still required to prevent polyp-related 
complications. These are valuable observations, but only well-designed, prospective studies 
can provide robust evidence for surveillance guidelines.
Another important question is whether the possible clinical benefit of surveillance outweighs 
the psychological burden of surveillance, as required according to the principles of Wilson & 
Jungner (Box 1). All currently proposed guidelines for PJS patients, including the Dutch sur-
veillance guidelines, are highly intensive and burdensome. Surveillance should already start at 
a young age and needs to be performed regularly. It concerns multiple organs, and several of 
the surveillance modalities are invasive. A recent review evaluated all studies that investigated 
psychological distress and quality of life in individuals under surveillance for hereditary cancer, 
including a report of our research group concerning PJS patients [497,519]. Although partici-
pating in surveillance programs in most common hereditary cancers was generally associated 
with normal levels of distress, surveillance of hereditary cancer syndromes with a high risk 
of multiple tumours, such as PJS, appeared to be associated with a worse quality of life, 
suggesting that these patients may be in need of psychological support. Therefore, if patients 
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need multiple surveillance examinations, ideally one physician who knows all the aspects of 
the disease should coordinate these examinations, and additionally guide the patients through 
surveillance. Furthermore, given the very low prevalence of PJS, care for these patients should 
be centred in a limited number of (academic) hospitals to ensure uniformity of care.
Despite the above considerations and proposals, the rarity of PJS is an obstacle for further 
research. PJS is considered an orphan disease, defined in the United States as a condition 
that affects fewer than 200.000 people [520]. In Europe most countries use the European 
Orphan Drug regulation definition of a prevalence of less than 1 in 2000 [521]. PJS is, due to 
its low prevalence, not a hot topic in the field of biomedical research. This translates for ex-
ample into difficulties in obtaining research funding, recruiting sufficient numbers of patients 
for meaningful research studies, finding valid statistical approaches when small numbers are 
involved, and finding a platform for the publication of results. One way to overcome a number 
of these problems is by joining forces. Currently, several groups of experts throughout the 
world are engaged in research of PJS individually. If these groups would form a network and 
cooperate, studies with high patient numbers can lead to convincing results concerning the 
nature of the disease, surveillance benefits, and treatment options. The establishment of such 
a multidisciplinary, international consortium is not easy and takes a lot of time and effort. But 
only in this way we will be able to contribute to a better future perspective for PJS patients.
CONCLUDING REMARKS
The tumour suppressor gene LKB1 links the rare Peutz-Jeghers syndrome and the develop-
ment of cancer. Disease characteristics and the natural course of PJS, as well as the function 
of LKB1, have been gradually unravelled in recent years. Novel insights as provided by this 
thesis, concerning the role of LKB1 in sporadic and PJS-associated cancer, have contributed 
to more understanding of this link. However, many uncertainties remain. Due to the elucidation 
of molecular mechanisms, some promising medical therapies for LKB1-associated cancer 
are on the horizon but are still being evaluated. In addition, evidence is accumulating that 
not only the luminal GI tract, but also other organs such as the pancreas and breasts require 
surveillance because of the considerably increased cancer risk. Though, the design of and 
adherence to surveillance guidelines is problematic due to the lack of robust evidence for the 
benefit of such surveillance programs. Therefore, research for the missing links between PJS 
and cancer should be continued.
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Summary
SUMMARY
Peutz-Jeghers syndrome (PJS) is a rare, autosomal dominant inherited disorder, first de-
scribed by the Dutch physician Jan Peutz in 1921. It is clinically characterized by mucocuta-
neous pigmentations, gastrointestinal (GI) polyposis and an increased cancer risk in adult life. 
Hamartomatous polyps can develop already in the first decade of life and may cause various 
complications, including abdominal pain, bleeding, anaemia, and acute intestinal obstruc-
tion. Cancer can develop at a later age, both in the GI tract as in other organs. The medical 
management of PJS mainly consists of surveillance, firstly to detect and remove hamartomas, 
and secondly to detect cancer at an early stage.
PJS is caused by germ line mutations in the LKB1 tumour suppressor gene. LKB1 is 
considered a “master kinase”, regulating a range of cellular processes via the AMPK/mTOR 
signalling pathway, a possible target for treatment. In chapter 2 the function and regulation of 
the LKB1/AMPK/mTOR signalling pathway is explained. In addition, we describe how aber-
rant signalling of this cascade can cause disease and cancer, and we reflect on the design and 
use of rational treatment targeting LKB1/AMPK/mTOR-associated cancer.
Despite the strong association between LKB1 germline mutations and the increased cancer 
risk in PJS patients, LKB1 is not commonly mutated in sporadic cancers, except for lung can-
cer. Its exact tumour suppressor functions in sporadic and PJS-associated colorectal cancer 
development remain elusive. In chapter 3 of this thesis, we investigated the role of LKB1 in 
colon cancer in vitro. To this aim, LKB1 expression was knocked down in HT29 human colon 
cancer cells. Although reduced LKB1 expression did not affect growth-related properties, it 
did induce migration of these cells by affecting cytoskeletal structures. This might suggest 
that the tumour suppressor LKB1 acts on the cancerous process through cytoskeletal rear-
rangements.
In addition, we studied which molecular pathways could be involved in LKB1-associated 
GI carcinogenesis. A unique sample set of tissue of 15 GI carcinomas and 9 dysplastic ham-
artomas of PJS patients was analysed at DNA and protein level. Our findings as described 
in chapter 4 suggest a role for mutant P53 in PJS-associated GI carcinogenesis, in addition 
to a haploinsufficient function of the LKB1 tumour suppressor gene. Loss of nuclear SMAD4 
and complete loss of LKB1 may be involved in dysplastic transformation of GI hamartomas. 
The BRAF and GNAS genes do not seem to be involved in the pathogenesis of GI tumours in 
PJS (chapter 4 and 5).
Chapter 6 provides a review of the literature concerning small bowel endoscopy in PJS 
patients. Radiologic and endoscopic imaging modalities with diagnostic value are discussed, 
as well as advanced endoscopy techniques that can serve as a diagnostic and therapeutic 
tool in the surveillance of the small bowel.
In chapter 7 and 8 we provide reliable estimates for respectively pancreatic and breast 
cancer risks in PJS patients. In addition, clinical and histological characteristics of PJS-
associated tumours are described in these chapters. For these studies, we used the Dutch 
PJS database, comprising of nearly all PJS patients in the Netherlands. Given the highly 
increased risk for pancreatico-biliary cancer (RR 96), PJS patients are eligible for surveillance 
within well-defined research programs (chapter 7). Based on the highly increased risk for 
breast cancer risk (RR 6), we advised to start annual breast cancer surveillance in female PJS 
patients at the age of 30 years, with mammography and MRI (chapter 8).
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In our final study, described in chapter 9, we assessed the attitude of PJS patients towards 
family planning, prenatal diagnosis (PND) and pregnancy termination, and pre-implantation 
genetic diagnosis (PGD) with a questionnaire study. In conclusion, the diagnosis of PJS 
influences the decisions regarding family planning in one third of PJS patients, especially in 
women. In addition, most patients have a negative attitude towards pregnancy termination 
after PND, while PGD in case of PJS is judged more acceptable.
Finally, this thesis concludes with a general discussion and future perspectives for PJS in 
chapter 10.
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SAMENVATTING
Het Peutz-Jeghers syndroom (PJS) is een zeldzame, autosomaal dominant overervende 
aandoening. De Nederlandse arts Jan Peutz beschreef in 1921 als eerste een familie waarin 
een aantal gezinsleden zowel gastro-intestinale poliepen als opvallende pigmentaties in het 
gezicht en op de slijmvliezen van de mondholte vertoonden. Tegenwoordig wordt PJS geka-
rakteriseerd door mucocutane pigmentaties, gastro-intestinale polyposis en een verhoogd 
kankerrisico op volwassen leeftijd.
De hamartomateuze PJS poliepen kunnen zich al op kinderleeftijd (< 10 jaar) manifesteren 
en kunnen klachten van buikpijn, bloedverlies, anemie of acute darmobstructie veroorzaken. 
Kanker kan zich op latere leeftijd ontwikkelen, zowel in het maag-darmkanaal als in andere 
organen. De zorg voor PJS patiënten bestaat voornamelijk uit surveillance; in eerste instantie 
om hamartomen te detecteren en te verwijderen en op latere leeftijd om kanker in een vroeg 
stadium te diagnosticeren.
PJS wordt veroorzaakt door een kiembaanmutatie in het LKB1 tumor suppressor gen. LKB1 
wordt beschouwd als een “master-kinase” en reguleert cellulaire processen via de AMPK/
mTOR signaleringscascade. Deze cascade is een mogelijk aangrijpingspunt voor therapie. In 
hoofdstuk 2 wordt de functie en regulatie van de LKB1/AMPK/mTOR signaleringscascade 
uitgelegd. Tevens wordt beschreven hoe gestoorde signalering van deze cascade kan leiden 
tot kanker en wijden we uit over mogelijke rationele behandeling hiervan.
Hoewel kiembaanmutaties van LKB1 sterk geassocieerd zijn met een verhoogd risico op 
het krijgen van kanker in PJS, is LKB1 niet vaak gemuteerd in sporadische kanker, behalve in 
longkanker. Wat de exacte tumor suppressor functies van LKB1 zijn in colorectaal kanker is 
dan ook nog onbekend. In hoofdstuk 3 van dit proefschrift hebben we in vitro de rol van LKB1 
in darmkanker onderzocht. Hiervoor werd de expressie van LKB1 in humane HT29 darmkan-
kercellen uitgeschakeld. Hoewel de verminderde expressie van LKB1 geen effect had op de 
groei-eigenschappen van deze cellen, leidde het wel tot meer migratie van deze cellen door 
aantasting van het cytoskelet. Dit zou kunnen suggereren dat de tumor suppressor LKB1 het 
kankerproces beïnvloed door modulatie van het cytoskelet.
In aanvulling op deze studie hebben we onderzocht welke moleculaire routes betrokken 
zijn bij LKB1-geassocieerde gastro-intestinale kankergroei. Weefsel van 15 gastro-intestinale 
carcinomen en 9 dysplastische hamartomen van PJS patiënten werd geanalyseerd op DNA- 
en eiwitniveau. Onze bevindingen (beschreven in hoofdstuk 4 en 5) suggereren een rol voor 
mutant P53, samen met de haplo-insufficiënte functie van LKB1, in PJS-geassocieerde 
gastro-intestinale kankergroei. Verlies van nucleair SMAD4 en volledig verlies van LKB1 zou 
betrokken kunnen zijn bij de dysplastische transformatie van gastro-intestinale hamartomen. 
De BRAF en GNAS genen lijken echter niet betrokken te zijn bij de pathogenese van gastro-
intestinale tumoren in PJS.
Hoofdstuk 6 geeft een overzicht van de beschikbare literatuur over dunne darmscopie bij 
PJS patiënten. Eerst bespreken we radiologische en endoscopische technieken met diagnos-
tische waarde. Vervolgens komen geavanceerde endoscopie-technieken aan bod, die zowel 
diagnostisch als therapeutisch ingezet kunnen worden bij de dunne darmsurveillance.
Hoofdstuk 7 en 8 verstrekken betrouwbare risicoschattingen voor pancreas- en borst-
kanker in PJS patiënten. Tevens beschrijven we de klinische en histologische kenmerken 
van de tumoren. Voor beide studies hebben we gebruik gemaakt van de Nederlandse PJS 
database, waarin nagenoeg alle PJS patiënten in Nederland zijn opgenomen. Gezien het 
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sterk verhoogde risico op kanker in de pancreatico-biliaire regio (RR 96) lijkt het wenselijk 
om pancreassurveillance aan te bieden aan PJS patiënten, maar alleen in goed omschreven 
onderzoeksprogramma’s (hoofdstuk 7). Daarnaast adviseren wij, gebaseerd op het sterk ver-
hoogde risico op borstkanker (RR 6), jaarlijkse borstkanker surveillance voor vrouwelijke PJS 
patiënten vanaf de leeftijd van 30 jaar, met mammografie en eventueel MRI (hoofdstuk 8).
Voor de laatste studie (beschreven in hoofdstuk 9) hebben we door middel van vragenlijs-
ten onderzocht hoe PJS patiënten denken over gezinsplanning, prenatale diagnostiek (PND) 
eventueel gevolgd door zwangerschapsbeëindiging en pre-implantatie genetische diagnos-
tiek (PGD). Het blijkt dat de diagnose PJS voor een derde van de patiënten de gezinsplanning 
beïnvloedt, voornamelijk voor vrouwen. Daarnaast hebben de meeste patiënten een negatief 
beeld van zwangerschapsbeëindiging na PND, terwijl ze PGD in geval van PJS meer ac-
ceptabel achten.
Tot slot wordt dit proefschrift afgesloten met een algemene discussie en toekomstperspec-
tieven (hoofdstuk 10).
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Een promotietraject tot een succesvol einde brengen is onmogelijk zonder de hulp van vele 
anderen! Graag wil ik een aantal mensen in het bijzonder bedanken.
Allereerst alle PJS patiënten, familieleden en nabestaanden. Hoewel lang niet altijd makkelijk, 
was en is jullie deelname en betrokkenheid onontbeerlijk voor het PJS-onderzoek, bedankt!
Mijn promotoren prof. E.J. Kuipers en prof. E.M.H. Mathus-Vliegen. Beste Ernst, bedankt voor 
de kans die jij mij geboden hebt om vanuit het Utrechtse onderzoek te komen doen in Rotter-
dam. Jouw enthousiasme is algemeen bekend en veel geprezen en heeft ook mij geïnspireerd 
en gemotiveerd in de afgelopen jaren. Het is een eer om onder jouw supervisie te promoveren. 
Beste Lisbeth, jouw jarenlange betrokkenheid bij alle ‘Peutzen’ is bewonderenswaardig en 
onmisbaar geweest voor het PJS-onderzoek. Bedankt voor je inzet en supervisie van mijn 
onderzoekstraject.
Mijn co-promotoren dr. W. van Veelen en dr. M.E. van Leerdam. Beste Monique, jij hebt 
mijn wetenschappelijke carrière op de rails gezet. Vooral in de beginperiode wist je mij in de 
juiste richting te sturen en me te temperen op momenten dat ik sneller praatte dan nadacht. 
Bedankt voor je begeleiding en betrokkenheid. Lieve Wendy, het begon allemaal toen ik zo’n 
4 jaar geleden opeens naast je bureau stond op zoek naar een stageplek. En nu sta ik hier! 
Zonder jouw geduld en talent om orde te scheppen in mijn chaos was dat niet gelukt. Het is 
een eer om jouw eerste promovenda te zijn! Ik bewonder jouw doorzettingsvermogen en wens 
je heel veel succes in Leiden en veel geluk met je gezin.
Mijn dank gaat tevens uit naar de leden van de leescommissie en promotiecommissie; voor 
het kritisch beoordelen van mijn proefschrift en de bereidwilligheid te opponeren.
Pieter Dewint, Evelien Dekker, Suzie Oppeneer, Anja Wagner, Heinz-Joseph Klumpen en Ferry 
Eskens wil ik bedanken voor hun betrokkenheid bij en inzet voor het PJS-onderzoek.
Wendy Holleman, Bernadette Lourens en Leonie Moree, bedankt voor al jullie secretariële 
ondersteuning.
Mijn paranimfen Lisanne Holster en Eelke Toxopeus. Lieve Lies, plotseling zat jij als nieuwe 
collega naast me op de flex, maar de lins was het keerpunt. En opruimwoede bleek niet 
ons enige raakvlak! Samen regelen we het wel, of het nou gaat om een skireis of een lift op 
Bonaire. Lieve Eel, wat had ik zonder jou naast me gemoeten in L-463?! Werk, lief en leed 
hebben we gedeeld, afgewisseld met de laatste roddels en tassen en schoenen shoppen op 
internet. Jullie zijn collega’s maar bovenal vriendinnen en ik bewonder jullie veerkracht en 
ambitie. Wat fijn dat jullie naast me staan tijdens mijn promotie!
Mijn collega’s van de afdeling MDL van het Erasmus MC; alle dakduiven, labmuizen en flexers. 
Bedankt voor vruchtbare overleggen, succesvolle samenwerkingen, noodzakelijke koffiemo-
menten om stoom af te blazen, gezellige onderonsjes op Hs-5, Ca-413 en L-463, schouders 
om op uit te huilen, uit de hand gelopen borrels en feestjes, ambitieuze fietstochten en onver-
182
Dankwoord
getelijke tripjes in binnen- en buitenland. Zonder zo’n fantastische en diverse groep collega’s 
was promoveren niet half zo leuk geweest. Lieve Femme, na een gesmeerde samenwerking 
kwam het frustrerende traject van submitten en re-submitten. Maar: there is a home for every 
manuscript! Ik ben trots op ons gezamenlijke meesterwerk. Werner en Jasper, illuster duo 
van het mollab, bedankt dat jullie mij wegwijs hebben gemaakt in de wondere wereld van het 
pipetteren; zonder jullie was het niets geworden met mijn wetenschappelijke carrière.
Al mijn lieve vrienden en vriendinnen uit Breda, Groningen en Den Haag, huisgenoten uit 
Utrecht, meiden van Cocoon en studiegenootjes met wie ik heerlijk kan eten, koffieleuten, 
lachen, filosoferen over de zin van het leven of kletsen over niks, borrelen, feesten en vakantie 
vieren. En bij wie ik bovendien altijd terecht kan. Bedankt voor al jullie interesse in mijn soms 
onbegrijpelijke bezigheden!
Lieve Eef, bedankt voor het meedenken over het omslagontwerp van mijn proefschrift.
Lieve Olivier, wat ben jij goed in wat je doet. Zonder jouw oog voor detail en perfectionisme 
was dit boekje nooit zo mooi geworden, bedankt!
Lieve Lisette, van ons knusse huisje aan de Jadelaan in Utrecht naar het stadse Rotterdam en 
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